US	US	PRP	0
20070003560	20070003560	CD	0
A1	A1	CD	0
20070104	20070104	CD	0
US	US	NNP	0
11471369	11471369	CD	0
20060620	20060620	CD	0
11	11	CD	0
20060101	20060101	CD	0
A	A	DT	0
A	A	NNP	0
61	61	CD	0
K	K	NNP	0
39	39	CD	0
40	40	CD	0
F	F	NN	0
I	I	PRP	0
20070104	20070104	CD	0
US	US	NNP	0
B	B	NNP	B-NP
H	H	NNP	I-NP
20060101	20060101	CD	0
A	A	DT	0
C	C	$	0
07	07	CD	0
H	H	NNP	0
21	21	CD	0
04	04	CD	0
L	L	NNP	0
I	I	NNP	0
20070104	20070104	CD	0
US	US	NNP	0
B	B	NNP	B-NP
H	H	NNP	I-NP
20060101	20060101	CD	0
A	A	DT	0
C	C	$	0
12	12	CD	0
P	P	NN	0
21	21	CD	0
06	06	CD	0
L	L	NNP	0
I	I	NNP	0
20070104	20070104	CD	0
US	US	NNP	0
B	B	NNP	B-NP
H	H	NNP	I-NP
20060101	20060101	CD	0
A	A	DT	0
C	C	$	0
12	12	CD	0
N	N	NNP	0
5	5	CD	0
06	06	CD	0
L	L	NNP	0
I	I	NNP	0
20070104	20070104	CD	0
US	US	NNP	0
B	B	NNP	B-NP
H	H	NNP	I-NP
20060101	20060101	CD	0
A	A	DT	0
C	C	$	0
07	07	CD	0
K	K	NNP	0
16	16	CD	0
12	12	CD	0
L	L	NNP	0
I	I	NNP	0
20070104	20070104	CD	0
US	US	NNP	0
B	B	NNP	B-NP
H	H	NNP	I-NP
US	US	NNP	0
424164100	424164100	CD	0
435069100	435069100	CD	0
435320100	435320100	CD	0
435326000	435326000	CD	0
530388400	530388400	CD	0
536023530	536023530	CD	0
humanized	humanized	VBN	B-NP
monoclonal	monoclonal	JJ	I-NP
antibody	antibody	NN	I-NP
that	that	WDT	0
protect	protect	VBP	0
against	against	IN	0
shiga	shiga	JJ	B-NP
toxin	toxin	NN	I-NP
induced	induced	NN	I-NP
disease	disease	NN	I-NP
US	US	NNP	0
09215163	09215163	CD	0
19981218	19981218	CD	0
PENDING	PENDING	NNP	0
US	US	NNP	0
11471369	11471369	CD	0
A1	A1	CD	0
20060620	20060620	CD	0
US	US	NNP	0
60068635	60068635	CD	0
19971223	19971223	CD	0
Stinson	Stinson	NNP	B-NP
Jeffrey	Jeffrey	NNP	I-NP
R	R	NNP	I-NP
.	.	.	I-NP
Davie	Davie	NNP	B-NP
FL	FL	NNP	I-NP
US	US	NNP	0
Weston	Weston	NNP	B-NP
FL	FL	NNP	I-NP
US	US	NNP	0
Bethesda	Bethesda	NNP	B-NP
MD	MD	NNP	I-NP
US	US	NNP	0
Rockville	Rockville	NNP	B-NP
MD	MD	NNP	I-NP
US	US	NNP	0
Sterling	Sterling	NNP	B-NP
VA	VA	NNP	I-NP
US	US	NNP	0
101	101	CD	0
FEDERAL	FEDERAL	NNP	B-NP
STREET	STREET	NNP	I-NP
BOSTON	BOSTON	NNP	I-NP
MA	MA	NNP	I-NP
02110	02110	CD	0
US	US	NNP	0
The	The	DT	0
present	present	JJ	0
invention	invention	NN	0
describes	describes	VBZ	0
the	the	DT	0
preparation	preparation	NN	B-NP
and	and	CC	0
use	use	NN	0
of	of	IN	0
biologically	biologically	NN	0
and	and	CC	0
immunologically	immunologically	JJ	0
active	active	JJ	0
humanized	humanized	JJ	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
to	to	TO	0
Shiga	Shiga	NNP	B-NP
toxin	toxin	NN	I-NP
,	,	,	0
a	a	DT	0
toxin	toxin	NN	B-NP
associated	associated	VBN	0
with	with	IN	0
hemorrhagic	hemorrhagic	NN	B-NP
colitis	colitis	NN	I-NP
and	and	CC	0
the	the	DT	0
potentially	potentially	RB	0
life-threatening	life-threatening	JJ	B-NP
sequela	sequela	JJ	I-NP
HUS	HUS	NNP	I-NP
transmitted	transmitted	VBD	0
by	by	IN	0
strains	strains	NNS	0
of	of	IN	0
pathogenic	pathogenic	JJ	B-NP
bacterium	bacterium	NN	I-NP
.	.	.	0
The	The	DT	0
present	present	JJ	0
invention	invention	NN	0
describes	describes	VBZ	0
how	how	WRB	0
these	these	DT	0
humanized	humanized	JJ	0
antibody	antibody	NN	B-NP
may	may	MD	0
be	be	VB	0
used	used	VBN	0
in	in	IN	0
the	the	DT	0
treatment	treatment	NN	0
or	or	CC	0
prevention	prevention	NN	0
of	of	IN	0
shiga	shiga	NN	B-NP
toxin	toxin	NN	I-NP
induced	induced	NN	I-NP
disease	disease	NN	I-NP
.	.	.	0
One	One	CD	0
aspect	aspect	NN	B-NP
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
is	is	VBZ	0
the	the	DT	0
humanized	humanized	JJ	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
which	which	WDT	0
binds	binds	VBZ	0
Shiga	Shiga	JJ	B-NP
toxin	toxin	NN	I-NP
where	where	WRB	0
the	the	DT	0
constant	constant	JJ	0
regions	regions	NNS	0
are	are	VBP	0
IgG1-kappa	IgG1-kappa	NNP	B-NP
and	and	CC	0
the	the	DT	0
variable	variable	JJ	0
regions	regions	NNS	0
are	are	VBP	0
murine	murine	VBN	0
in	in	IN	0
origin	origin	NN	0
.	.	.	0
Yet	Yet	RB	0
another	another	DT	0
aspect	aspect	NN	B-NP
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
is	is	VBZ	0
expression	expression	JJ	B-NP
vector	vector	NN	I-NP
and	and	CC	0
host	host	NN	B-NP
cell	cell	NN	I-NP
transformed	transformed	VBN	0
with	with	IN	0
such	such	JJ	0
vectors	vectors	NN	0
which	which	WDT	0
express	express	VBP	0
the	the	DT	0
humanized	humanized	JJ	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
of	of	IN	0
the	the	DT	0
present	present	JJ	0
invention	invention	NN	0
.	.	.	0
This	This	DT	0
application	application	NN	0
is	is	VBZ	0
a	a	DT	0
continuation	continuation	NN	B-NP
of	of	IN	0
U.S.	U.S.	NNP	0
patent	patent	NN	0
application	application	NN	0
Ser	Ser	NNP	0
.	.	.	0
No.	No.	NNP	0
09	09	CD	0
/	/	CD	0
215,163	215,163	CD	0
,	,	,	0
filed	filed	VBD	0
Dec.	Dec.	NNP	0
18	18	CD	0
,	,	,	0
1998	1998	CD	0
,	,	,	0
which	which	WDT	0
claims	claims	VBZ	0
the	the	DT	0
benefit	benefit	NN	0
of	of	IN	0
U.S.	U.S.	NNP	0
Provisional	Provisional	NNP	0
Application	Application	NNP	0
No.	No.	NNP	0
60	60	CD	0
/	/	CD	0
068,635	068,635	CD	0
,	,	,	0
filed	filed	VBD	0
Dec.	Dec.	NNP	0
23	23	CD	0
,	,	,	0
1997	1997	CD	0
,	,	,	0
each	each	DT	0
of	of	IN	0
which	which	WDT	0
is	is	VBZ	0
hereby	hereby	VBN	0
incorporated	incorporated	VBN	0
by	by	IN	0
reference	reference	NN	0
.	.	.	0
The	The	DT	0
invention	invention	NN	0
relates	relates	VBZ	0
to	to	TO	0
a	a	DT	0
family	family	NN	0
of	of	IN	0
multi-unit	multi-unit	JJ	B-NP
bacterial	bacterial	JJ	I-NP
protein	protein	NN	I-NP
that	that	WDT	0
are	are	VBP	0
associated	associated	VBN	0
with	with	IN	0
hemorrhagic	hemorrhagic	JJ	B-NP
colitis	colitis	NN	I-NP
and	and	CC	0
the	the	DT	0
life-threatening	life-threatening	JJ	B-NP
sequela	sequela	NN	I-NP
,	,	,	0
hemolytic	hemolytic	JJ	B-NP
uremic	uremic	JJ	I-NP
syndrome	syndrome	NN	I-NP
.	.	.	0
These	These	DT	0
proteins	proteins	NNS	0
,	,	,	0
defined	defined	VBN	0
as	as	IN	0
members	members	NNS	0
of	of	IN	0
the	the	DT	0
Shiga	Shiga	JJ	B-NP
toxin	toxin	NN	I-NP
family	family	NN	I-NP
,	,	,	0
have	have	VBP	0
been	been	VBN	0
utilized	utilized	VBN	0
in	in	IN	0
the	the	DT	0
isolation	isolation	NN	0
and	and	CC	0
murine	murine	JJ	B-NP
monoclonal	monoclonal	JJ	I-NP
antibody	antibody	NN	I-NP
identification	identification	NN	I-NP
.	.	.	0
The	The	DT	0
invention	invention	NN	0
further	further	RBR	0
relates	relates	JJ	0
to	to	TO	0
the	the	DT	0
construction	construction	NN	B-NP
of	of	IN	0
humanized	humanized	JJ	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
which	which	WDT	0
incorporate	incorporate	VBZ	0
the	the	DT	0
mouse	mouse	NN	0
variable	variable	NN	0
regions	regions	NNS	0
.	.	.	0
It	It	PRP	0
also	also	RB	0
relates	relates	VBZ	0
to	to	TO	0
antibody	antibody	NN	B-NP
to	to	TO	0
shiga	shiga	NN	B-NP
toxin	toxin	NN	I-NP
or	or	CC	0
toxoid	toxoid	NN	B-NP
,	,	,	0
both	both	DT	0
monoclonal	monoclonal	NN	B-NP
and	and	CC	0
polyclonal	polyclonal	NN	B-NP
,	,	,	0
and	and	CC	0
their	their	PRP$	0
use	use	NN	0
in	in	IN	0
treating	treating	VBG	0
,	,	,	0
diagnosing	diagnosing	VBG	0
,	,	,	0
and	and	CC	0
preventing	preventing	VBG	0
of	of	IN	0
disease	disease	NN	0
and	and	CC	0
infections	infections	NNS	0
caused	caused	VBN	0
by	by	IN	0
pathogenic	pathogenic	JJ	B-NP
E.	E.	NNP	I-NP
cus	cus	NN	I-NP
.	.	.	0
Finally	Finally	RB	0
,	,	,	0
the	the	DT	0
invention	invention	NN	0
relates	relates	VBZ	0
to	to	TO	0
preparing	preparing	VBG	0
the	the	DT	0
humanized	humanized	JJ	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
to	to	TO	0
proteins	proteins	NNS	0
of	of	IN	0
the	the	DT	0
Shiga	Shiga	JJ	B-NP
toxin	toxin	NN	I-NP
family	family	NN	I-NP
.	.	.	0
Enterohemorrhagic	Enterohemorrhagic	NNP	B-NP
Escherichia	Escherichia	NNP	I-NP
cus	cus	NN	I-NP
(	(	-LRB-	0
EHEC	EHEC	NNP	B-NP
)	)	-RRB-	0
are	are	VBP	0
associated	associated	VBN	0
with	with	IN	0
food-borne	food-borne	JJ	B-NP
outbreak	outbreak	NN	I-NP
of	of	IN	0
bloody	bloody	JJ	0
diarrhea	diarrhea	NN	0
or	or	CC	0
hemorrhagic	hemorrhagic	JJ	B-NP
colitis	colitis	NN	I-NP
(	(	-LRB-	0
HC	HC	NNP	B-NP
)	)	-RRB-	0
and	and	CC	0
the	the	DT	0
hemolytic	hemolytic	JJ	B-NP
uremic	uremic	JJ	I-NP
syndrome	syndrome	NN	I-NP
(	(	-LRB-	0
HUS	HUS	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
(	(	-LRB-	0
Spika	Spika	NNP	0
,	,	,	0
J.	J.	NNP	0
et	et	NNP	0
al.	al.	NNP	0
,	,	,	0
J.	J.	NNP	B-NP
Pediatr.	Pediatr.	NNP	I-NP
,	,	,	0
109	109	CD	0
:	:	:	0
287-291	287-291	CD	0
(	(	-LRB-	0
1986	1986	CD	0
)	)	-RRB-	0
;	;	:	0
Remis	Remis	NNP	0
,	,	,	0
R.	R.	NNP	0
,	,	,	0
Ann	Ann	NNP	0
.	.	.	0
Intern	Intern	NNP	0
.	.	.	0
Med.	Med.	NNP	B-NP
,	,	,	0
101	101	CD	0
:	:	:	0
624-626	624-626	CD	0
(	(	-LRB-	0
1984	1984	CD	0
)	)	-RRB-	0
;	;	:	0
Riley	Riley	NNP	0
,	,	,	0
L.	L.	NNP	0
et	et	NNP	0
al.	al.	NNP	0
,	,	,	0
N.	N.	NNP	0
Engl	Engl	NNP	0
.	.	.	0
J.	J.	NNP	B-NP
Med.	Med.	NNP	I-NP
,	,	,	0
308	308	CD	0
:	:	:	0
681-685	681-685	CD	0
(	(	-LRB-	0
1983	1983	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
.	.	.	0
EHEC	EHEC	NNP	B-NP
infection	infection	NN	I-NP
can	can	MD	0
be	be	VB	0
deadly	deadly	JJ	0
and	and	CC	0
poses	poses	VBZ	0
a	a	DT	0
significant	significant	JJ	0
threat	threat	NN	0
to	to	TO	0
the	the	DT	0
young	young	JJ	0
and	and	CC	0
the	the	DT	0
elderly	elderly	JJ	0
,	,	,	0
who	who	WP	0
are	are	VBP	0
the	the	DT	0
most	most	RBS	0
likely	likely	JJ	0
to	to	TO	0
develop	develop	VB	0
serious	serious	JJ	B-NP
complication	complication	NN	I-NP
from	from	IN	0
ehec	ehec	NN	B-NP
infection	infection	NN	I-NP
.	.	.	0
Several	Several	JJ	0
outbreaks	outbreaks	NNS	0
and	and	CC	0
hemorrhagic	hemorrhagic	NN	B-NP
colitis	colitis	NN	I-NP
sporadic	sporadic	JJ	I-NP
case	case	NN	I-NP
and	and	CC	0
hemolytic	hemolytic	NN	B-NP
uremic	uremic	NN	I-NP
syndrome	syndrome	NN	I-NP
have	have	VBP	0
occurred	occurred	VBN	0
over	over	IN	0
the	the	DT	0
past	past	JJ	0
few	few	JJ	0
years	years	NNS	0
,	,	,	0
with	with	IN	0
the	the	DT	0
largest	largest	JJS	0
U.S.	U.S.	NNP	0
outbreak	outbreak	NN	0
in	in	IN	0
1993	1993	CD	0
.	.	.	0
In	In	IN	0
that	that	DT	0
outbreak	outbreak	NN	0
,	,	,	0
over	over	IN	0
500	500	CD	0
cases	cases	NNS	0
of	of	IN	0
hemorrhagic	hemorrhagic	NN	B-NP
colitis	colitis	NN	I-NP
and	and	CC	0
hemolytic	hemolytic	NN	B-NP
uremic	uremic	NN	I-NP
syndrome	syndrome	NN	I-NP
were	were	VBD	0
traced	traced	VBN	0
to	to	TO	0
contaminated	contaminated	VB	0
hamburgers	hamburgers	VBN	0
from	from	IN	0
a	a	DT	0
Jack-in-the	Jack-in-the	JJ	B-NP
Box	Box	NNP	I-NP
fast	fast	JJ	0
food	food	NN	B-NP
restaurant	restaurant	NN	I-NP
.	.	.	0
(	(	-LRB-	0
Centers	Centers	NNS	0
for	for	IN	0
Disease	Disease	NNP	B-NP
Control	Control	NNP	I-NP
and	and	CC	0
Prevention	Prevention	NNP	0
,	,	,	0
Morbid	Morbid	NNP	0
.	.	.	0
Mortal	Mortal	NNP	0
.	.	.	0
Weekly	Weekly	NNP	0
Rep.	Rep.	NNP	0
,	,	,	0
42	42	CD	0
:	:	:	0
258	258	CD	0
(	(	-LRB-	0
1993	1993	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
.	.	.	0
In	In	IN	0
July	July	NNP	0
1996	1996	CD	0
,	,	,	0
a	a	DT	0
large	large	JJ	0
outbreak	outbreak	NN	0
of	of	IN	0
enterohemorrhagic	enterohemorrhagic	NN	B-NP
escherichia	escherichia	NN	I-NP
coli	coli	NN	I-NP
in	in	IN	0
Japan	Japan	NNP	0
resulted	resulted	VBD	0
in	in	IN	0
over	over	IN	0
10,000	10,000	CD	0
infected	infected	JJ	0
individuals	individuals	NNS	0
and	and	CC	0
8	8	CD	0
deaths	deaths	NNS	0
.	.	.	0
Many	Many	JJ	0
Japanese	Japanese	JJ	0
children	children	NNS	0
required	required	VBN	B-NP
hospitalization	hospitalization	NN	I-NP
.	.	.	0
Primarily	Primarily	RB	0
,	,	,	0
hemorrhagic	hemorrhagic	NN	B-NP
colitis	colitis	NN	I-NP
and	and	CC	0
hemolytic	hemolytic	NN	B-NP
uremic	uremic	NN	I-NP
syndrome	syndrome	NN	I-NP
are	are	VBP	0
transmitted	transmitted	VBN	0
by	by	IN	0
the	the	DT	0
ingestion	ingestion	NN	B-NP
of	of	IN	0
contaminated	contaminated	JJ	0
food	food	NN	0
,	,	,	0
particularly	particularly	RB	0
undercooked	undercooked	JJ	B-NP
beef	beef	NN	I-NP
product	product	NN	I-NP
,	,	,	0
such	such	JJ	0
as	as	IN	0
hamburger	hamburger	NN	0
.	.	.	0
(	(	-LRB-	0
Doyle	Doyle	FW	0
et	et	FW	0
al.	al.	FW	0
,	,	,	0
J.	J.	NNP	0
Appl	Appl	NNP	0
.	.	.	0
Environ	Environ	NNP	B-NP
.	.	.	0
Microbiol.	Microbiol.	CD	B-NP
53	53	CD	0
:	:	:	0
2394	2394	CD	0
(	(	-LRB-	0
1987	1987	CD	0
)	)	-RRB-	0
;	;	:	0
Samadpour	Samadpour	NN	B-NP
et	et	FW	0
al.	al.	FW	0
,	,	,	0
J	J	NNP	0
Appl	Appl	NNP	0
.	.	.	0
Environ	Environ	NNP	B-NP
.	.	.	0
Microbiol.	Microbiol.	CD	B-NP
60	60	CD	0
:	:	:	0
1038	1038	CD	0
(	(	-LRB-	0
1994	1994	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
.	.	.	0
With	With	IN	0
the	the	DT	0
prevalence	prevalence	NN	0
of	of	IN	0
enterohemorrhagic	enterohemorrhagic	NN	B-NP
escherichia	escherichia	NN	I-NP
coli	coli	NN	I-NP
in	in	IN	0
cattle	cattle	NNS	0
and	and	CC	0
the	the	DT	0
subjective	subjective	JJ	B-NP
nature	nature	NN	I-NP
of	of	IN	0
differentiating	differentiating	VBG	0
between	between	IN	0
cooked	cooked	NN	0
and	and	CC	0
undercooked	undercooked	JJ	B-NP
hamburger	hamburger	NN	I-NP
,	,	,	0
a	a	DT	0
stop	stop	NN	0
at	at	IN	0
a	a	DT	0
fast	fast	JJ	0
food	food	NN	B-NP
restaurant	restaurant	NN	I-NP
or	or	CC	0
a	a	DT	0
family	family	NN	B-NP
barbecue	barbecue	NN	I-NP
can	can	MD	0
result	result	VB	0
in	in	IN	0
tragedy	tragedy	NN	0
.	.	.	0
hemorrhagic	hemorrhagic	NN	B-NP
colitis	colitis	NN	I-NP
and	and	CC	0
hemolytic	hemolytic	NN	B-NP
uremic	uremic	NN	I-NP
syndrome	syndrome	NN	I-NP
appear	appear	VBP	0
to	to	TO	0
be	be	VB	0
mediated	mediated	VBN	0
by	by	IN	0
the	the	DT	0
toxin	toxin	NN	B-NP
produced	produced	VBN	0
by	by	IN	0
enterohemorrhagic	enterohemorrhagic	NN	B-NP
escherichia	escherichia	NN	I-NP
coli	coli	NN	I-NP
and	and	CC	0
Shigella	Shigella	NNP	B-NP
dysenteria	dysenteria	NN	I-NP
(	(	-LRB-	0
for	for	IN	0
a	a	DT	0
review	review	NN	0
,	,	,	0
see	see	VB	0
O	O	NNP	0
'	'	POS	0
Brien	Brien	NNP	0
and	and	CC	0
Holmes	Holmes	NNP	0
,	,	,	0
Microbiol	Microbiol	NNP	B-NP
.	.	.	0
Rev.	Rev.	NNP	B-NP
,	,	,	0
51	51	CD	0
:	:	:	0
206-220	206-220	CD	0
(	(	-LRB-	0
1987	1987	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
.	.	.	0
These	These	DT	0
bacteria	bacteria	NNS	0
produce	produce	VBP	0
a	a	DT	0
family	family	NN	0
of	of	IN	0
closely	closely	RB	0
related	related	VBN	0
cytotoxin	cytotoxin	NN	B-NP
that	that	WDT	0
collectively	collectively	RB	0
will	will	MD	0
be	be	VB	0
called	called	VBN	0
shiga	shiga	NN	B-NP
toxin	toxin	NN	I-NP
for	for	IN	0
the	the	DT	0
purpose	purpose	NN	0
of	of	IN	0
this	this	DT	0
application	application	NN	0
.	.	.	0
shiga	shiga	NN	B-NP
toxin	toxin	NN	I-NP
(	(	-LRB-	0
alternatively	alternatively	RB	0
,	,	,	0
verotoxin	verotoxin	NN	B-NP
)	)	-RRB-	0
have	have	VBP	0
cytotoxic	cytotoxic	VBN	0
,	,	,	0
and	and	CC	0
enterotoxic	enterotoxic	JJ	B-NP
activity	activity	NN	I-NP
(	(	-LRB-	0
Strockbine	Strockbine	NNP	B-NP
,	,	,	0
N.	N.	NNP	0
et	et	NNP	0
al.	al.	NNP	0
,	,	,	0
Infect	Infect	NNP	0
.	.	.	0
Immun.	Immun.	NNP	B-NP
,	,	,	0
53	53	CD	0
:	:	:	0
135-140	135-140	CD	0
(	(	-LRB-	0
1986	1986	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
.	.	.	0
Based	Based	VBN	0
on	on	IN	0
the	the	DT	0
exhibition	exhibition	NN	0
of	of	IN	0
immunological	immunological	JJ	B-NP
non-cross-reactivity	non-cross-reactivity	NN	I-NP
,	,	,	0
the	the	DT	0
shiga	shiga	NN	B-NP
toxin	toxin	NN	I-NP
have	have	VBP	0
been	been	VBN	0
divided	divided	VBN	0
into	into	IN	0
two	two	CD	0
groups	groups	NNS	0
.	.	.	0
(	(	-LRB-	0
Strockbine	Strockbine	NN	B-NP
et	et	FW	0
al.	al.	FW	0
,	,	,	0
supra	supra	CD	0
)	)	-RRB-	0
.	.	.	0
These	These	DT	0
groups	groups	NNS	0
have	have	VBP	0
been	been	VBN	0
designated	designated	VBN	0
Shiga	Shiga	JJ	B-NP
toxin	toxin	NN	I-NP
type	type	NN	I-NP
1	1	CD	0
(	(	-LRB-	0
Stx1	Stx1	NNP	B-NP
)	)	-RRB-	0
and	and	CC	0
Shiga	Shiga	NNP	B-NP
toxin	toxin	NN	I-NP
type	type	NN	I-NP
2	2	CD	0
(	(	-LRB-	0
Stx2	Stx2	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
Stx1	Stx1	JJ	B-NP
group	group	NN	I-NP
contains	contains	VBZ	0
the	the	DT	0
prototype	prototype	NN	B-NP
Stx1	Stx1	CD	I-NP
toxin	toxin	NN	I-NP
from	from	IN	0
enterohemorrhagic	enterohemorrhagic	NN	B-NP
escherichia	escherichia	NN	I-NP
coli	coli	NN	I-NP
as	as	IN	0
well	well	RB	0
as	as	IN	0
the	the	DT	0
Shiga	Shiga	JJ	B-NP
toxin	toxin	NN	I-NP
from	from	IN	0
Shigella	Shigella	NNP	B-NP
dysenteriae	dysenteriae	JJ	I-NP
type	type	NN	I-NP
1	1	CD	0
.	.	.	0
In	In	IN	0
recent	recent	JJ	0
years	years	NNS	0
,	,	,	0
other	other	JJ	0
types	types	NNS	0
of	of	IN	0
toxins	toxins	NNS	0
have	have	VBP	0
been	been	VBN	0
discovered	discovered	VBN	0
and	and	CC	0
considered	considered	VBN	0
to	to	TO	0
be	be	VB	0
members	members	NNS	0
of	of	IN	0
the	the	DT	0
Stx2	Stx2	JJ	B-NP
group	group	NN	I-NP
.	.	.	0
These	These	DT	0
are	are	VBP	0
Stx2e	Stx2e	RB	0
,	,	,	0
Stx2c	Stx2c	NNP	0
,	,	,	0
and	and	CC	0
Stx2d	Stx2d	NNP	0
.	.	.	0
(	(	-LRB-	0
Lindgren	Lindgren	FW	0
et	et	FW	0
al.	al.	FW	0
,	,	,	0
Infection	Infection	NNP	B-NP
and	and	CC	0
Immunology	Immunology	NNP	B-NP
,	,	,	0
61	61	CD	0
:	:	:	0
3832	3832	CD	0
(	(	-LRB-	0
1993	1993	CD	0
)	)	-RRB-	0
;	;	:	0
Schmitt	Schmitt	NNP	0
,	,	,	0
C.	C.	NNP	0
et	et	NNP	0
al.	al.	NNP	0
,	,	,	0
Infect	Infect	NNP	0
.	.	.	0
Immun.	Immun.	NNP	B-NP
,	,	,	0
59	59	CD	0
:	:	:	0
1065-1073	1065-1073	CD	0
(	(	-LRB-	0
1991	1991	CD	0
)	)	-RRB-	0
;	;	:	0
Marques	Marques	NNP	0
,	,	,	0
L.	L.	NNP	0
et	et	NNP	0
al.	al.	NNP	0
,	,	,	0
fem	fem	NN	B-NP
Lett.	Lett.	NNP	0
,	,	,	0
44	44	CD	0
:	:	:	0
33-38	33-38	CD	0
(	(	-LRB-	0
1987	1987	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
.	.	.	0
For	For	IN	0
the	the	DT	0
purposes	purposes	NNS	0
of	of	IN	0
this	this	DT	0
application	application	NN	0
the	the	DT	0
term	term	NN	B-NP
Shiga	Shiga	NN	I-NP
toxin	toxin	NN	I-NP
encompasses	encompasses	FW	0
Shiga	Shiga	NN	B-NP
toxin	toxin	NN	I-NP
and	and	CC	0
any	any	DT	0
other	other	JJ	0
toxins	toxins	NN	0
in	in	IN	0
the	the	DT	0
Stx1	Stx1	NNP	B-NP
or	or	CC	0
Stx2	Stx2	CD	B-NP
group	group	NN	I-NP
or	or	CC	0
their	their	PRP$	0
variants	variants	NN	0
.	.	.	0
The	The	DT	0
abbreviation	abbreviation	JJ	B-NP
Stx	Stx	NNP	I-NP
will	will	MD	0
refer	refer	VB	0
to	to	TO	0
the	the	DT	0
toxin	toxin	NN	B-NP
protein	protein	NN	I-NP
itself	itself	PRP	0
.	.	.	0
Despite	Despite	IN	0
this	this	DT	0
knowledge	knowledge	NN	0
about	about	IN	0
the	the	DT	0
results	results	NNS	0
of	of	IN	0
exposure	exposure	NN	0
to	to	TO	0
these	these	DT	0
toxins	toxins	NN	0
,	,	,	0
currently	currently	RB	0
there	there	EX	0
is	is	VBZ	0
no	no	DT	0
known	known	JJ	0
cure	cure	NN	0
or	or	CC	0
vaccine	vaccine	NN	0
for	for	IN	0
hemorrhagic	hemorrhagic	NN	B-NP
colitis	colitis	NN	I-NP
or	or	CC	0
hemolytic	hemolytic	NN	B-NP
uremic	uremic	NN	I-NP
syndrome	syndrome	NN	I-NP
.	.	.	0
Antibiotics	Antibiotics	NNP	0
may	may	MD	0
even	even	RB	0
make	make	VB	0
the	the	DT	0
severe	severe	JJ	0
complication	complication	NN	B-NP
worse	worse	JJR	0
by	by	IN	0
increasing	increasing	VBG	B-NP
toxin	toxin	NN	I-NP
release	release	NN	I-NP
from	from	IN	0
bacteria	bacteria	NNS	0
.	.	.	0
Thus	Thus	RB	0
,	,	,	0
there	there	EX	0
is	is	VBZ	0
a	a	DT	0
need	need	NN	0
for	for	IN	0
a	a	DT	0
compound	compound	NN	B-NP
to	to	TO	0
prevent	prevent	VB	0
or	or	CC	0
to	to	TO	0
treat	treat	VB	0
the	the	DT	0
enterohemorrhagic	enterohemorrhagic	NN	B-NP
escherichia	escherichia	NN	I-NP
coli	coli	NN	I-NP
complication	complication	NN	I-NP
produced	produced	VBD	0
by	by	IN	0
Shiga	Shiga	NNP	B-NP
toxin	toxin	NN	I-NP
.	.	.	0
Such	Such	PDT	0
a	a	DT	0
compound	compound	NN	B-NP
could	could	MD	0
be	be	VB	0
used	used	VBN	0
to	to	TO	0
treat	treat	VB	0
infected	infected	JJ	0
patients	patients	NNS	0
and	and	CC	0
decrease	decrease	VB	0
the	the	DT	0
toxin	toxin	NN	B-NP
systemic	systemic	JJ	I-NP
effect	effect	NN	I-NP
on	on	IN	0
the	the	DT	0
cn	cn	NN	B-NP
,	,	,	0
blood	blood	NN	0
and	and	CC	0
kidneys	kidneys	NN	0
.	.	.	0
In	In	IN	0
addition	addition	NN	B-NP
,	,	,	0
if	if	IN	0
the	the	DT	0
toxin	toxin	NN	B-NP
could	could	MD	0
be	be	VB	0
neutralized	neutralized	NNS	0
,	,	,	0
antibiotics	antibiotics	NNS	0
could	could	MD	0
be	be	VB	0
safely	safely	RB	0
given	given	VBN	0
to	to	TO	0
kill	kill	VB	0
the	the	DT	0
bacteria	bacteria	NNS	0
in	in	IN	0
the	the	DT	0
GI	GI	NNP	B-NP
tract	tract	NN	I-NP
.	.	.	0
Such	Such	PDT	0
a	a	DT	0
compound	compound	NN	B-NP
could	could	MD	0
also	also	RB	0
be	be	VB	0
used	used	VBN	0
to	to	TO	0
prevent	prevent	VB	0
infectious	infectious	JJ	B-NP
complication	complication	NN	I-NP
,	,	,	0
by	by	IN	0
treating	treating	VBG	0
exposed	exposed	VBN	0
or	or	CC	0
high	high	JJ	0
risk	risk	NN	B-NP
individual	individual	JJ	I-NP
before	before	IN	0
they	they	PRP	0
acquire	acquire	VB	0
EHEC	EHEC	JJ	B-NP
infection	infection	NN	I-NP
.	.	.	0
Such	Such	JJ	0
individuals	individuals	NNS	0
would	would	MD	0
include	include	VB	0
children	children	NNS	0
in	in	IN	0
day	day	NN	0
care	care	NN	0
or	or	CC	0
the	the	DT	0
elderly	elderly	JJ	0
in	in	IN	0
nursing	nursing	NN	B-NP
home	home	NN	I-NP
,	,	,	0
where	where	WRB	0
a	a	DT	0
case	case	NN	0
of	of	IN	0
EHEC	EHEC	NNP	B-NP
diarrhea	diarrhea	NN	I-NP
has	has	VBZ	0
been	been	VBN	0
detected	detected	VBN	0
.	.	.	0
These	These	DT	0
individuals	individuals	NNS	0
are	are	VBP	0
at	at	IN	0
increased	increased	JJ	0
risk	risk	NN	0
to	to	TO	0
develop	develop	VB	0
severe	severe	JJ	0
complication	complication	NN	B-NP
and	and	CC	0
spread	spread	NN	0
of	of	IN	0
enterohemorrhagic	enterohemorrhagic	NN	B-NP
escherichia	escherichia	NN	I-NP
coli	coli	NN	I-NP
in	in	IN	0
these	these	DT	0
environments	environments	NN	0
is	is	VBZ	0
not	not	RB	0
unusual	unusual	JJ	0
.	.	.	0
The	The	DT	0
knowledge	knowledge	NN	0
of	of	IN	0
the	the	DT	0
immunological	immunological	NN	B-NP
cross	cross	VBP	0
reactivity	reactivity	VBN	0
of	of	IN	0
the	the	DT	0
shiga	shiga	NN	B-NP
toxin	toxin	NN	I-NP
offers	offers	VBZ	0
a	a	DT	0
tantalizing	tantalizing	JJ	0
prospect	prospect	NN	0
for	for	IN	0
pharmacological	pharmacological	JJ	B-NP
approach	approach	NN	I-NP
to	to	TO	0
EHEC	EHEC	NNP	B-NP
treatment	treatment	NN	I-NP
.	.	.	0
Currently	Currently	RB	0
,	,	,	0
there	there	EX	0
are	are	VBP	0
no	no	RB	0
known	known	VBN	0
prophylactic	prophylactic	NNS	0
or	or	CC	0
therapeutic	therapeutic	JJ	B-NP
agent	agent	NN	I-NP
available	available	JJ	0
for	for	IN	0
this	this	DT	0
disease	disease	NN	0
.	.	.	0
Accordingly	Accordingly	RB	0
,	,	,	0
there	there	EX	0
is	is	VBZ	0
a	a	DT	0
need	need	NN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
to	to	TO	0
provide	provide	VB	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
that	that	WDT	0
can	can	MD	0
bind	bind	VB	0
to	to	TO	0
shiga	shiga	NN	B-NP
toxin	toxin	NN	I-NP
which	which	WDT	0
could	could	MD	0
prevent	prevent	VB	0
or	or	CC	0
lessen	lessen	VB	0
the	the	DT	0
devastating	devastating	JJ	0
effects	effects	NNS	0
of	of	IN	0
these	these	DT	0
toxins	toxins	NN	0
.	.	.	0
There	There	EX	0
is	is	VBZ	0
also	also	RB	0
a	a	DT	0
need	need	NN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
for	for	IN	0
data	data	NNS	0
concerning	concerning	VBG	0
the	the	DT	0
binding	binding	JJ	0
site	site	NN	0
of	of	IN	0
such	such	JJ	0
antibody	antibody	NN	B-NP
so	so	RB	0
that	that	IN	0
other	other	JJ	0
antibody	antibody	NN	B-NP
with	with	IN	0
similar	similar	JJ	0
abilities	abilities	NNS	0
can	can	MD	0
be	be	VB	0
identified	identified	VBN	0
and	and	CC	0
isolated	isolated	VBN	0
.	.	.	0
There	There	EX	0
is	is	VBZ	0
a	a	DT	0
related	related	JJ	0
need	need	NN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
for	for	IN	0
humanized	humanized	NN	0
or	or	CC	0
other	other	JJ	0
chimeric	chimeric	NN	B-NP
human/mouse	human/mouse	NN	I-NP
monoclonal	monoclonal	JJ	I-NP
antibody	antibody	NN	I-NP
.	.	.	0
In	In	IN	0
well	well	RB	0
publicized	publicized	VBN	B-NP
study	study	NN	I-NP
,	,	,	0
patients	patients	FW	0
administered	administered	VBN	B-NP
murine	murine	NN	I-NP
anti-TNF	anti-TNF	NN	I-NP
(	(	-LRB-	0
tumor	tumor	NN	B-NP
necrosis	necrosis	NN	I-NP
factor	factor	NN	I-NP
)	)	-RRB-	0
developed	developed	VBD	B-NP
anti-murine	anti-murine	JJ	I-NP
antibody	antibody	NN	I-NP
response	response	NN	I-NP
monoclonal	monoclonal	JJ	I-NP
antibody	antibody	NN	I-NP
to	to	TO	0
the	the	DT	0
administered	administered	JJ	0
antibody	antibody	NN	B-NP
.	.	.	0
(	(	-LRB-	0
See	See	VB	0
,	,	,	0
e.g.	e.g.	NNP	0
,	,	,	0
Exley	Exley	NNP	0
A.	A.	NNP	0
R.	R.	NNP	0
,	,	,	0
et	et	FW	0
al.	al.	FW	0
,	,	,	0
Lancet	Lancet	NNP	0
335	335	CD	0
:	:	:	0
1275-1277	1275-1277	CD	0
(	(	-LRB-	0
1990	1990	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
.	.	.	0
This	This	DT	0
type	type	NN	0
of	of	IN	0
immune	immune	JJ	0
response	response	NN	0
to	to	TO	0
the	the	DT	0
treatment	treatment	NN	B-NP
regimen	regimen	NN	I-NP
,	,	,	0
commonly	commonly	RB	0
referred	referred	VBN	0
to	to	TO	0
as	as	IN	0
the	the	DT	0
HAMA	HAMA	NNP	B-NP
response	response	NN	I-NP
(	(	-LRB-	0
for	for	IN	0
human	human	JJ	0
anti-mouse	anti-mouse	JJ	B-NP
antibody	antibody	NN	I-NP
)	)	-RRB-	0
,	,	,	0
decreases	decreases	VBZ	0
the	the	DT	0
effectiveness	effectiveness	NN	0
of	of	IN	0
the	the	DT	0
treatment	treatment	NN	0
and	and	CC	0
may	may	MD	0
even	even	RB	0
render	render	VB	0
the	the	DT	0
treatment	treatment	NN	0
completely	completely	RB	0
ineffective	ineffective	JJ	0
.	.	.	0
Humanized	Humanized	NNP	0
or	or	CC	0
chimeric	chimeric	JJ	B-NP
human/mouse	human/mouse	NN	I-NP
monoclonal	monoclonal	NN	I-NP
antibody	antibody	NN	I-NP
have	have	VBP	0
been	been	VBN	0
shown	shown	VBN	0
to	to	TO	0
significantly	significantly	RB	0
decrease	decrease	VB	0
the	the	DT	0
HAMA	HAMA	NNP	B-NP
response	response	NN	I-NP
and	and	CC	0
to	to	TO	0
increase	increase	VB	0
the	the	DT	0
therapeutic	therapeutic	JJ	B-NP
effectiveness	effectiveness	NN	I-NP
.	.	.	0
(	(	-LRB-	0
LoBuglio	LoBuglio	NN	B-NP
et	et	FW	0
al.	al.	FW	0
,	,	,	0
P.N.A.S.	P.N.A.S.	CD	B-NP
86	86	CD	0
:	:	:	0
4220-4224	4220-4224	CD	0
(	(	-LRB-	0
June	June	NNP	0
1989	1989	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
.	.	.	0
To	To	TO	0
satisfy	satisfy	VB	0
these	these	DT	0
needs	needs	NNS	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
,	,	,	0
applicants	applicants	NNS	0
provide	provide	VBP	0
humanized	humanized	JJ	0
mouse	mouse	NN	0
monoclonal	monoclonal	NN	B-NP
antibody	antibody	NN	I-NP
to	to	TO	0
Shiga	Shiga	NNP	B-NP
toxin	toxin	NN	I-NP
1	1	CD	0
and	and	CC	0
Shiga	Shiga	NNP	B-NP
toxin	toxin	NN	I-NP
2	2	CD	0
.	.	.	0
In	In	IN	0
addition	addition	NN	B-NP
,	,	,	0
this	this	DT	0
invention	invention	NN	0
sets	sets	VBZ	0
forth	forth	RB	0
the	the	DT	0
variable	variable	JJ	0
region	region	NN	0
associated	associated	VBN	0
with	with	IN	0
Shiga	Shiga	NNP	B-NP
toxin	toxin	NN	I-NP
neutralization	neutralization	NN	I-NP
as	as	IN	0
well	well	RB	0
as	as	IN	0
the	the	DT	0
specific	specific	JJ	0
determining	determining	VBG	B-NP
region	region	NN	I-NP
complementarity	complementarity	NNS	I-NP
(	(	-LRB-	0
CDRs	CDRs	NNP	B-NP
)	)	-RRB-	0
of	of	IN	0
the	the	DT	0
variable	variable	JJ	0
region	region	NN	0
.	.	.	0
The	The	DT	0
present	present	JJ	0
invention	invention	NN	0
particularly	particularly	RB	0
provides	provides	VBZ	0
human	human	JJ	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
,	,	,	0
derived	derived	VBN	0
from	from	IN	0
the	the	DT	0
mouse	mouse	FW	0
13c4	13c4	NN	B-NP
monoclonal	monoclonal	JJ	I-NP
antibody	antibody	NN	I-NP
and	and	CC	0
11E10	11E10	NNP	B-NP
,	,	,	0
which	which	WDT	0
are	are	VBP	0
specifically	specifically	RB	0
reactive	reactive	VBN	0
with	with	IN	0
Stx1	Stx1	NNP	B-NP
and	and	CC	0
Stx2	Stx2	NNP	B-NP
,	,	,	0
respectively	respectively	RB	0
.	.	.	0
In	In	IN	0
another	another	DT	0
aspect	aspect	NN	B-NP
,	,	,	0
the	the	DT	0
invention	invention	NN	0
includes	includes	VBZ	0
a	a	DT	0
pharmaceutical	pharmaceutical	JJ	B-NP
composition	composition	NN	I-NP
and	and	CC	0
a	a	DT	0
method	method	NN	0
of	of	IN	0
treatment	treatment	NN	0
with	with	IN	0
such	such	JJ	0
composition	composition	NN	0
which	which	WDT	0
will	will	MD	0
prevent	prevent	VB	0
or	or	CC	0
treat	treat	VB	0
Shiga	Shiga	JJ	B-NP
toxin	toxin	NN	I-NP
induced	induced	NN	I-NP
disease	disease	NN	I-NP
.	.	.	0
It	It	PRP	0
is	is	VBZ	0
to	to	TO	0
be	be	VB	0
understood	understood	VBN	0
that	that	IN	0
both	both	PDT	0
the	the	DT	0
foregoing	foregoing	JJ	0
general	general	JJ	0
description	description	NN	0
and	and	CC	0
the	the	DT	0
following	following	JJ	0
detailed	detailed	JJ	0
description	description	NNS	0
are	are	VBP	0
exemplary	exemplary	JJ	0
and	and	CC	0
explanatory	explanatory	JJ	0
and	and	CC	0
are	are	VBP	0
intended	intended	VBN	0
to	to	TO	0
provide	provide	VB	0
further	further	JJ	0
explanation	explanation	NN	0
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
as	as	IN	0
claimed	claimed	VBN	0
.	.	.	0
The	The	DT	0
accompanying	accompanying	JJ	0
drawings	drawings	NNS	0
are	are	VBP	0
included	included	VBN	0
to	to	TO	0
provide	provide	VB	0
a	a	DT	0
further	further	JJ	0
understanding	understanding	NN	0
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
and	and	CC	0
are	are	VBP	0
incorporated	incorporated	VBN	0
in	in	IN	0
and	and	CC	0
constitute	constitute	VB	0
a	a	DT	0
part	part	NN	0
of	of	IN	0
this	this	DT	0
specification	specification	NN	B-NP
.	.	.	0
They	They	PRP	0
illustrate	illustrate	VBP	0
several	several	JJ	0
embodiments	embodiments	NN	0
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
and	and	CC	0
,	,	,	0
together	together	RB	0
with	with	IN	0
the	the	DT	0
description	description	NN	0
,	,	,	0
serve	serve	VBP	0
to	to	TO	0
explain	explain	VB	0
the	the	DT	0
principles	principles	NNS	0
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
.	.	.	0
FIG.	FIG.	CD	0
1	1	CD	0
provides	provides	VBZ	0
a	a	DT	0
schematic	schematic	JJ	B-NP
representation	representation	NN	I-NP
of	of	IN	0
the	the	DT	0
general	general	JJ	0
cloning	cloning	JJ	B-NP
strategy	strategy	NN	I-NP
used	used	VBN	0
for	for	IN	0
cloning	cloning	VBG	0
the	the	DT	0
variable	variable	JJ	0
region	region	NN	0
gene	gene	NN	0
fragments	fragments	NNS	0
of	of	IN	0
both	both	PDT	0
the	the	DT	0
11E10	11E10	NNP	B-NP
and	and	CC	0
13c4	13c4	NN	B-NP
antibody	antibody	NN	I-NP
.	.	.	0
FIG.	FIG.	CD	0
2	2	CD	0
lists	lists	NNS	0
the	the	DT	0
oligonucleotide	oligonucleotide	JJ	B-NP
sequence	sequence	NN	I-NP
used	used	VBN	0
for	for	IN	0
PCR	PCR	NNP	B-NP
amplification	amplification	NN	I-NP
of	of	IN	0
the	the	DT	0
variable	variable	JJ	0
regions	regions	NNS	0
of	of	IN	0
the	the	DT	0
13C4	13C4	JJ	B-NP
antibody	antibody	NN	I-NP
.	.	.	0
FIG.	FIG.	CD	0
3	3	CD	0
recites	recites	CD	0
the	the	DT	0
DNA	DNA	NN	B-NP
and	and	CC	0
amino	amino	JJ	0
acid	acid	NN	B-NP
consensus	consensus	NN	I-NP
sequence	sequence	NN	I-NP
for	for	IN	0
the	the	DT	0
variable	variable	JJ	0
regions	regions	NNS	0
of	of	IN	0
both	both	PDT	0
the	the	DT	0
heavy	heavy	JJ	0
and	and	CC	0
light	light	JJ	0
chains	chains	NNS	0
of	of	IN	0
the	the	DT	0
13C4	13C4	JJ	B-NP
antibody	antibody	NN	I-NP
.	.	.	0
The	The	DT	0
DNA	DNA	NN	B-NP
consensus	consensus	NN	I-NP
sequence	sequence	NN	I-NP
was	was	VBD	0
determined	determined	VBN	0
using	using	VBG	0
automated	automated	JJ	0
fluorescent	fluorescent	JJ	0
dye-terminator	dye-terminator	JJ	B-NP
sequence	sequence	NN	I-NP
reaction	reaction	NN	I-NP
of	of	IN	0
the	the	DT	0
amplified	amplified	JJ	0
cDNAs	cDNAs	JJ	B-NP
analyzed	analyzed	NN	I-NP
with	with	IN	0
an	an	DT	0
ABI	ABI	NNP	B-NP
373	373	CD	0
sequencing	sequencing	JJ	B-NP
instrument	instrument	NN	I-NP
.	.	.	0
The	The	DT	0
complementarity	complementarity	NN	B-NP
determining	determining	VBG	I-NP
region	region	NN	I-NP
were	were	VBD	0
identified	identified	VBN	0
according	according	VBG	0
to	to	TO	0
the	the	DT	0
nomenclature	nomenclature	NN	0
of	of	IN	0
Kabat	Kabat	NNP	0
and	and	CC	0
Wu	Wu	NNP	0
(	(	-LRB-	0
Kabat	Kabat	NNP	0
,	,	,	0
et	et	FW	0
al.	al.	FW	0
(	(	-LRB-	0
1991	1991	CD	0
)	)	-RRB-	0
,	,	,	0
Sequences	Sequences	NNP	0
of	of	IN	0
Proteins	Proteins	NNPS	0
of	of	IN	0
Immunological	Immunological	NNP	B-NP
Interest	Interest	NNP	I-NP
,	,	,	0
Vol	Vol	NNP	B-NP
.	.	.	0
I	I	PRP	0
,	,	,	0
5th	5th	JJ	B-NP
edition	edition	NN	I-NP
,	,	,	0
U.S.	U.S.	NNP	0
Department	Department	NNP	0
of	of	IN	0
Health	Health	NNP	0
and	and	CC	0
Human	Human	NNP	0
Services	Services	NNPS	0
)	)	-RRB-	0
and	and	CC	0
are	are	VBP	0
located	located	VBN	0
as	as	RB	0
follows	follows	VBZ	0
:	:	:	0
Heavy	Heavy	NNP	0
chain	chain	NN	B-NP
cdr	cdr	NN	I-NP
:	:	:	0
CDR1-aa31-35	CDR1-aa31-35	CD	B-NP
(	(	-LRB-	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
19	19	CD	0
)	)	-RRB-	0
CDR2-aa50-66	CDR2-aa50-66	NNP	B-NP
CDR3-aa99-111	CDR3-aa99-111	NNP	I-NP
Light	Light	NNP	0
chain	chain	NN	B-NP
cdr	cdr	NN	I-NP
:	:	:	0
CDR1-aa24-34	CDR1-aa24-34	CD	B-NP
(	(	-LRB-	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
21	21	CD	0
)	)	-RRB-	0
CDR2-aa50-56	CDR2-aa50-56	NN	B-NP
CDR3-aa89-97	CDR3-aa89-97	NN	I-NP
FIG.	FIG.	CD	0
4	4	CD	0
illustrates	illustrates	VBZ	0
the	the	DT	0
strategy	strategy	NN	0
for	for	IN	0
mammalian	mammalian	JJ	B-NP
expression	expression	NN	I-NP
vector	vector	NNS	I-NP
construction	construction	NN	I-NP
tKMC249A	tKMC249A	VBP	0
containing	containing	VBG	0
the	the	DT	0
variable	variable	JJ	0
regions	regions	NNS	0
of	of	IN	0
the	the	DT	0
13C4	13C4	JJ	B-NP
antibody	antibody	NN	I-NP
.	.	.	0
FIG.	FIG.	CD	0
5	5	CD	0
lists	lists	NNS	0
the	the	DT	0
oligonucleotide	oligonucleotide	NN	B-NP
used	used	VBN	0
for	for	IN	0
PCR	PCR	NNP	B-NP
amplification	amplification	NN	I-NP
of	of	IN	0
the	the	DT	0
variable	variable	JJ	0
regions	regions	NNS	0
of	of	IN	0
the	the	DT	0
11E10	11E10	JJ	B-NP
antibody	antibody	NN	I-NP
.	.	.	0
FIG.	FIG.	CD	0
6	6	CD	0
recites	recites	CD	0
the	the	DT	0
DNA	DNA	NN	B-NP
and	and	CC	0
amino	amino	JJ	0
acid	acid	NN	B-NP
consensus	consensus	NN	I-NP
sequence	sequence	NN	I-NP
for	for	IN	0
the	the	DT	0
variable	variable	JJ	0
regions	regions	NNS	0
of	of	IN	0
both	both	PDT	0
the	the	DT	0
heavy	heavy	JJ	0
and	and	CC	0
light	light	JJ	0
chains	chains	NNS	0
of	of	IN	0
the	the	DT	0
11E10	11E10	JJ	B-NP
antibody	antibody	NN	I-NP
.	.	.	0
The	The	DT	0
DNA	DNA	NN	B-NP
consensus	consensus	NN	I-NP
sequence	sequence	NN	I-NP
was	was	VBD	0
determined	determined	VBN	0
using	using	VBG	0
automated	automated	JJ	0
fluorescent	fluorescent	JJ	0
dye-terminator	dye-terminator	JJ	B-NP
sequence	sequence	NN	I-NP
reaction	reaction	NN	I-NP
of	of	IN	0
the	the	DT	0
amplified	amplified	JJ	0
cDNAs	cDNAs	JJ	B-NP
analyzed	analyzed	NN	I-NP
with	with	IN	0
an	an	DT	0
ABI	ABI	NNP	B-NP
373	373	CD	0
sequencing	sequencing	JJ	B-NP
instrument	instrument	NN	I-NP
.	.	.	0
The	The	DT	0
complementarity	complementarity	NN	B-NP
determining	determining	VBG	I-NP
region	region	NN	I-NP
were	were	VBD	0
identified	identified	VBN	0
according	according	VBG	0
to	to	TO	0
the	the	DT	0
nomenclature	nomenclature	NN	0
of	of	IN	0
Kabat	Kabat	NNP	0
and	and	CC	0
Wu	Wu	NNP	0
(	(	-LRB-	0
Kabat	Kabat	NNP	0
and	and	CC	0
Wu	Wu	NNP	0
;	;	:	0
supra	supra	LS	0
)	)	-RRB-	0
and	and	CC	0
are	are	VBP	0
located	located	VBN	0
as	as	RB	0
follows	follows	VBZ	0
:	:	:	0
Heavy	Heavy	NNP	0
chain	chain	NN	B-NP
cdr	cdr	NN	I-NP
:	:	:	0
CDR1-aa31-35	CDR1-aa31-35	CD	B-NP
(	(	-LRB-	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
44	44	CD	0
)	)	-RRB-	0
CDR2-aa50-66	CDR2-aa50-66	NNP	B-NP
CDR3-aa99-108	CDR3-aa99-108	NNP	I-NP
Light	Light	NNP	0
chain	chain	NN	B-NP
cdr	cdr	NN	I-NP
:	:	:	0
CDR1-aa24-40	CDR1-aa24-40	CD	B-NP
(	(	-LRB-	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
42	42	CD	0
)	)	-RRB-	0
CDR2-aa56-62	CDR2-aa56-62	NN	B-NP
CDR3-aa95-103	CDR3-aa95-103	NN	I-NP
FIG.	FIG.	CD	0
7	7	CD	0
illustrates	illustrates	VBZ	0
the	the	DT	0
strategy	strategy	NN	0
for	for	IN	0
mammalian	mammalian	JJ	B-NP
expression	expression	NN	I-NP
vector	vector	NNS	I-NP
construction	construction	NN	I-NP
pACE4	pACE4	VBP	0
containing	containing	VBG	0
the	the	DT	0
variable	variable	JJ	0
regions	regions	NNS	0
of	of	IN	0
the	the	DT	0
11E10	11E10	JJ	B-NP
antibody	antibody	NN	I-NP
.	.	.	0
FIG.	FIG.	CD	0
8	8	CD	0
shows	shows	NNS	0
the	the	DT	0
anti-Stx1	anti-Stx1	CD	B-NP
13C4	13C4	CD	I-NP
antibody	antibody	NN	I-NP
production	production	NN	I-NP
ELISA	ELISA	NNP	I-NP
and	and	CC	0
demonstrates	demonstrates	VBZ	0
that	that	IN	0
the	the	DT	0
H13C4	H13C4	JJ	0
cell	cell	NN	0
line	line	NN	0
produces	produces	VBZ	0
an	an	DT	0
antibody	antibody	NN	B-NP
consisting	consisting	VBG	0
of	of	IN	0
human	human	JJ	0
IgG	IgG	JJ	0
and	and	CC	0
kappa	kappa	JJ	B-NP
constant	constant	JJ	0
domains	domains	NN	0
.	.	.	0
FIG.	FIG.	CD	0
9	9	CD	0
shows	shows	NNS	0
the	the	DT	0
anti-Stx1	anti-Stx1	CD	B-NP
13C4	13C4	CD	I-NP
toxin	toxin	NN	I-NP
binding	binding	JJ	0
activity	activity	NN	B-NP
ELISA	ELISA	NNP	I-NP
and	and	CC	0
demonstrates	demonstrates	VBZ	0
that	that	IN	0
the	the	DT	0
antibody	antibody	NN	B-NP
produced	produced	VBN	0
by	by	IN	0
the	the	DT	0
H13C4	H13C4	JJ	0
cell	cell	NN	0
line	line	NN	0
binds	binds	NN	0
to	to	TO	0
Stx1	Stx1	CD	B-NP
toxin	toxin	NN	I-NP
.	.	.	0
FIG.	FIG.	CD	0
10	10	CD	0
shows	shows	NNS	0
the	the	DT	0
anti-Stx2	anti-Stx2	CD	B-NP
11E10	11E10	CD	I-NP
antibody	antibody	NN	I-NP
production	production	NN	I-NP
ELISA	ELISA	NNP	I-NP
and	and	CC	0
demonstrates	demonstrates	VBZ	0
that	that	IN	0
the	the	DT	0
H11E10	H11E10	JJ	0
cell	cell	NN	0
line	line	NN	0
produces	produces	VBZ	0
an	an	DT	0
antibody	antibody	NN	B-NP
consisting	consisting	VBG	0
of	of	IN	0
human	human	JJ	0
IgG	IgG	JJ	0
and	and	CC	0
kappa	kappa	JJ	B-NP
constant	constant	JJ	0
domains	domains	NN	0
.	.	.	0
FIG.	FIG.	CD	0
11	11	CD	0
shows	shows	NNS	0
the	the	DT	0
anti-Stx2	anti-Stx2	CD	B-NP
11E10	11E10	CD	I-NP
toxin	toxin	NN	I-NP
binding	binding	JJ	0
activity	activity	NN	B-NP
ELISA	ELISA	NNP	I-NP
and	and	CC	0
demonstrates	demonstrates	VBZ	0
that	that	IN	0
the	the	DT	0
antibody	antibody	NN	B-NP
produced	produced	VBN	0
by	by	IN	0
the	the	DT	0
H11E10	H11E10	JJ	0
cell	cell	NN	0
line	line	NN	0
binds	binds	NN	0
to	to	TO	0
Stx2	Stx2	CD	B-NP
toxin	toxin	NN	I-NP
.	.	.	0
FIG.	FIG.	CD	0
12	12	CD	0
illustrates	illustrates	VBZ	0
the	the	DT	0
strategy	strategy	NN	0
for	for	IN	0
construction	construction	NN	B-NP
of	of	IN	0
the	the	DT	0
plasmid	plasmid	JJ	0
pCDNA3mut.LCPL.LCVK	pCDNA3mut.LCPL.LCVK	NN	0
.	.	.	0
FIG.	FIG.	CD	0
13	13	CD	0
illustrates	illustrates	VBZ	0
the	the	DT	0
strategy	strategy	NN	0
for	for	IN	0
construction	construction	NN	B-NP
of	of	IN	0
the	the	DT	0
plasmid	plasmid	JJ	0
pCDNA3mut.HCPL.HCV2b	pCDNA3mut.HCPL.HCV2b	NN	0
.	.	.	0
FIG.	FIG.	CD	0
14	14	CD	0
illustrates	illustrates	VBZ	0
the	the	DT	0
strategy	strategy	NN	0
for	for	IN	0
plasmids	plasmids	JJ	B-NP
psun9	psun9	NN	I-NP
construction	construction	NN	I-NP
and	and	CC	0
pSUN9	pSUN9	NNP	B-NP
:	:	:	0
kappa	kappa	CD	B-NP
.	.	.	0
FIG.	FIG.	CD	0
15	15	CD	0
illustrates	illustrates	VBZ	0
the	the	DT	0
strategy	strategy	NN	0
for	for	IN	0
plasmids	plasmids	JJ	B-NP
psun10	psun10	NN	I-NP
construction	construction	NN	I-NP
and	and	CC	0
pSUN10	pSUN10	NNP	B-NP
:	:	:	0
IgG1	IgG1	CD	B-NP
.	.	.	0
FIG.	FIG.	CD	0
16	16	CD	0
illustrates	illustrates	VBZ	0
the	the	DT	0
strategy	strategy	NN	0
for	for	IN	0
plasmid	plasmid	JJ	B-NP
pjrs311	pjrs311	NN	I-NP
construction	construction	NN	I-NP
.	.	.	0
FIG.	FIG.	CD	0
17	17	CD	0
illustrates	illustrates	VBZ	0
the	the	DT	0
strategy	strategy	NN	0
for	for	IN	0
plasmid	plasmid	JJ	B-NP
pjrs315	pjrs315	NN	I-NP
construction	construction	NN	I-NP
.	.	.	0
additional	additional	JJ	B-NP
feature	feature	NN	I-NP
and	and	CC	0
advantages	advantages	NNS	0
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
will	will	MD	0
be	be	VB	0
set	set	VBN	0
forth	forth	RB	0
in	in	IN	0
the	the	DT	0
description	description	NN	0
which	which	WDT	0
follows	follows	VBZ	0
.	.	.	0
The	The	DT	0
objectives	objectives	NNS	0
and	and	CC	0
other	other	JJ	0
advantages	advantages	NNS	0
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
will	will	MD	0
be	be	VB	0
realized	realized	VBN	0
and	and	CC	0
attained	attained	VBN	0
by	by	IN	0
the	the	DT	0
composition	composition	NN	0
of	of	IN	0
matter	matter	NN	0
and	and	CC	0
process	process	NN	0
particularly	particularly	RB	0
pointed	pointed	VBD	0
out	out	RP	0
in	in	IN	0
the	the	DT	0
written	written	JJ	0
description	description	NN	0
and	and	CC	0
the	the	DT	0
claims	claims	NNS	0
hereof	hereof	VBP	0
as	as	RB	0
well	well	RB	0
as	as	IN	0
the	the	DT	0
appended	appended	JJ	0
drawings	drawings	NNS	0
.	.	.	0
To	To	TO	0
achieve	achieve	VB	0
these	these	DT	0
and	and	CC	0
other	other	JJ	0
advantages	advantages	NNS	0
and	and	CC	0
in	in	IN	0
accordance	accordance	NN	0
with	with	IN	0
the	the	DT	0
purpose	purpose	NN	0
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
,	,	,	0
as	as	RB	0
embodied	embodied	VBN	0
and	and	CC	0
broadly	broadly	RB	0
described	described	VBN	0
,	,	,	0
the	the	DT	0
invention	invention	NN	0
describes	describes	VBZ	0
monoclonal	monoclonal	JJ	B-NP
humanized	humanized	JJ	I-NP
antibody	antibody	NN	I-NP
which	which	WDT	0
bind	bind	VBZ	0
shiga	shiga	NN	B-NP
toxin	toxin	NN	I-NP
protein	protein	NN	I-NP
.	.	.	0
The	The	DT	0
present	present	JJ	0
invention	invention	NN	0
relates	relates	VBZ	0
to	to	TO	0
humanized	humanized	VB	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
that	that	IN	0
bind	bind	NN	0
to	to	TO	0
shiga	shiga	NN	B-NP
toxin	toxin	NN	I-NP
protein	protein	NN	I-NP
,	,	,	0
and	and	CC	0
the	the	DT	0
use	use	NN	0
of	of	IN	0
such	such	JJ	0
antibody	antibody	NN	B-NP
in	in	IN	0
the	the	DT	0
treatment	treatment	NN	0
or	or	CC	0
prevention	prevention	NN	0
of	of	IN	0
Shiga	Shiga	NNP	B-NP
toxin-induced	toxin-induced	JJ	0
diseases	diseases	NNS	0
.	.	.	0
antibody	antibody	NN	B-NP
are	are	VBP	0
proteinaceous	proteinaceous	JJ	B-NP
structure	structure	NN	I-NP
made	made	VBD	0
up	up	RP	0
of	of	IN	0
two	two	CD	0
heavy	heavy	JJ	0
and	and	CC	0
two	two	CD	0
light	light	JJ	0
chains	chains	NNS	0
.	.	.	0
The	The	DT	0
five	five	CD	0
different	different	JJ	0
classes	classes	NNS	0
of	of	IN	0
higher	higher	JJR	0
vertebrate	vertebrate	JJ	0
antibody	antibody	NN	B-NP
IgM	IgM	JJ	0
,	,	,	0
IgD	IgD	NNP	B-NP
,	,	,	0
IgG	IgG	NNP	B-NP
,	,	,	0
IgA	IgA	JJ	0
and	and	CC	0
IgE	IgE	NN	B-NP
are	are	VBP	0
distinguished	distinguished	VBN	0
by	by	IN	0
their	their	PRP$	0
heavy	heavy	JJ	0
chains	chains	NNS	0
(	(	-LRB-	0
mu	mu	UH	B-NP
,	,	,	0
delta	delta	NN	0
,	,	,	0
gamma	gamma	NN	B-NP
,	,	,	0
alpha	alpha	NN	0
and	and	CC	0
epsilon	epsilon	NN	B-NP
,	,	,	0
respectively	respectively	RB	0
)	)	-RRB-	0
.	.	.	0
Each	Each	DT	0
class	class	NN	0
has	has	VBZ	0
further	further	JJ	0
subclas	subclas	NN	B-NP
;	;	:	0
IgG	IgG	NNP	B-NP
,	,	,	0
for	for	IN	0
example	example	NN	0
,	,	,	0
may	may	MD	0
be	be	VB	0
IgG1	IgG1	CD	B-NP
,	,	,	0
IgG2	IgG2	NNP	B-NP
,	,	,	0
IgG3	IgG3	NNP	B-NP
,	,	,	0
or	or	CC	0
IgG4	IgG4	NNP	B-NP
,	,	,	0
where	where	WRB	0
the	the	DT	0
heavy	heavy	JJ	0
chain	chain	NN	0
is	is	VBZ	0
gamma	gamma	CD	B-NP
1	1	CD	0
,	,	,	0
gamma	gamma	CD	B-NP
2	2	CD	0
,	,	,	0
gamma	gamma	CD	B-NP
3	3	CD	0
or	or	CC	0
gamma	gamma	CD	B-NP
4	4	CD	0
,	,	,	0
respectively	respectively	RB	0
.	.	.	0
The	The	DT	0
pair	pair	NN	0
of	of	IN	0
light	light	JJ	0
chains	chains	NNS	0
in	in	IN	0
these	these	DT	0
classes	classes	NNS	0
or	or	CC	0
subclas	subclas	NN	B-NP
may	may	MD	0
be	be	VB	0
either	either	DT	0
kappa	kappa	NN	B-NP
or	or	CC	0
lambda	lambda	NN	B-NP
.	.	.	0
antibody	antibody	NN	B-NP
are	are	VBP	0
further	further	RB	0
divided	divided	VBN	0
into	into	IN	0
a	a	DT	0
constant	constant	JJ	0
region	region	NN	0
and	and	CC	0
a	a	DT	0
variable	variable	JJ	0
region	region	NN	0
.	.	.	0
For	For	IN	0
both	both	PDT	0
the	the	DT	0
heavy	heavy	JJ	0
and	and	CC	0
light	light	JJ	0
chains	chains	NNS	0
,	,	,	0
the	the	DT	0
carboxy-terminal	carboxy-terminal	JJ	B-NP
end	end	NN	I-NP
make	make	VBP	0
up	up	RP	0
the	the	DT	0
constant	constant	JJ	0
sequence	sequence	NN	0
region	region	NN	0
,	,	,	0
while	while	IN	0
the	the	DT	0
amino	amino	JJ	0
terminal	terminal	NN	B-NP
end	end	NN	I-NP
contain	contain	VBP	0
the	the	DT	0
variable	variable	JJ	0
sequence	sequence	NN	0
region	region	NN	0
.	.	.	0
Within	Within	IN	0
these	these	DT	0
variable	variable	JJ	0
regions	regions	NNS	0
,	,	,	0
the	the	DT	0
determining	determining	VBG	B-NP
region	region	NN	I-NP
complementarity	complementarity	NN	I-NP
(	(	-LRB-	0
CDRs	CDRs	NNP	B-NP
)	)	-RRB-	0
are	are	VBP	0
located	located	VBN	0
which	which	WDT	0
are	are	VBP	0
primarily	primarily	RB	0
responsible	responsible	JJ	0
for	for	IN	0
the	the	DT	0
observed	observed	JJ	0
antigen	antigen	NN	B-NP
binding	binding	NNS	0
which	which	WDT	0
is	is	VBZ	0
characteristic	characteristic	VBN	0
of	of	IN	0
antibody	antibody	NN	B-NP
.	.	.	0
humanized	humanized	VBN	B-NP
monoclonal	monoclonal	JJ	I-NP
antibody	antibody	NN	I-NP
mean	mean	VBP	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
originally	originally	RB	0
from	from	IN	0
a	a	DT	0
non-human	non-human	JJ	B-NP
source	source	NN	I-NP
to	to	TO	0
which	which	WDT	0
human	human	JJ	0
components	components	NNS	0
have	have	VBP	0
been	been	VBN	0
substituted	substituted	VBN	0
.	.	.	0
In	In	IN	0
a	a	DT	0
preferred	preferred	JJ	0
embodiment	embodiment	NN	0
,	,	,	0
the	the	DT	0
humanized	humanized	JJ	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
of	of	IN	0
this	this	DT	0
invention	invention	NNS	0
comprise	comprise	VBP	0
variable	variable	JJ	0
regions	regions	NNS	0
which	which	WDT	0
derive	derive	VBZ	0
from	from	IN	0
non-human	non-human	JJ	B-NP
source	source	NN	I-NP
and	and	CC	0
constant	constant	JJ	0
regions	regions	NNS	0
which	which	WDT	0
derive	derive	VBZ	0
from	from	IN	0
human	human	JJ	0
sources	sources	NNS	0
.	.	.	0
As	As	RB	0
set	set	VBN	0
forth	forth	RB	0
above	above	RB	0
,	,	,	0
shiga	shiga	NN	B-NP
toxin	toxin	NN	I-NP
protein	protein	NN	I-NP
(	(	-LRB-	0
Stx	Stx	NNP	B-NP
)	)	-RRB-	0
refer	refer	VBP	0
to	to	TO	0
the	the	DT	0
family	family	NN	0
of	of	IN	0
multi-unit	multi-unit	JJ	B-NP
bacterial	bacterial	JJ	I-NP
protein	protein	NN	I-NP
produced	produced	VBN	0
by	by	IN	0
enterohemorrhagic	enterohemorrhagic	NN	B-NP
escherichia	escherichia	NN	I-NP
coli	coli	NN	I-NP
and	and	CC	0
Shigella	Shigella	NNP	B-NP
dysenteriae	dysenteriae	NN	I-NP
which	which	WDT	0
are	are	VBP	0
associated	associated	VBN	0
with	with	IN	0
outbreaks	outbreaks	NNS	0
of	of	IN	0
shiga	shiga	NN	B-NP
toxin	toxin	NN	I-NP
induced	induced	NN	I-NP
disease	disease	NN	I-NP
.	.	.	0
shiga	shiga	NN	B-NP
toxin	toxin	NN	I-NP
protein	protein	NN	I-NP
are	are	VBP	0
meant	meant	VBN	0
to	to	TO	0
encompass	encompass	VB	0
shigella	shigella	NN	B-NP
dysenteriae-type	dysenteriae-type	NNP	I-NP
stx	stx	NN	I-NP
1	1	CD	0
and	and	CC	0
Stx	Stx	NNP	B-NP
type	type	NN	I-NP
1	1	CD	0
and	and	CC	0
type	type	NN	0
2	2	CD	0
,	,	,	0
and	and	CC	0
type	type	NN	0
2	2	CD	0
variant	variant	JJ	0
toxins	toxins	NN	0
of	of	IN	0
E.	E.	NNP	B-NP
cus	cus	NN	I-NP
.	.	.	0
shiga	shiga	NN	B-NP
toxin-induced	toxin-induced	JJ	I-NP
disease	disease	NN	I-NP
of	of	IN	0
humans	humans	NNS	0
include	include	VBP	0
bloody	bloody	JJ	0
diarrhea	diarrhea	NN	0
,	,	,	0
hemorrhagic	hemorrhagic	JJ	B-NP
colitis	colitis	NN	I-NP
,	,	,	0
hemolytic	hemolytic	JJ	B-NP
uremic	uremic	JJ	I-NP
syndrome	syndrome	NN	I-NP
,	,	,	0
and	and	CC	0
thrombotic	thrombotic	JJ	B-NP
thrombocytopenic	thrombocytopenic	JJ	I-NP
purpura	purpura	NN	I-NP
.	.	.	0
In	In	IN	0
a	a	DT	0
more	more	RBR	0
specific	specific	JJ	0
embodiment	embodiment	NN	0
,	,	,	0
the	the	DT	0
invention	invention	NN	0
relates	relates	VBZ	0
to	to	TO	0
humanized	humanized	VB	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
that	that	WDT	0
have	have	VBP	0
the	the	DT	0
same	same	JJ	0
binding	binding	JJ	0
specificity	specificity	NN	0
of	of	IN	0
at	at	IN	0
least	least	JJS	0
two	two	CD	0
well	well	RB	0
characterized	characterized	VBN	0
murine	murine	JJ	B-NP
monoclonal	monoclonal	JJ	I-NP
antibody	antibody	NN	I-NP
.	.	.	0
These	These	DT	0
two	two	CD	0
monoclonal	monoclonal	CD	B-NP
antibody	antibody	NN	I-NP
were	were	VBD	0
developed	developed	VBN	0
in	in	IN	0
Dr.	Dr.	NNP	B-NP
Alison	Alison	NNP	B-NP
O	O	NNP	I-NP
'	'	POS	0
Brien	Brien	NNP	0
's	's	POS	0
laboratory	laboratory	NN	0
as	as	IN	0
set	set	VBN	0
forth	forth	RB	0
in	in	IN	0
Strockbine	Strockbine	NNP	B-NP
,	,	,	0
N.	N.	NNP	0
A.	A.	NNP	0
et	et	NNP	0
al.	al.	NNP	0
,	,	,	0
Infection	Infection	NNP	B-NP
and	and	CC	0
Immunity	Immunity	NNP	0
,	,	,	0
1985	1985	CD	0
,	,	,	0
50	50	CD	0
:	:	:	0
695-700	695-700	CD	0
and	and	CC	0
Perera	Perera	NNP	0
,	,	,	0
L.	L.	NNP	B-NP
P.	P.	NNP	I-NP
et	et	NNP	0
al.	al.	NNP	0
,	,	,	0
J.	J.	NNP	0
Clinical	Clinical	NNP	B-NP
Microbiol.	Microbiol.	NNP	I-NP
,	,	,	0
1988	1988	CD	0
,	,	,	0
26	26	CD	0
:	:	:	0
2127-2131	2127-2131	CD	0
,	,	,	0
and	and	CC	0
have	have	VBP	0
been	been	VBN	0
deposited	deposited	VBN	0
at	at	IN	0
the	the	DT	0
ATCC	ATCC	NNP	B-NP
as	as	RB	0
set	set	VBN	0
forth	forth	RB	0
below	below	RB	0
.	.	.	0
By	By	IN	0
same	same	JJ	0
binding	binding	JJ	0
specificity	specificity	NN	0
is	is	VBZ	0
meant	meant	VBN	0
a	a	DT	0
level	level	NN	0
of	of	IN	0
binding	binding	VBG	0
sufficiently	sufficiently	RB	0
detectable	detectable	VBN	0
in	in	IN	0
a	a	DT	0
standard	standard	JJ	0
binding	binding	JJ	0
assay	assay	NN	B-NP
to	to	TO	0
distinguish	distinguish	VB	0
between	between	IN	0
toxin	toxin	NN	B-NP
binding	binding	NNS	0
and	and	CC	0
non-specific	non-specific	JJ	B-NP
background	background	NN	I-NP
binding	binding	NN	I-NP
as	as	IN	0
exemplified	exemplified	NN	0
by	by	IN	0
appropriate	appropriate	JJ	0
controls	controls	NNS	0
(	(	-LRB-	0
for	for	IN	0
examples	examples	NNS	0
,	,	,	0
see	see	VB	0
FIG.	FIG.	CD	0
9	9	CD	0
and	and	CC	0
FIG.	FIG.	CD	0
11	11	CD	0
)	)	-RRB-	0
.	.	.	0
Those	Those	DT	0
of	of	IN	0
ordinary	ordinary	JJ	B-NP
skill	skill	NN	I-NP
in	in	IN	0
the	the	DT	0
art	art	NN	0
can	can	MD	0
readily	readily	RB	0
test	test	VB	0
for	for	IN	0
binding	binding	JJ	0
levels	levels	NNS	0
using	using	VBG	0
routine	routine	JJ	B-NP
skill	skill	NN	I-NP
and	and	CC	0
techniques	techniques	NNS	0
.	.	.	0
In	In	IN	0
another	another	DT	0
preferred	preferred	JJ	0
embodiment	embodiment	NN	0
,	,	,	0
the	the	DT	0
humanized	humanized	JJ	0
antibody	antibody	NN	B-NP
are	are	VBP	0
characterized	characterized	VBN	0
by	by	IN	0
their	their	PRP$	0
structural	structural	JJ	B-NP
feature	feature	NN	I-NP
.	.	.	0
In	In	IN	0
one	one	CD	0
aspect	aspect	NN	B-NP
of	of	IN	0
this	this	DT	0
embodiment	embodiment	NN	0
,	,	,	0
the	the	DT	0
constant	constant	JJ	0
region	region	NN	0
is	is	VBZ	0
a	a	DT	0
human	human	JJ	0
constant	constant	JJ	0
region	region	NN	0
and	and	CC	0
the	the	DT	0
variable	variable	JJ	0
region	region	NN	0
derives	derives	VBZ	0
from	from	IN	0
a	a	DT	0
rodent	rodent	NN	B-NP
,	,	,	0
preferably	preferably	RB	0
a	a	DT	0
mouse	mouse	NN	0
.	.	.	0
Although	Although	IN	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
these	these	DT	0
,	,	,	0
the	the	DT	0
four	four	CD	0
variable	variable	CD	B-NP
region	region	NN	I-NP
set	set	VBD	0
forth	forth	RB	0
in	in	IN	0
the	the	DT	0
specification	specification	NN	B-NP
,	,	,	0
particularly	particularly	RB	0
in	in	IN	0
FIG.	FIG.	CD	0
3	3	CD	0
and	and	CC	0
FIG.	FIG.	CD	0
6	6	CD	0
,	,	,	0
are	are	VBP	0
preferred	preferred	VBN	0
.	.	.	0
Of	Of	IN	0
course	course	NN	0
,	,	,	0
the	the	DT	0
invention	invention	NN	0
includes	includes	VBZ	0
modification	modification	NN	B-NP
(	(	-LRB-	0
i.e.	i.e.	FW	0
,	,	,	0
deletions	deletions	NNS	0
,	,	,	0
additions	additions	NNS	0
,	,	,	0
and	and	CC	0
substitution	substitution	NN	B-NP
)	)	-RRB-	0
that	that	WDT	0
do	do	VBP	0
not	not	RB	0
appreciably	appreciably	RB	0
diminish	diminish	VB	0
the	the	DT	0
characteristic	characteristic	JJ	0
binding	binding	NNS	0
associated	associated	VBN	0
with	with	IN	0
the	the	DT	0
exemplified	exemplified	JJ	0
variable	variable	JJ	0
regions	regions	NNS	0
.	.	.	0
In	In	IN	0
yet	yet	RB	0
another	another	DT	0
embodiment	embodiment	NN	0
,	,	,	0
the	the	DT	0
CDRs	CDRs	JJ	0
of	of	IN	0
the	the	DT	0
variable	variable	JJ	0
region	region	NN	0
are	are	VBP	0
employed	employed	VBN	0
in	in	IN	0
the	the	DT	0
invention	invention	NN	0
.	.	.	0
As	As	RB	0
noted	noted	VBD	0
above	above	RB	0
,	,	,	0
complementarity	complementarity	NN	B-NP
determining	determining	VBG	I-NP
region	region	NN	I-NP
are	are	VBP	0
located	located	VBN	0
in	in	IN	0
the	the	DT	0
variable	variable	JJ	0
regions	regions	NNS	0
of	of	IN	0
both	both	PDT	0
the	the	DT	0
light	light	NN	0
and	and	CC	0
heavy	heavy	JJ	0
chains	chains	NNS	0
and	and	CC	0
are	are	VBP	0
responsible	responsible	JJ	0
for	for	IN	0
antigen	antigen	JJ	B-NP
binding	binding	NN	I-NP
.	.	.	0
In	In	IN	0
view	view	NN	0
of	of	IN	0
the	the	DT	0
ready	ready	JJ	0
ability	ability	NN	B-NP
of	of	IN	0
those	those	DT	0
in	in	IN	0
this	this	DT	0
art	art	NN	0
to	to	TO	0
determine	determine	VB	0
the	the	DT	0
cdr	cdr	NN	B-NP
region	region	NN	I-NP
,	,	,	0
the	the	DT	0
present	present	JJ	0
invention	invention	NN	0
is	is	VBZ	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
the	the	DT	0
CDRs	CDRs	JJ	0
specifically	specifically	RB	0
set	set	VBN	0
forth	forth	RB	0
.	.	.	0
Indeed	Indeed	RB	0
,	,	,	0
the	the	DT	0
vectors	vectors	NN	0
created	created	VBN	0
by	by	IN	0
the	the	DT	0
applicants	applicants	NNS	0
and	and	CC	0
described	described	VBN	0
in	in	IN	0
great	great	JJ	0
detail	detail	NN	0
below	below	RB	0
are	are	VBP	0
sufficient	sufficient	JJ	0
for	for	IN	0
use	use	NN	0
with	with	IN	0
any	any	DT	0
CDRs	CDRs	JJ	0
of	of	IN	0
non-human	non-human	JJ	B-NP
antibody	antibody	NN	I-NP
to	to	TO	0
shiga	shiga	NN	B-NP
toxin	toxin	NN	I-NP
.	.	.	0
In	In	IN	0
the	the	DT	0
most	most	RBS	0
preferred	preferred	JJ	0
embodiment	embodiment	NN	0
of	of	IN	0
the	the	DT	0
present	present	JJ	0
invention	invention	NN	0
,	,	,	0
the	the	DT	0
humanized	humanized	JJ	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
derives	derives	VBZ	0
its	its	PRP$	0
constant	constant	JJ	0
regions	regions	NNS	0
from	from	IN	0
IgG1-kappa	IgG1-kappa	NNP	B-NP
and	and	CC	0
its	its	PRP$	0
variable	variable	JJ	0
regions	regions	NNS	0
from	from	IN	0
all	all	DT	0
or	or	CC	0
part	part	NN	0
of	of	IN	0
the	the	DT	0
sequences	sequences	NN	0
as	as	IN	0
set	set	VBN	0
forth	forth	RB	0
in	in	IN	0
FIGS.	FIGS.	CD	0
3	3	CD	0
and	and	CC	0
6	6	CD	0
.	.	.	0
In	In	IN	0
further	further	JJ	0
embodiments	embodiments	NN	0
,	,	,	0
the	the	DT	0
invention	invention	NN	0
also	also	RB	0
relates	relates	VBZ	0
to	to	TO	0
the	the	DT	0
expression	expression	NN	B-NP
vector	vector	NN	I-NP
which	which	WDT	0
code	code	NN	0
for	for	IN	0
these	these	DT	0
monoclonal	monoclonal	JJ	B-NP
humanized	humanized	JJ	I-NP
antibody	antibody	NN	I-NP
,	,	,	0
and	and	CC	0
to	to	TO	0
host	host	VB	0
cells	cells	NNS	0
which	which	WDT	0
have	have	VBP	0
been	been	VBN	0
transformed	transformed	VBN	0
with	with	IN	0
such	such	JJ	0
expression	expression	NN	B-NP
vector	vector	NN	I-NP
.	.	.	0
Finally	Finally	RB	0
,	,	,	0
the	the	DT	0
invention	invention	NN	0
comprises	comprises	VBZ	0
the	the	DT	0
pharmaceutical	pharmaceutical	JJ	B-NP
composition	composition	NN	I-NP
and	and	CC	0
the	the	DT	0
methods	methods	NNS	0
of	of	IN	0
use	use	NN	0
of	of	IN	0
these	these	DT	0
humanized	humanized	JJ	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
to	to	TO	0
treat	treat	VB	0
or	or	CC	0
prevent	prevent	VB	0
shiga	shiga	NN	B-NP
toxin-producing	toxin-producing	JJ	I-NP
bacterial	bacterial	JJ	I-NP
infection	infection	NN	I-NP
.	.	.	0
As	As	IN	0
a	a	DT	0
pharmaceutical	pharmaceutical	JJ	0
,	,	,	0
this	this	DT	0
invention	invention	NN	0
includes	includes	VBZ	0
but	but	CC	0
is	is	VBZ	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
diluents	diluents	VB	0
and	and	CC	0
carriers	carriers	NNS	0
known	known	VBN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
,	,	,	0
such	such	JJ	0
as	as	IN	0
saline	saline	NN	0
and	and	CC	0
sucrose	sucrose	JJ	B-NP
solution	solution	NN	I-NP
appropriate	appropriate	JJ	0
for	for	IN	0
application	application	NN	0
to	to	TO	0
patients	patients	NNS	0
.	.	.	0
As	As	RB	0
used	used	VBN	0
herein	herein	NN	0
,	,	,	0
patients	patients	NNS	0
refers	refers	VBZ	0
to	to	TO	0
any	any	DT	0
susceptible	susceptible	JJ	0
mammal	mammal	NN	0
,	,	,	0
such	such	JJ	0
as	as	IN	0
dogs	dogs	NNS	0
,	,	,	0
horses	horses	NNS	0
,	,	,	0
mice	mice	NNS	0
,	,	,	0
etc.	etc.	FW	0
,	,	,	0
but	but	CC	0
is	is	VBZ	0
particularly	particularly	RB	0
preferred	preferred	VBN	0
to	to	TO	0
mean	mean	VB	0
humans	humans	NNS	0
.	.	.	0
The	The	DT	0
invention	invention	NN	0
further	further	RB	0
involves	involves	VBZ	0
the	the	DT	0
administration	administration	NN	B-NP
of	of	IN	0
a	a	DT	0
therapeutically	therapeutically	JJ	0
effective	effective	JJ	0
amount	amount	NN	0
,	,	,	0
as	as	RB	0
well	well	RB	0
as	as	IN	0
a	a	DT	0
prophylatically	prophylatically	JJ	0
effective	effective	JJ	0
amount	amount	NN	0
,	,	,	0
of	of	IN	0
the	the	DT	0
humanized	humanized	JJ	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
.	.	.	0
As	As	IN	0
those	those	DT	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
would	would	MD	0
recognize	recognize	VB	0
,	,	,	0
a	a	DT	0
therapeutically	therapeutically	JJ	0
effective	effective	JJ	0
amount	amount	NN	0
is	is	VBZ	0
a	a	DT	0
dose	dose	NN	0
that	that	IN	0
ameliorates	ameliorates	JJ	0
edema	edema	NN	B-NP
,	,	,	0
thrombocytopenia	thrombocytopenia	NN	B-NP
,	,	,	0
and	and	CC	0
uremia	uremia	VB	0
associated	associated	VBN	0
with	with	IN	0
EHEC-mediated	EHEC-mediated	NNP	B-NP
HUS	HUS	NNP	I-NP
.	.	.	0
Similarly	Similarly	RB	0
,	,	,	0
a	a	DT	0
prophylactically	prophylactically	JJ	0
effective	effective	JJ	0
amount	amount	NN	0
is	is	VBZ	0
a	a	DT	0
dose	dose	NN	0
that	that	WDT	0
prevents	prevents	VBZ	0
exposed	exposed	VBN	0
individuals	individuals	NNS	0
from	from	IN	0
developing	developing	VBG	0
these	these	DT	0
symptom	symptom	NN	B-NP
.	.	.	0
The	The	DT	0
following	following	JJ	0
examples	examples	NNS	0
illustrate	illustrate	VBP	0
specific	specific	JJ	0
embodiments	embodiments	NN	0
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
.	.	.	0
antibody	antibody	NN	B-NP
13c4	13c4	NN	I-NP
anti-stx	anti-stx	NN	I-NP
i	i	NN	I-NP
humanization	humanization	NN	I-NP
The	The	DT	0
following	following	JJ	0
examples	examples	NNS	0
1-3	1-3	VBP	0
relate	relate	VBN	0
to	to	TO	0
anti-StxI	anti-StxI	JJ	B-NP
antibody	antibody	NN	I-NP
13C4	13C4	NN	I-NP
and	and	CC	0
its	its	PRP$	0
humanized	humanized	JJ	0
counterpart	counterpart	NN	0
H13C4	H13C4	NN	0
.	.	.	0
The	The	DT	0
hybridoma	hybridoma	JJ	B-NP
cell	cell	NN	I-NP
producing	producing	VBG	0
the	the	DT	0
13C4	13C4	JJ	B-NP
antibody	antibody	NN	I-NP
(	(	-LRB-	0
Anti-Stx	Anti-Stx	NNP	B-NP
1	1	CD	0
)	)	-RRB-	0
was	was	VBD	0
deposited	deposited	VBN	0
on	on	IN	0
Dec.	Dec.	NNP	0
2	2	CD	0
,	,	,	0
1987	1987	CD	0
,	,	,	0
at	at	IN	0
the	the	DT	0
American	American	NNP	0
Type	Type	NNP	B-NP
Culture	Culture	NNP	I-NP
Collection	Collection	NNP	I-NP
,	,	,	0
10801	10801	CD	0
University	University	NNP	0
Boulevard	Boulevard	NNP	0
,	,	,	0
manassa	manassa	NNP	B-NP
,	,	,	0
Va.	Va.	NNP	0
,	,	,	0
20110-2209	20110-2209	NNP	0
,	,	,	0
under	under	IN	0
Accession	Accession	NNP	B-NP
No	No	NNP	0
.	.	.	0
CRL	CRL	NNP	B-NP
1794	1794	CD	0
,	,	,	0
and	and	CC	0
can	can	MD	0
be	be	VB	0
obtained	obtained	VBN	0
from	from	IN	0
the	the	DT	0
ATCC	ATCC	NNP	B-NP
,	,	,	0
or	or	CC	0
,	,	,	0
as	as	RB	0
here	here	RB	0
,	,	,	0
from	from	IN	0
Dr.	Dr.	NNP	B-NP
Alison	Alison	NNP	B-NP
O	O	NNP	I-NP
'	'	POS	0
Brien	Brien	NNP	0
(	(	-LRB-	0
for	for	IN	0
details	details	NNS	0
of	of	IN	0
hybridoma	hybridoma	JJ	B-NP
preparation	preparation	NN	I-NP
,	,	,	0
see	see	VB	0
Strockbine	Strockbine	NNP	B-NP
,	,	,	0
N.	N.	NNP	0
A.	A.	NNP	0
et	et	NNP	0
al.	al.	NNP	0
,	,	,	0
Infection	Infection	NNP	B-NP
and	and	CC	0
Immunity	Immunity	NNP	0
,	,	,	0
50	50	CD	0
:	:	:	0
695-700	695-700	CD	0
(	(	-LRB-	0
1985	1985	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
.	.	.	0
A	A	DT	0
vial	vial	NN	0
of	of	IN	0
cells	cells	NNS	0
was	was	VBD	0
thawed	thawed	JJ	0
and	and	CC	0
resuspended	resuspended	NN	B-NP
in	in	IN	0
IMDM	IMDM	NNP	B-NP
(	(	-LRB-	0
Mediatech	Mediatech	NNP	B-NP
)	)	-RRB-	0
complete	complete	JJ	0
media	media	NNS	0
supplemented	supplemented	VBN	0
with	with	IN	0
10	10	CD	0
%	%	NN	0
FBS	FBS	NNP	B-NP
(	(	-LRB-	0
Irvine	Irvine	NNP	0
)	)	-RRB-	0
.	.	.	0
Total	Total	JJ	B-NP
RNA	RNA	NNP	I-NP
was	was	VBD	0
isolated	isolated	VBN	0
from	from	IN	0
1	1	CD	0
107	107	CD	0
13c4	13c4	NN	B-NP
cell	cell	NN	I-NP
using	using	VBG	0
the	the	DT	0
Midi	Midi	NNP	B-NP
RNA	RNA	NNP	I-NP
Isolation	Isolation	NNP	I-NP
kit	kit	NN	I-NP
(	(	-LRB-	0
Qiagen	Qiagen	NNP	B-NP
)	)	-RRB-	0
following	following	VBG	0
the	the	DT	0
manufacturer	manufacturer	NN	0
's	's	POS	0
procedure	procedure	NN	0
.	.	.	0
The	The	DT	0
RNA	RNA	NNP	B-NP
was	was	VBD	0
dissolved	dissolved	VBN	0
in	in	IN	0
10	10	CD	0
mm	mm	NN	B-NP
tri	tri	NNP	I-NP
,	,	,	0
0.1	0.1	CD	0
mM	mM	JJ	B-NP
EDTA	EDTA	NNP	I-NP
(	(	-LRB-	0
pH	pH	NNP	B-NP
8.4	8.4	CD	0
)	)	-RRB-	0
containing	containing	VBG	0
0.03	0.03	CD	0
U	U	NNP	0
/	/	NNP	0
g	g	VBD	0
Prime	Prime	NNP	B-NP
RNase	RNase	NNP	I-NP
Inhibitor	Inhibitor	NNP	I-NP
(	(	-LRB-	0
5	5	CD	0
-3	-3	CD	0
)	)	-RRB-	0
to	to	TO	0
a	a	DT	0
final	final	JJ	B-NP
concentration	concentration	NN	I-NP
of	of	IN	0
0.25	0.25	CD	0
g	g	CD	0
/	/	CD	0
l	l	NN	0
.	.	.	0
FIG.	FIG.	CD	0
1	1	CD	0
shows	shows	NNS	0
the	the	DT	0
strategy	strategy	NN	0
for	for	IN	0
cloning	cloning	VBG	0
the	the	DT	0
variable	variable	JJ	0
region	region	NN	0
gene	gene	NN	0
fragments	fragments	NNS	0
and	and	CC	0
FIG.	FIG.	CD	0
2	2	CD	0
lists	lists	NNS	0
the	the	DT	0
oligonucleotide	oligonucleotide	JJ	B-NP
primer	primer	NN	I-NP
used	used	VBN	0
.	.	.	0
The	The	DT	0
13C4	13C4	JJ	B-NP
total	total	JJ	I-NP
RNA	RNA	NNP	I-NP
(	(	-LRB-	0
2	2	CD	0
g	g	CD	0
)	)	-RRB-	0
was	was	VBD	0
converted	converted	VBN	0
to	to	TO	0
cDNA	cDNA	JJ	0
by	by	IN	0
using	using	VBG	0
Superscript	Superscript	NNP	0
1l-MMLV	1l-MMLV	NNP	0
Reverse	Reverse	NNP	0
Transcriptase	Transcriptase	NNP	0
(	(	-LRB-	0
Life	Life	NNP	0
Technologies	Technologies	NNPS	0
)	)	-RRB-	0
and	and	CC	0
mouse	mouse	NN	B-NP
kappum	kappum	NN	I-NP
(	(	-LRB-	0
oKA57	oKA57	NNP	B-NP
,	,	,	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
57	57	CD	0
)	)	-RRB-	0
and	and	CC	0
mouse	mouse	CD	0
CH1	CH1	CD	B-NP
(	(	-LRB-	0
JS300	JS300	NNP	B-NP
,	,	,	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
6	6	CD	0
)	)	-RRB-	0
specific	specific	JJ	0
priming	priming	NN	0
,	,	,	0
according	according	VBG	0
to	to	TO	0
the	the	DT	0
manufacturer	manufacturer	NN	0
's	's	POS	0
procedures	procedures	NNS	0
.	.	.	0
The	The	DT	0
first	first	JJ	0
strand	strand	JJ	0
cdna	cdna	NN	B-NP
synthesis	synthesis	NN	I-NP
product	product	NN	I-NP
were	were	VBD	0
then	then	RB	0
purified	purified	VBP	0
using	using	VBG	0
a	a	DT	0
membrane	membrane	JJ	0
concentrator	concentrator	JJ	B-NP
device	device	NN	I-NP
(	(	-LRB-	0
Amicon	Amicon	NNP	B-NP
Centricon	Centricon	NNP	I-NP
30	30	CD	0
or	or	CC	0
Millipore	Millipore	NNP	B-NP
UltraFree	UltraFree	NNP	I-NP
15	15	CD	0
)	)	-RRB-	0
.	.	.	0
Of	Of	IN	0
the	the	DT	0
cDNA	cDNA	JJ	B-NP
recovered	recovered	NN	I-NP
,	,	,	0
3	3	CD	0
l	l	NNS	0
was	was	VBD	0
used	used	VBN	0
as	as	IN	0
pcr	pcr	NN	B-NP
template	template	JJ	I-NP
dna	dna	NN	I-NP
.	.	.	0
typical	typical	JJ	B-NP
pcr	pcr	NN	I-NP
amplification	amplification	NN	I-NP
reaction	reaction	NN	I-NP
(	(	-LRB-	0
100	100	CD	0
l	l	CD	0
)	)	-RRB-	0
contained	contained	VBD	B-NP
template	template	JJ	I-NP
DNA	DNA	NN	I-NP
,	,	,	0
50	50	CD	0
pmole	pmole	NN	B-NP
of	of	IN	0
the	the	DT	0
appropriate	appropriate	JJ	0
primers	primers	NNS	0
(	(	-LRB-	0
JSS9	JSS9	NNP	B-NP
,	,	,	0
JSS10	JSS10	NNP	B-NP
,	,	,	0
JSS11	JSS11	NNP	B-NP
,	,	,	0
JSS12	JSS12	NNP	B-NP
,	,	,	0
JS153	JS153	NNP	B-NP
JSS154	JSS154	NNP	I-NP
SEQ	SEQ	NNP	I-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
9-12	9-12	CD	0
for	for	IN	0
light	light	JJ	0
chains	chains	NNS	0
;	;	:	0
JSS1	JSS1	CD	B-NP
,	,	,	0
JSS2	JSS2	NNP	B-NP
,	,	,	0
JSS3	JSS3	NNP	B-NP
,	,	,	0
JSS4	JSS4	NNP	B-NP
,	,	,	0
JSS8	JSS8	NNP	B-NP
and	and	CC	0
oKA-143	oKA-143	NNP	B-NP
SEQ	SEQ	NNP	I-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
1-5	1-5	CD	0
and	and	CC	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
15	15	CD	0
for	for	IN	0
heavy	heavy	JJ	0
chains	chains	NNS	0
)	)	-RRB-	0
,	,	,	0
2.5	2.5	CD	0
units	units	NNS	0
of	of	IN	0
ExTaq	ExTaq	JJ	B-NP
polymerasa	polymerasa	NN	I-NP
(	(	-LRB-	0
PanVera	PanVera	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
1	1	CD	0
ExTaq	ExTaq	JJ	B-NP
reaction	reaction	NN	I-NP
buffer	buffer	NN	I-NP
,	,	,	0
200	200	CD	0
M	M	NNP	0
dNTP	dNTP	NNP	B-NP
,	,	,	0
and	and	CC	0
2	2	CD	0
mM	mM	JJ	B-NP
MgCl2	MgCl2	NN	I-NP
.	.	.	0
Each	Each	DT	0
of	of	IN	0
the	the	DT	0
templates	templates	NN	0
was	was	VBD	0
denatured	denatured	VBN	0
by	by	IN	0
an	an	DT	0
initial	initial	JJ	0
incubation	incubation	NN	0
at	at	IN	0
96	96	CD	0
C.	C.	NNP	0
for	for	IN	0
1	1	CD	0
min	min	NN	B-NP
.	.	.	0
The	The	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
product	product	NN	I-NP
were	were	VBD	0
amplified	amplified	VBN	0
by	by	IN	0
40	40	CD	0
or	or	CC	0
50	50	CD	0
thermal	thermal	JJ	B-NP
cycle	cycle	NN	I-NP
of	of	IN	0
59	59	CD	0
to	to	TO	0
72	72	CD	0
C.	C.	NNP	0
for	for	IN	0
30	30	CD	0
sec.	sec.	CD	0
,	,	,	0
72	72	CD	0
C.	C.	NNP	0
for	for	IN	0
30	30	CD	0
sec.	sec.	CD	0
,	,	,	0
then	then	RB	0
96	96	CD	0
C.	C.	NNP	0
for	for	IN	0
1	1	CD	0
min.	min.	CD	B-NP
and	and	CC	0
a	a	DT	0
final	final	JJ	B-NP
extension	extension	NN	I-NP
step	step	NN	I-NP
at	at	IN	0
72	72	CD	0
C.	C.	NNP	0
for	for	IN	0
5	5	CD	0
min	min	NN	B-NP
.	.	.	0
The	The	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
product	product	NN	I-NP
were	were	VBD	0
amplified	amplified	VBN	0
by	by	IN	0
6	6	CD	0
thermal	thermal	JJ	B-NP
cycle	cycle	NN	I-NP
of	of	IN	0
46	46	CD	0
,	,	,	0
48	48	CD	0
or	or	CC	0
54	54	CD	0
C.	C.	NNP	0
for	for	IN	0
30	30	CD	0
sec.	sec.	CD	0
,	,	,	0
72	72	CD	0
C.	C.	NNP	0
for	for	IN	0
30	30	CD	0
sec.	sec.	CD	0
,	,	,	0
then	then	RB	0
96	96	CD	0
C.	C.	NNP	0
for	for	IN	0
1	1	CD	0
min	min	NN	B-NP
followed	followed	VBN	0
by	by	IN	0
35	35	CD	0
step	step	NN	B-NP
cycle	cycle	NN	I-NP
of	of	IN	0
60	60	CD	0
C.	C.	NNP	0
for	for	IN	0
1	1	CD	0
min	min	NN	B-NP
,	,	,	0
then	then	RB	0
96	96	CD	0
C.	C.	NNP	0
for	for	IN	0
1	1	CD	0
min.	min.	CD	B-NP
and	and	CC	0
a	a	DT	0
final	final	JJ	B-NP
extension	extension	NN	I-NP
step	step	NN	I-NP
at	at	IN	0
72	72	CD	0
C.	C.	NNP	0
for	for	IN	0
5	5	CD	0
min	min	NN	B-NP
.	.	.	0
The	The	DT	0
pcr	pcr	NN	B-NP
product	product	NN	I-NP
from	from	IN	0
the	the	DT	0
successful	successful	JJ	0
reactions	reactions	NNS	0
were	were	VBD	0
purified	purified	VBN	0
using	using	VBG	0
the	the	DT	0
Wizard	Wizard	NNP	B-NP
PCR	PCR	NNP	I-NP
Purification	Purification	NNP	I-NP
system	system	NN	I-NP
(	(	-LRB-	0
Promega	Promega	NNP	B-NP
)	)	-RRB-	0
as	as	IN	0
per	per	IN	0
the	the	DT	0
manufacturer	manufacturer	NN	0
's	's	POS	0
procedure	procedure	NN	0
.	.	.	0
The	The	DT	0
heavy	heavy	JJ	0
chain	chain	NN	0
and	and	CC	0
light	light	JJ	0
chain	chain	NN	B-NP
pcr	pcr	NN	I-NP
product	product	NN	I-NP
(	(	-LRB-	0
approximately	approximately	RB	0
400	400	CD	0
bp	bp	CD	B-NP
)	)	-RRB-	0
were	were	VBD	0
then	then	RB	0
cloned	cloned	VBN	0
into	into	IN	0
a	a	DT	0
dna	dna	NN	B-NP
sequence	sequence	NN	I-NP
determination	determination	NN	I-NP
bacterial	bacterial	JJ	I-NP
vector	vector	NN	I-NP
.	.	.	0
pcr	pcr	NN	B-NP
fragment	fragment	NN	I-NP
ligation	ligation	NN	I-NP
were	were	VBD	0
carried	carried	VBN	0
out	out	RP	0
into	into	IN	0
the	the	DT	0
pCR-2.1	pCR-2.1	JJ	B-NP
T	T	NN	B-NP
/	/	VBZ	I-NP
A	A	DT	I-NP
style	style	NN	I-NP
cloning	cloning	NN	I-NP
vector	vector	NN	I-NP
(	(	-LRB-	0
Invitrogen	Invitrogen	NNP	B-NP
)	)	-RRB-	0
following	following	VBG	0
the	the	DT	0
manufacturer	manufacturer	NN	0
's	's	POS	0
procedures	procedures	NNS	0
using	using	VBG	0
1	1	CD	0
:	:	:	0
1	1	CD	0
,	,	,	0
3	3	LS	0
:	:	:	0
1	1	CD	0
and	and	CC	0
5	5	CD	0
:	:	:	0
1	1	CD	0
insert	insert	NN	0
to	to	TO	0
molar	molar	JJ	B-NP
ratio	ratio	NN	I-NP
vector	vector	VB	I-NP
.	.	.	0
One	One	CD	0
half	half	NN	0
of	of	IN	0
each	each	DT	0
of	of	IN	0
the	the	DT	0
ligation	ligation	JJ	B-NP
reaction	reaction	NN	I-NP
was	was	VBD	0
used	used	VBN	0
to	to	TO	0
transform	transform	VB	0
competent	competent	JJ	0
xl1	xl1	NN	B-NP
blue	blue	JJ	I-NP
cell	cell	NN	I-NP
.	.	.	0
containing	containing	VBG	B-NP
dna	dna	NN	I-NP
insert	insert	NN	I-NP
heavy	heavy	JJ	I-NP
chain	chain	NN	I-NP
plasmid	plasmid	NNS	I-NP
clone	clone	NN	I-NP
were	were	VBD	0
identified	identified	VBN	0
using	using	VBG	0
diagnostic	diagnostic	JJ	B-NP
restriction	restriction	NN	I-NP
enzyme	enzyme	NN	I-NP
digest	digest	NN	I-NP
with	with	IN	0
EcoRI	EcoRI	NNP	B-NP
(	(	-LRB-	0
new	new	JJ	B-NP
england	england	NNP	I-NP
biolab	biolab	NN	I-NP
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
plasmid	plasmid	NN	B-NP
dna	dna	NN	I-NP
sequence	sequence	NN	I-NP
(	(	-LRB-	0
tKMC217B	tKMC217B	NNP	0
)	)	-RRB-	0
containing	containing	VBG	B-NP
insert	insert	NN	I-NP
of	of	IN	0
the	the	DT	0
appropriate	appropriate	JJ	0
size	size	NN	0
(	(	-LRB-	0
400	400	CD	0
bp	bp	CD	B-NP
)	)	-RRB-	0
were	were	VBD	0
then	then	RB	0
determined	determined	VBN	0
.	.	.	0
The	The	DT	0
final	final	JJ	B-NP
consensus	consensus	NN	I-NP
DNA	DNA	NN	I-NP
sequence	sequence	NN	I-NP
of	of	IN	0
the	the	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
is	is	VBZ	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
3	3	CD	0
.	.	.	0
The	The	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
pcr	pcr	NN	I-NP
product	product	NN	I-NP
were	were	VBD	0
identified	identified	VBN	0
differently	differently	RB	0
.	.	.	0
The	The	DT	0
hybridoma	hybridoma	JJ	B-NP
cell	cell	NN	I-NP
line	line	NN	I-NP
that	that	WDT	0
expresses	expresses	VBZ	0
the	the	DT	0
13C4	13C4	JJ	B-NP
antibody	antibody	NN	I-NP
was	was	VBD	0
made	made	VBN	0
by	by	IN	0
fusing	fusing	JJ	0
mouse	mouse	NN	B-NP
splenocyte	splenocyte	NN	I-NP
with	with	IN	0
the	the	DT	0
SP2	SP2	CD	B-NP
/	/	CD	0
0	0	CD	0
myeloma	myeloma	JJ	B-NP
cell	cell	NN	I-NP
line	line	NN	I-NP
.	.	.	0
The	The	DT	0
SP2	SP2	CD	B-NP
/	/	CD	0
0	0	CD	0
cell	cell	NN	0
line	line	NN	0
transcribes	transcribes	VBD	0
a	a	DT	0
kappa	kappa	JJ	B-NP
pseudogene	pseudogene	NN	I-NP
light	light	JJ	0
chain	chain	NN	0
.	.	.	0
The	The	DT	0
pseudogene	pseudogene	JJ	B-NP
transcript	transcript	NN	I-NP
,	,	,	0
when	when	WRB	0
converted	converted	VBN	0
to	to	TO	0
cDNA	cDNA	JJ	0
by	by	IN	0
RT-PCR	RT-PCR	NNP	B-NP
,	,	,	0
contains	contains	VBZ	0
an	an	DT	0
AflIII	AflIII	JJ	B-NP
restriction	restriction	NN	I-NP
site	site	NN	I-NP
.	.	.	0
light	light	JJ	B-NP
chain	chain	NN	I-NP
candidate	candidate	NN	I-NP
clone	clone	NN	I-NP
(	(	-LRB-	0
tKMC226	tKMC226	CD	B-NP
227	227	CD	0
)	)	-RRB-	0
were	were	VBD	0
digested	digested	VBN	0
with	with	IN	0
AflIII	AflIII	NNP	B-NP
(	(	-LRB-	0
new	new	JJ	B-NP
england	england	NNP	I-NP
biolab	biolab	NN	I-NP
)	)	-RRB-	0
using	using	VBG	0
the	the	DT	0
manufacturer	manufacturer	NN	0
's	's	POS	0
procedures	procedures	NNS	0
to	to	TO	0
identify	identify	VB	0
clones	clones	NNS	0
containing	containing	VBG	B-NP
insert	insert	NN	I-NP
of	of	IN	0
the	the	DT	0
appropriate	appropriate	JJ	0
size	size	NN	0
(	(	-LRB-	0
403	403	CD	0
bp	bp	NN	B-NP
;	;	:	0
no	no	DT	0
AflIII	AflIII	JJ	B-NP
site	site	NN	I-NP
is	is	VBZ	0
present	present	JJ	0
in	in	IN	0
these	these	DT	0
products	products	NNS	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
final	final	JJ	B-NP
consensus	consensus	NN	I-NP
DNA	DNA	NN	I-NP
sequence	sequence	NN	I-NP
of	of	IN	0
the	the	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
is	is	VBZ	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
3	3	CD	0
with	with	IN	0
the	the	DT	0
complementarity	complementarity	NN	B-NP
determining	determining	VBG	I-NP
region	region	NN	I-NP
indicated	indicated	VBD	0
by	by	IN	0
underlining	underlining	NN	0
.	.	.	0
The	The	DT	0
heavy	heavy	JJ	0
and	and	CC	0
light	light	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
were	were	VBD	0
then	then	RB	0
subcloned	subcloned	VBN	0
into	into	IN	0
mammalian	mammalian	JJ	B-NP
expression	expression	NN	I-NP
plasmid	plasmid	NN	I-NP
vector	vector	NN	I-NP
for	for	IN	0
the	the	DT	0
production	production	NN	0
of	of	IN	0
recombinant	recombinant	FW	0
chimeric	chimeric	NN	B-NP
mouse/human	mouse/human	NN	I-NP
antibody	antibody	NN	I-NP
molecule	molecule	NN	I-NP
.	.	.	0
The	The	DT	0
vectors	vectors	JJ	0
result	result	NN	0
in	in	IN	0
the	the	DT	0
production	production	NN	0
of	of	IN	0
recombinant	recombinant	JJ	0
antibody	antibody	NN	0
molecules	molecules	NNS	0
under	under	IN	0
the	the	DT	0
control	control	NN	0
of	of	IN	0
CMV	CMV	NNP	0
transcriptional	transcriptional	NN	B-NP
promoter	promoter	NN	I-NP
.	.	.	0
The	The	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
molecule	molecule	NN	I-NP
are	are	VBP	0
direct	direct	JJ	0
cDNA	cDNA	JJ	0
constructs	constructs	NN	0
that	that	IN	0
fuse	fuse	VBG	0
the	the	DT	0
variable	variable	JJ	0
region	region	NN	0
sequence	sequence	NN	0
directly	directly	RB	0
into	into	IN	0
the	the	DT	0
human	human	JJ	0
IgG1	IgG1	CD	B-NP
constant	constant	JJ	0
domain	domain	NN	0
.	.	.	0
The	The	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
molecule	molecule	NN	I-NP
,	,	,	0
on	on	IN	0
the	the	DT	0
other	other	JJ	0
hand	hand	NN	0
,	,	,	0
have	have	VBP	0
a	a	DT	0
mouse	mouse	NN	B-NP
kappa	kappa	VBZ	I-NP
intron	intron	JJ	I-NP
region	region	NN	I-NP
3	3	CD	0
of	of	IN	0
the	the	DT	0
variable	variable	JJ	0
region	region	NN	0
coding	coding	NN	0
fragment	fragment	NN	0
.	.	.	0
After	After	IN	0
splicing	splicing	NN	0
,	,	,	0
the	the	DT	0
variable	variable	JJ	0
region	region	NN	0
becomes	becomes	VBZ	0
fused	fused	VBN	0
to	to	TO	0
a	a	DT	0
human	human	JJ	0
kappa	kappa	JJ	B-NP
constant	constant	JJ	0
region	region	NN	B-NP
exon	exon	NN	I-NP
(	(	-LRB-	0
FIG.	FIG.	CD	0
4	4	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
vector	vector	NN	B-NP
selectable	selectable	JJ	I-NP
marker	marker	NN	I-NP
in	in	IN	0
mammalian	mammalian	JJ	B-NP
cell	cell	NN	I-NP
is	is	VBZ	0
aminoglycoside	aminoglycoside	JJ	B-NP
phosphotransferasa	phosphotransferasa	NN	I-NP
(	(	-LRB-	0
neo	neo	LS	B-NP
)	)	-RRB-	0
,	,	,	0
using	using	VBG	0
the	the	DT	0
drug	drug	NN	B-NP
G418	G418	NNP	I-NP
(	(	-LRB-	0
CellTech	CellTech	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
A.	A.	NNP	0
Creation	Creation	NNP	0
of	of	IN	0
the	the	DT	0
expression	expression	NN	B-NP
vector	vector	NN	I-NP
To	To	TO	0
create	create	VB	0
the	the	DT	0
heavy	heavy	JJ	0
and	and	CC	0
light	light	JJ	0
required	required	VBN	B-NP
dna	dna	NN	I-NP
fragment	fragment	NN	I-NP
ligation	ligation	NN	I-NP
chain	chain	NN	I-NP
expression	expression	NN	I-NP
vector	vector	NN	I-NP
and	and	CC	0
site	site	NN	0
directed	directed	VBD	0
mutagenesis	mutagenesis	JJ	B-NP
step	step	NN	I-NP
.	.	.	0
The	The	DT	0
result	result	NN	0
was	was	VBD	0
vectors	vectors	NNS	0
that	that	WDT	0
express	express	VBP	0
both	both	DT	0
antibody	antibody	NN	B-NP
chain	chain	NN	I-NP
with	with	IN	0
CMV	CMV	NNP	0
promoter	promoter	VBD	0
driven	driven	VBN	0
transcription	transcription	NN	B-NP
.	.	.	0
Neomycin	Neomycin	JJ	B-NP
resistance	resistance	NN	I-NP
serves	serves	VBZ	0
as	as	IN	0
a	a	DT	0
dominant	dominant	JJ	0
mammalian	mammalian	JJ	B-NP
cell	cell	NN	I-NP
transfection	transfection	NN	I-NP
selectable	selectable	JJ	I-NP
marker	marker	NN	I-NP
.	.	.	0
In	In	IN	0
addition	addition	NN	B-NP
,	,	,	0
these	these	DT	0
vectors	vectors	NNS	0
have	have	VBP	0
been	been	VBN	0
designed	designed	VBN	0
to	to	TO	0
allow	allow	VB	0
convenient	convenient	JJ	0
cloning	cloning	NN	B-NP
of	of	IN	0
any	any	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
as	as	IN	0
EcoRV	EcoRV	JJ	B-NP
/	/	CD	I-NP
BstBI	BstBI	JJ	I-NP
fragment	fragment	NN	I-NP
,	,	,	0
any	any	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
as	as	IN	0
a	a	DT	0
NruI	NruI	JJ	B-NP
/	/	CD	I-NP
EcoRI	EcoRI	JJ	I-NP
fragment	fragment	NN	I-NP
,	,	,	0
and	and	CC	0
any	any	DT	0
heavy	heavy	JJ	0
chain	chain	NN	0
constant	constant	JJ	0
domain	domain	NN	0
as	as	IN	0
an	an	DT	0
EcoRI	EcoRI	JJ	B-NP
/	/	CD	I-NP
NotI	NotI	JJ	I-NP
fragment	fragment	NN	I-NP
.	.	.	0
These	These	DT	0
restriction	restriction	NN	B-NP
site	site	NN	I-NP
were	were	VBD	0
chosen	chosen	VBN	0
because	because	IN	0
they	they	PRP	0
occur	occur	VBP	0
rarely	rarely	RB	0
(	(	-LRB-	0
if	if	IN	0
ever	ever	RB	0
)	)	-RRB-	0
in	in	IN	0
human	human	JJ	0
and	and	CC	0
mouse	mouse	JJ	0
variable	variable	JJ	0
regions	regions	NNS	0
.	.	.	0
There	There	EX	0
is	is	VBZ	0
a	a	DT	0
mouse	mouse	NN	B-NP
J	J	NNP	I-NP
region	region	NN	I-NP
/	/	NN	I-NP
kappa	kappa	NNP	I-NP
intron	intron	NN	I-NP
fragment	fragment	NN	I-NP
fused	fused	FW	0
to	to	TO	0
a	a	DT	0
human	human	JJ	0
kappum	kappum	NN	B-NP
exon	exon	VBP	I-NP
so	so	RB	0
that	that	IN	0
after	after	IN	0
post-transcriptional	post-transcriptional	JJ	B-NP
splicing	splicing	NNS	0
a	a	DT	0
mouse	mouse	JJ	0
human	human	JJ	0
chimeric	chimeric	NN	B-NP
kappa	kappa	VBP	I-NP
light	light	JJ	0
chain	chain	NN	0
is	is	VBZ	0
produced	produced	VBN	0
.	.	.	0
Lastly	Lastly	NNP	0
,	,	,	0
the	the	DT	0
vectors	vectors	NN	0
were	were	VBD	0
designed	designed	VBN	0
to	to	TO	0
facilitate	facilitate	VB	0
excision	excision	NN	0
(	(	-LRB-	0
BglII	BglII	NNP	B-NP
/	/	NNP	I-NP
NheI	NheI	NNP	I-NP
)	)	-RRB-	0
of	of	IN	0
a	a	DT	0
whole	whole	JJ	0
antibody	antibody	NN	B-NP
expression	expression	NN	I-NP
cassette	cassette	NN	I-NP
from	from	IN	0
one	one	CD	0
vector	vector	NN	B-NP
to	to	TO	0
be	be	VB	0
ligated	ligated	VBN	0
into	into	IN	0
a	a	DT	0
second	second	JJ	0
vector	vector	NN	B-NP
cut	cut	NN	I-NP
with	with	IN	0
BamHI	BamHI	NNP	B-NP
/	/	NNP	I-NP
NheI	NheI	NNP	I-NP
,	,	,	0
creating	creating	VBG	0
an	an	DT	0
expression	expression	NN	B-NP
vector	vector	NN	I-NP
with	with	IN	0
the	the	DT	0
apparatus	apparatus	NN	B-NP
for	for	IN	0
both	both	DT	0
chains	chains	NNS	0
.	.	.	0
The	The	DT	0
backbone	backbone	NN	0
of	of	IN	0
the	the	DT	0
vector	vector	NN	B-NP
was	was	VBD	0
the	the	DT	0
plasmid	plasmid	JJ	B-NP
pCDNA3	pCDNA3	NNP	I-NP
(	(	-LRB-	0
Invitrogen	Invitrogen	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
This	This	DT	0
plasmid	plasmid	NN	B-NP
was	was	VBD	0
cut	cut	VBN	0
with	with	IN	0
HindIII	HindIII	NNP	B-NP
/	/	NNP	I-NP
XhoI	XhoI	NNP	I-NP
and	and	CC	0
a	a	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
polylinker	polylinker	NN	I-NP
DNA	DNA	NN	I-NP
fragment	fragment	NN	I-NP
was	was	VBD	0
inserted	inserted	VBN	0
to	to	TO	0
create	create	VB	0
the	the	DT	0
starting	starting	VBG	0
light	light	JJ	0
chain	chain	NN	B-NP
vector	vector	VBD	I-NP
pCDNA3.LCPL	pCDNA3.LCPL	CD	I-NP
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
12	12	CD	0
)	)	-RRB-	0
.	.	.	0
This	This	DT	0
linker	linker	NN	B-NP
contained	contained	VBD	0
the	the	DT	0
restriction	restriction	NN	B-NP
site	site	NN	I-NP
HindIII	HindIII	JJ	0
,	,	,	0
KpnI	KpnI	NNP	B-NP
,	,	,	0
ClaI	ClaI	NNP	B-NP
,	,	,	0
PmlI	PmlI	NNP	B-NP
,	,	,	0
EcoRV	EcoRV	NNP	B-NP
,	,	,	0
XmaI	XmaI	NNP	B-NP
,	,	,	0
BamHI	BamHI	JJ	0
and	and	CC	0
XhoI	XhoI	JJ	0
to	to	TO	0
facilitate	facilitate	VB	0
subsequent	subsequent	JJ	0
cloning	cloning	JJ	B-NP
step	step	NN	I-NP
.	.	.	0
A	A	DT	0
SmaII	SmaII	JJ	B-NP
/	/	NNP	I-NP
BclI	BclI	NNP	I-NP
DNA	DNA	NNP	I-NP
fragment	fragment	VBZ	0
containing	containing	VBG	0
a	a	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
leader	leader	NN	I-NP
,	,	,	0
mouse	mouse	JJ	B-NP
anti-CKMB	anti-CKMB	JJ	I-NP
kappa	kappa	JJ	I-NP
light	light	JJ	0
chain	chain	NN	B-NP
genomic	genomic	NN	I-NP
fragment	fragment	NN	I-NP
,	,	,	0
and	and	CC	0
3	3	CD	0
UTR	UTR	NNP	B-NP
was	was	VBD	0
cloned	cloned	VBN	0
into	into	IN	0
the	the	DT	0
pcdna3	pcdna3	NN	B-NP
ecorv/bamhi	ecorv/bamhi	NN	I-NP
site	site	NN	I-NP
.	.	.	0
The	The	DT	0
mouse	mouse	NN	B-NP
kappa	kappa	NN	I-NP
intron	intron	NN	I-NP
,	,	,	0
exon	exon	NN	B-NP
,	,	,	0
and	and	CC	0
3	3	CD	0
UTR	UTR	NN	B-NP
in	in	IN	0
this	this	DT	0
fragment	fragment	NN	0
was	was	VBD	0
derived	derived	VBN	0
from	from	IN	0
LCPXK2	LCPXK2	NNP	B-NP
received	received	VBD	0
from	from	IN	0
Dr.	Dr.	NNP	B-NP
Richard	Richard	NNP	0
Near	Near	NNP	0
(	(	-LRB-	0
Near	Near	NNP	0
,	,	,	0
R.	R.	NNP	B-NP
I.	I.	NNP	I-NP
et	et	NNP	0
al.	al.	NNP	0
,	,	,	0
1990	1990	CD	0
,	,	,	0
Mol	Mol	NNP	B-NP
.	.	.	0
Immunol.	Immunol.	CD	B-NP
27	27	CD	0
:	:	:	0
901-909	901-909	CD	0
)	)	-RRB-	0
.	.	.	0
mutagenesi	mutagenesi	NN	B-NP
was	was	VBD	0
then	then	RB	0
performed	performed	VBN	0
to	to	TO	0
eliminate	eliminate	VB	0
an	an	DT	0
NruI	NruI	JJ	0
(	(	-LRB-	0
209	209	LS	0
)	)	-RRB-	0
,	,	,	0
MluI	MluI	NNP	B-NP
(	(	-LRB-	0
229	229	CD	0
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
BstBI	BstBI	NNP	B-NP
(	(	-LRB-	0
2962	2962	CD	0
)	)	-RRB-	0
and	and	CC	0
to	to	TO	0
introduce	introduce	VB	0
an	an	DT	0
NheI	NheI	JJ	0
(	(	-LRB-	0
1229	1229	CD	0
)	)	-RRB-	0
and	and	CC	0
a	a	DT	0
BamHI	BamHI	JJ	0
(	(	-LRB-	0
1214	1214	CD	0
)	)	-RRB-	0
site	site	NN	0
to	to	TO	0
create	create	VB	0
the	the	DT	0
plasmid	plasmid	JJ	0
pCDNA3mut.LCPL.LCVK	pCDNA3mut.LCPL.LCVK	NNP	0
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
12	12	CD	0
)	)	-RRB-	0
.	.	.	0
A	A	DT	0
second	second	JJ	0
heavy	heavy	JJ	0
chain	chain	NN	0
vector	vector	NN	0
pCDNA3mut.HCPL	pCDNA3mut.HCPL	NN	0
was	was	VBD	0
constructed	constructed	VBN	0
from	from	IN	0
the	the	DT	0
pCDNA3mut.LCPL.LCVK	pCDNA3mut.LCPL.LCVK	JJ	0
plasmid	plasmid	NN	0
by	by	IN	0
replacing	replacing	VBG	0
the	the	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
expression	expression	NN	I-NP
region	region	NN	I-NP
(	(	-LRB-	0
HindIII	HindIII	NNP	B-NP
/	/	NNP	I-NP
XhoI	XhoI	NNP	I-NP
)	)	-RRB-	0
with	with	IN	0
a	a	DT	0
heavy	heavy	JJ	0
chain	chain	NN	0
polylinker	polylinker	VBZ	0
consisting	consisting	VBG	0
of	of	IN	0
restriction	restriction	NN	B-NP
site	site	NN	I-NP
HpaI	HpaI	JJ	0
,	,	,	0
BspEI	BspEI	NNP	B-NP
,	,	,	0
EcoRV	EcoRV	NNP	B-NP
,	,	,	0
KpnI	KpnI	NNP	B-NP
,	,	,	0
and	and	CC	0
Xhol	Xhol	NNP	B-NP
.	.	.	0
This	This	DT	0
plasmid	plasmid	NN	B-NP
was	was	VBD	0
digested	digested	VBN	0
with	with	IN	0
EcorRV	EcorRV	JJ	0
and	and	CC	0
KpnI	KpnI	JJ	0
.	.	.	0
A	A	DT	0
SmaI	SmaI	JJ	B-NP
/	/	CD	I-NP
KpnI	KpnI	JJ	I-NP
digested	digested	JJ	I-NP
DNA	DNA	NN	I-NP
fragment	fragment	NN	I-NP
containing	containing	VBG	0
a	a	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
leader	leader	NN	I-NP
and	and	CC	0
an	an	DT	0
anti-CKMB	anti-CKMB	JJ	0
IgG2b	IgG2b	CD	0
mouse	mouse	NN	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
genomic	genomic	NN	I-NP
fragment	fragment	NN	I-NP
was	was	VBD	0
then	then	RB	0
ligated	ligated	VBN	0
into	into	IN	0
the	the	DT	0
EcoRV	EcoRV	JJ	0
/	/	FW	0
KpnI	KpnI	FW	0
digested	digested	VBN	B-NP
plasmid	plasmid	NN	I-NP
.	.	.	0
A	A	DT	0
KpnI	KpnI	JJ	B-NP
/	/	CD	I-NP
SalI	SalI	JJ	I-NP
oligonucleotida	oligonucleotida	NN	I-NP
fragment	fragment	VBP	0
containing	containing	VBG	0
a	a	DT	0
3	3	CD	0
UTR	UTR	NNP	B-NP
and	and	CC	0
a	a	DT	0
NotI	NotI	JJ	0
upstream	upstream	NN	0
of	of	IN	0
the	the	DT	0
SalI	SalI	JJ	B-NP
site	site	NN	I-NP
was	was	VBD	0
subsequently	subsequently	RB	0
cloned	cloned	VBN	0
into	into	IN	0
the	the	DT	0
KpnI	KpnI	JJ	0
/	/	FW	0
XhoI	XhoI	FW	0
digested	digested	VBN	B-NP
plasmid	plasmid	NN	I-NP
,	,	,	0
(	(	-LRB-	0
knocking	knocking	VBG	0
out	out	RP	0
the	the	DT	0
XhoI	XhoI	JJ	B-NP
site	site	NN	I-NP
)	)	-RRB-	0
,	,	,	0
to	to	TO	0
create	create	VB	0
the	the	DT	0
plasmid	plasmid	JJ	0
pCDNA3mut.HCPL.HCV2b	pCDNA3mut.HCPL.HCV2b	NNP	0
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
13	13	CD	0
)	)	-RRB-	0
.	.	.	0
A	A	DT	0
human	human	JJ	0
kappa	kappa	JJ	B-NP
light	light	JJ	0
chain	chain	NN	0
constant	constant	JJ	0
domain	domain	NN	0
was	was	VBD	0
then	then	RB	0
cloned	cloned	VBN	0
into	into	IN	0
pCDNA3mut.LCPL.LCVK	pCDNA3mut.LCPL.LCVK	CD	0
as	as	IN	0
a	a	DT	0
EcoNI	EcoNI	JJ	B-NP
/	/	CD	I-NP
XhoI	XhoI	JJ	I-NP
fragment	fragment	NN	I-NP
generating	generating	VBG	0
the	the	DT	0
plasmid	plasmid	JJ	0
tKMC180C2	tKMC180C2	NN	0
.	.	.	0
A	A	DT	0
human	human	JJ	0
IgG1	IgG1	CD	B-NP
constant	constant	JJ	0
domain	domain	NN	0
was	was	VBD	0
cloned	cloned	VBN	0
into	into	IN	0
pSUN10	pSUN10	CD	B-NP
as	as	IN	0
a	a	DT	0
EcoRI	EcoRI	JJ	B-NP
/	/	CD	I-NP
NotI	NotI	JJ	I-NP
fragment	fragment	NN	I-NP
creating	creating	VBG	0
the	the	DT	0
plasmid	plasmid	JJ	B-NP
pJRS313	pJRS313	NN	I-NP
.	.	.	0
The	The	DT	0
variable	variable	JJ	0
regions	regions	NNS	0
of	of	IN	0
13C4	13C4	NNP	B-NP
were	were	VBD	0
cloned	cloned	VBN	0
into	into	IN	0
these	these	DT	0
two	two	CD	0
vectors	vectors	NNS	0
(	(	-LRB-	0
as	as	RB	0
described	described	VBN	0
above	above	IN	0
)	)	-RRB-	0
.	.	.	0
A	A	DT	0
BglII	BglII	JJ	B-NP
/	/	CD	I-NP
NheI	NheI	JJ	I-NP
fragment	fragment	NN	I-NP
from	from	IN	0
the	the	DT	0
human	human	JJ	0
heavy	heavy	JJ	0
chain	chain	NN	0
vector	vector	NN	0
tKMC229C	tKMC229C	NN	0
was	was	VBD	0
then	then	RB	0
cloned	cloned	VBN	0
into	into	IN	0
the	the	DT	0
human	human	JJ	0
light	light	JJ	0
chain	chain	NN	B-NP
vector	vector	NN	I-NP
tKMC231D	tKMC231D	RB	0
cut	cut	VB	0
BamHI	BamHI	JJ	0
/	/	CD	0
NheI	NheI	JJ	0
to	to	TO	0
create	create	VB	0
tKMC249A	tKMC249A	NNP	0
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
4	4	CD	0
)	)	-RRB-	0
.	.	.	0
B.	B.	NNP	B-NP
Subcloning	Subcloning	NNP	I-NP
the	the	DT	0
variable	variable	JJ	B-NP
region	region	NN	I-NP
into	into	IN	0
the	the	DT	0
expression	expression	NN	B-NP
vector	vector	NN	I-NP
The	The	DT	0
variable	variable	JJ	0
region	region	NN	0
gene	gene	NN	0
fragments	fragments	NNS	0
were	were	VBD	0
re-amplified	re-amplified	JJ	0
by	by	IN	0
PCR	PCR	NNP	B-NP
using	using	VBG	0
primers	primers	NNS	0
that	that	WDT	0
adapted	adapted	VBD	0
the	the	DT	0
fragments	fragments	NN	0
for	for	IN	0
cloning	cloning	NN	B-NP
into	into	IN	0
the	the	DT	0
expression	expression	NN	B-NP
vector	vector	NN	I-NP
(	(	-LRB-	0
see	see	VB	0
FIGS.	FIGS.	CD	0
2	2	CD	0
and	and	CC	0
4	4	LS	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
front	front	NN	I-NP
primer	primer	NN	I-NP
(	(	-LRB-	0
oKA143	oKA143	NNP	B-NP
,	,	,	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
15	15	CD	0
)	)	-RRB-	0
includes	includes	VBZ	0
a	a	DT	0
5	5	CD	0
tail	tail	NN	0
that	that	IN	0
encodes	encodes	VBG	0
the	the	DT	0
C-terminus	C-terminus	JJ	B-NP
of	of	IN	0
the	the	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
leader	leader	NN	I-NP
and	and	CC	0
an	an	DT	0
cloning	cloning	NN	B-NP
nrui	nrui	NN	I-NP
restriction	restriction	NN	I-NP
site	site	NN	I-NP
,	,	,	0
while	while	IN	0
the	the	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
reverse	reverse	NN	I-NP
primer	primer	NN	I-NP
(	(	-LRB-	0
oKA144	oKA144	NNP	B-NP
,	,	,	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
14	14	CD	0
)	)	-RRB-	0
adds	adds	VBZ	0
a	a	DT	0
3	3	CD	0
cloning	cloning	NN	B-NP
ecori	ecori	NN	I-NP
restriction	restriction	NN	I-NP
site	site	NN	I-NP
.	.	.	0
The	The	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
front	front	NN	I-NP
primer	primer	NN	I-NP
(	(	-LRB-	0
oKA145	oKA145	NNP	B-NP
,	,	,	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
16	16	CD	0
)	)	-RRB-	0
introduces	introduces	VBZ	0
an	an	DT	0
EcoRV	EcoRV	JJ	B-NP
restriction	restriction	NN	I-NP
site	site	NN	I-NP
at	at	IN	0
the	the	DT	0
N-terminus	N-terminus	JJ	B-NP
of	of	IN	0
the	the	DT	0
light	light	JJ	0
cloning	cloning	NN	B-NP
chain	chain	NN	I-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
,	,	,	0
while	while	IN	0
the	the	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
reverse	reverse	NN	I-NP
primer	primer	NN	I-NP
(	(	-LRB-	0
oKA146	oKA146	NNP	B-NP
,	,	,	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
17	17	CD	0
)	)	-RRB-	0
adds	adds	VBZ	0
a	a	DT	0
3	3	CD	0
joining	joining	VBG	B-NP
region-kappa	region-kappa	JJ	I-NP
exon	exon	JJ	I-NP
splice	splice	NNS	I-NP
junction	junction	VBP	I-NP
dna	dna	NN	I-NP
sequence	sequence	NN	I-NP
followed	followed	VBN	0
by	by	IN	0
a	a	DT	0
cloning	cloning	NN	B-NP
bstbi	bstbi	NN	I-NP
restriction	restriction	NN	I-NP
site	site	NN	I-NP
.	.	.	0
pcr	pcr	NN	B-NP
reaction	reaction	NN	I-NP
were	were	VBD	0
performed	performed	VBN	0
with	with	IN	0
reagents	reagents	VBG	0
as	as	RB	0
described	described	VBN	0
above	above	IN	0
and	and	CC	0
with	with	IN	0
templates	templates	NN	0
of	of	IN	0
1-2	1-2	CD	0
ng	ng	NN	0
of	of	IN	0
PvuI	PvuI	NNP	B-NP
(	(	-LRB-	0
new	new	JJ	B-NP
england	england	NNP	I-NP
biolab	biolab	NN	I-NP
)	)	-RRB-	0
digested	digested	JJ	0
plasmid	plasmid	NN	B-NP
;	;	:	0
each	each	DT	0
of	of	IN	0
these	these	DT	0
templates	templates	NN	0
was	was	VBD	0
denatured	denatured	VBN	0
by	by	IN	0
an	an	DT	0
initial	initial	JJ	0
one	one	CD	0
minute	minute	NN	B-NP
incubation	incubation	NN	I-NP
at	at	IN	0
96	96	CD	0
C.	C.	CD	0
The	The	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
product	product	NN	I-NP
were	were	VBD	0
amplified	amplified	VBN	0
by	by	IN	0
35	35	CD	0
thermal	thermal	JJ	B-NP
cycle	cycle	NN	I-NP
of	of	IN	0
55	55	CD	0
or	or	CC	0
60	60	CD	0
C.	C.	NNP	0
for	for	IN	0
30	30	CD	0
sec.	sec.	CD	0
,	,	,	0
72	72	CD	0
C.	C.	NNP	0
for	for	IN	0
30	30	CD	0
sec.	sec.	CD	0
,	,	,	0
then	then	RB	0
96	96	CD	0
C.	C.	NNP	0
for	for	IN	0
1	1	CD	0
min	min	NN	B-NP
and	and	CC	0
a	a	DT	0
final	final	JJ	B-NP
extension	extension	NN	I-NP
step	step	NN	I-NP
at	at	IN	0
72	72	CD	0
C.	C.	NNP	0
for	for	IN	0
5	5	CD	0
min	min	NN	B-NP
.	.	.	0
The	The	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
product	product	NN	I-NP
were	were	VBD	0
amplified	amplified	VBN	0
by	by	IN	0
8	8	CD	0
thermal	thermal	JJ	B-NP
cycle	cycle	NN	I-NP
of	of	IN	0
55	55	CD	0
or	or	CC	0
60	60	CD	0
C.	C.	NNP	0
for	for	IN	0
30	30	CD	0
sec.	sec.	CD	0
,	,	,	0
72	72	CD	0
C.	C.	NNP	0
for	for	IN	0
30	30	CD	0
sec.	sec.	CD	0
,	,	,	0
then	then	RB	0
96	96	CD	0
C.	C.	NNP	0
for	for	IN	0
1	1	CD	0
min	min	NN	B-NP
followed	followed	VBN	0
by	by	IN	0
30	30	CD	0
step	step	NN	B-NP
cycle	cycle	NN	I-NP
of	of	IN	0
60	60	CD	0
C.	C.	NNP	0
for	for	IN	0
1	1	CD	0
min	min	NN	B-NP
,	,	,	0
then	then	RB	0
96	96	CD	0
C.	C.	NNP	0
for	for	IN	0
1	1	CD	0
min	min	NN	B-NP
,	,	,	0
and	and	CC	0
a	a	DT	0
final	final	JJ	B-NP
extension	extension	NN	I-NP
step	step	NN	I-NP
at	at	IN	0
72	72	CD	0
C.	C.	NNP	0
for	for	IN	0
5	5	CD	0
min	min	NN	B-NP
.	.	.	0
The	The	DT	0
13C4	13C4	JJ	B-NP
heavy	heavy	JJ	I-NP
chain	chain	NN	I-NP
PCR	PCR	NNP	I-NP
product	product	NN	I-NP
(	(	-LRB-	0
approximately	approximately	RB	0
400	400	CD	0
bp	bp	CD	B-NP
)	)	-RRB-	0
was	was	VBD	0
purified	purified	VBN	0
using	using	VBG	0
qiaquick	qiaquick	NN	B-NP
pcr	pcr	NN	I-NP
purification	purification	NN	I-NP
column	column	NN	I-NP
(	(	-LRB-	0
Qiagen	Qiagen	NNP	B-NP
)	)	-RRB-	0
as	as	RB	0
described	described	VBN	0
by	by	IN	0
the	the	DT	0
manufacturer	manufacturer	NN	0
's	's	POS	0
instruction	instruction	NN	B-NP
and	and	CC	0
subsequently	subsequently	RB	0
digested	digested	VBN	0
with	with	IN	0
NruI	NruI	JJ	0
and	and	CC	0
EcoRI	EcoRI	NNP	B-NP
(	(	-LRB-	0
new	new	JJ	B-NP
england	england	NNP	I-NP
biolab	biolab	NN	I-NP
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
digested	digested	JJ	0
pcr	pcr	NN	B-NP
product	product	NN	I-NP
were	were	VBD	0
purified	purified	VBN	0
using	using	VBG	0
the	the	DT	0
Wizard	Wizard	NNP	B-NP
PCR	PCR	NNP	I-NP
Purification	Purification	NNP	I-NP
system	system	NN	I-NP
(	(	-LRB-	0
Promega	Promega	NNP	B-NP
)	)	-RRB-	0
as	as	IN	0
per	per	IN	0
manufacturer	manufacturer	NN	0
's	's	POS	0
procedure	procedure	NN	0
and	and	CC	0
ligated	ligated	NN	0
into	into	IN	0
NruI	NruI	JJ	B-NP
/	/	CD	I-NP
EcoRI	EcoRI	JJ	I-NP
digested	digested	NN	I-NP
and	and	CC	0
gel-purified	gel-purified	NNP	0
pJRS3I3	pJRS3I3	NNP	0
,	,	,	0
resulting	resulting	VBG	0
in	in	IN	0
plasmid	plasmid	CD	0
tKMC229C	tKMC229C	CD	0
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
4	4	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
final	final	JJ	B-NP
consensus	consensus	NN	I-NP
DNA	DNA	NN	I-NP
sequence	sequence	NN	I-NP
of	of	IN	0
the	the	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
and	and	CC	0
proper	proper	JJ	0
splicing	splicing	NN	0
of	of	IN	0
the	the	DT	0
restriction	restriction	NN	B-NP
site	site	NN	I-NP
were	were	VBD	0
confirmed	confirmed	VBN	0
in	in	IN	0
this	this	DT	0
construct	construct	NN	0
.	.	.	0
The	The	DT	0
13C4	13C4	JJ	0
light	light	JJ	0
chain	chain	NN	B-NP
PCR	PCR	NNP	I-NP
product	product	NN	I-NP
(	(	-LRB-	0
approximately	approximately	RB	0
350	350	CD	0
bp	bp	CD	B-NP
)	)	-RRB-	0
was	was	VBD	0
purified	purified	VBN	0
using	using	VBG	0
qiaquick	qiaquick	NN	B-NP
pcr	pcr	NN	I-NP
purification	purification	NN	I-NP
column	column	NN	I-NP
(	(	-LRB-	0
Qiagen	Qiagen	NNP	B-NP
)	)	-RRB-	0
as	as	RB	0
described	described	VBN	0
by	by	IN	0
the	the	DT	0
manufacturer	manufacturer	NN	0
's	's	POS	0
instruction	instruction	NN	B-NP
and	and	CC	0
subsequently	subsequently	RB	0
digested	digested	VBN	0
with	with	IN	0
EcoRV	EcoRV	JJ	0
and	and	CC	0
BstBI	BstBI	NNP	B-NP
(	(	-LRB-	0
new	new	JJ	B-NP
england	england	NNP	I-NP
biolab	biolab	NN	I-NP
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
digested	digested	JJ	0
pcr	pcr	NN	B-NP
product	product	NN	I-NP
were	were	VBD	0
purified	purified	VBN	0
using	using	VBG	0
qiaquick	qiaquick	NN	B-NP
pcr	pcr	NN	I-NP
purification	purification	NN	I-NP
column	column	NN	I-NP
(	(	-LRB-	0
Qiagen	Qiagen	NNP	B-NP
)	)	-RRB-	0
as	as	IN	0
per	per	IN	0
manufacturer	manufacturer	NN	0
's	's	POS	0
procedure	procedure	NN	0
and	and	CC	0
ligated	ligated	NN	0
into	into	IN	0
EcoRV	EcoRV	JJ	B-NP
/	/	CD	I-NP
BstBI	BstBI	JJ	I-NP
digested	digested	NN	I-NP
and	and	CC	0
gel-purified	gel-purified	NNP	0
tKMC180C2	tKMC180C2	NNP	0
(	(	-LRB-	0
as	as	RB	0
described	described	VBN	0
above	above	IN	0
)	)	-RRB-	0
,	,	,	0
resulting	resulting	VBG	0
in	in	IN	0
plasmid	plasmid	CD	0
tKMC231D	tKMC231D	CD	0
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
4	4	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
final	final	JJ	B-NP
consensus	consensus	NN	I-NP
DNA	DNA	NN	I-NP
sequence	sequence	NN	I-NP
of	of	IN	0
the	the	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
and	and	CC	0
proper	proper	JJ	0
splicing	splicing	NN	0
of	of	IN	0
the	the	DT	0
restriction	restriction	NN	B-NP
site	site	NN	I-NP
were	were	VBD	0
confirmed	confirmed	VBN	0
in	in	IN	0
this	this	DT	0
construct	construct	NN	0
.	.	.	0
A.	A.	NNP	0
Transfection	Transfection	NNP	B-NP
of	of	IN	0
NSO	NSO	NNP	B-NP
Cells	Cells	NNPS	0
The	The	DT	0
plasmid	plasmid	JJ	0
tKMC249A	tKMC249A	NN	0
was	was	VBD	0
transfected	transfected	VBN	0
into	into	IN	0
NSO	NSO	NNP	B-NP
cells	cells	NNS	0
(	(	-LRB-	0
Baxter	Baxter	NNP	0
International	International	NNP	0
,	,	,	0
Inc.	Inc.	NNP	0
,	,	,	0
Durante	Durante	NNP	0
,	,	,	0
Calif.	Calif.	NNP	0
)	)	-RRB-	0
using	using	VBG	0
electroporation	electroporation	NN	B-NP
after	after	IN	0
linearization	linearization	NN	B-NP
with	with	IN	0
PvuI	PvuI	NNP	B-NP
(	(	-LRB-	0
new	new	JJ	B-NP
england	england	NNP	I-NP
biolab	biolab	NN	I-NP
)	)	-RRB-	0
.	.	.	0
40	40	CD	0
microgram	microgram	NN	B-NP
of	of	IN	0
the	the	DT	0
digested	digested	JJ	0
plasmid	plasmid	NN	B-NP
was	was	VBD	0
mixed	mixed	VBN	0
with	with	IN	0
1	1	CD	0
107	107	CD	0
cells	cells	NNS	0
in	in	IN	0
a	a	DT	0
total	total	JJ	B-NP
volume	volume	NN	I-NP
of	of	IN	0
800	800	CD	0
microliter	microliter	NN	B-NP
in	in	IN	0
a	a	DT	0
0.4	0.4	CD	0
centimeter	centimeter	CD	B-NP
cuvetta	cuvetta	NN	I-NP
and	and	CC	0
subjected	subjected	VBN	0
to	to	TO	0
a	a	DT	0
pulse	pulse	NN	0
of	of	IN	0
250	250	CD	0
mA	mA	NN	0
,	,	,	0
960	960	CD	0
F.	F.	CD	0
The	The	DT	0
cells	cells	NNS	0
were	were	VBD	0
plated	plated	VBN	0
out	out	RP	0
after	after	IN	0
24	24	CD	0
hours	hours	NNS	0
into	into	IN	0
96-well	96-well	CD	0
tissue	tissue	NN	0
culture	culture	NN	0
plates	plates	NN	0
,	,	,	0
6	6	CD	0
plates	plates	NN	0
with	with	IN	0
200	200	CD	0
l	l	NN	B-NP
/	/	VBP	I-NP
well	well	RB	I-NP
,	,	,	0
and	and	CC	0
incubated	incubated	NN	0
at	at	IN	0
37	37	CD	0
C.	C.	NNP	0
and	and	CC	0
10	10	CD	0
%	%	NN	0
CO2	CO2	NN	B-NP
.	.	.	0
As	As	IN	0
colonies	colonies	NNS	0
appeared	appeared	VBD	0
,	,	,	0
the	the	DT	0
supernatant	supernatant	NN	B-NP
were	were	VBD	0
assayed	assayed	VBN	0
for	for	IN	0
the	the	DT	0
production	production	NN	0
of	of	IN	0
humanized	humanized	JJ	0
antibody	antibody	NN	B-NP
and	and	CC	0
for	for	IN	0
the	the	DT	0
capability	capability	NN	0
of	of	IN	0
the	the	DT	0
expressed	expressed	JJ	0
antibody	antibody	NN	B-NP
to	to	TO	0
bind	bind	VB	0
to	to	TO	0
Stx1	Stx1	CD	B-NP
.	.	.	0
antibody	antibody	NN	B-NP
production	production	NN	I-NP
b.	b.	NN	I-NP
assay	assay	NN	I-NP
Antibody	Antibody	NN	B-NP
production	production	NN	I-NP
and	and	CC	0
activity	activity	NN	0
assays	assays	NN	0
for	for	IN	0
the	the	DT	0
stable	stable	JJ	0
transfectant	transfectant	NN	B-NP
were	were	VBD	0
performed	performed	VBN	0
as	as	RB	0
described	described	VBN	0
below	below	RB	0
.	.	.	0
These	These	DT	0
assays	assays	JJ	0
demonstrate	demonstrate	NN	0
that	that	IN	0
the	the	DT	0
transfection	transfection	NN	B-NP
of	of	IN	0
cells	cells	NNS	0
with	with	IN	0
this	this	DT	0
plasmid	plasmid	JJ	0
construct	construct	NN	0
can	can	MD	0
result	result	VB	0
in	in	IN	0
the	the	DT	0
production	production	NN	0
of	of	IN	0
a	a	DT	0
stable	stable	JJ	0
cell	cell	NN	0
line	line	NN	0
that	that	WDT	0
produces	produces	VBZ	0
a	a	DT	0
humanized	humanized	JJ	0
13c4	13c4	NN	B-NP
mouse	mouse	NN	I-NP
hybridoma	hybridoma	NN	I-NP
antibody	antibody	NN	I-NP
chimeric	chimeric	JJ	I-NP
version	version	NN	I-NP
(	(	-LRB-	0
designated	designated	VBN	0
H13C4	H13C4	CD	0
)	)	-RRB-	0
.	.	.	0
antibody	antibody	NN	B-NP
production	production	NN	I-NP
elisa	elisa	NNP	I-NP
assay	assay	NN	I-NP
were	were	VBD	0
performed	performed	VBN	0
in	in	IN	0
8-well	8-well	CD	0
strips	strips	NNS	0
from	from	IN	0
96-well	96-well	FW	0
microtiter	microtiter	NN	B-NP
plate	plate	NN	I-NP
(	(	-LRB-	0
Maxisorp	Maxisorp	NNP	B-NP
F8	F8	NNP	I-NP
;	;	:	0
Nunc	Nunc	NNP	B-NP
,	,	,	0
Inc.	Inc.	NNP	0
)	)	-RRB-	0
coated	coated	VBN	0
at	at	IN	0
a	a	DT	0
1	1	CD	0
:	:	:	0
500	500	CD	0
dilution	dilution	NN	0
with	with	IN	0
Goat	Goat	NNP	B-NP
anti-Human	anti-Human	JJ	I-NP
IgG	IgG	JJ	I-NP
antibody	antibody	NN	I-NP
(	(	-LRB-	0
Pierce	Pierce	NNP	0
or	or	CC	0
Biodesign	Biodesign	NNP	B-NP
International	International	NNP	0
)	)	-RRB-	0
using	using	VBG	0
a	a	DT	0
Tris-HCl	Tris-HCl	JJ	B-NP
coating	coating	NN	I-NP
buffer	buffer	NN	I-NP
,	,	,	0
pH	pH	JJ	0
8.5	8.5	CD	0
.	.	.	0
The	The	DT	0
plates	plates	NN	0
were	were	VBD	0
covered	covered	VBN	0
and	and	CC	0
incubated	incubated	JJ	0
overnight	overnight	JJ	0
at	at	IN	0
4	4	CD	0
c.	c.	NN	B-NP
plate	plate	NN	I-NP
were	were	VBD	0
then	then	RB	0
washed	washed	VBN	0
once	once	RB	0
with	with	IN	0
a	a	DT	0
wash	wash	JJ	B-NP
storage	storage	NN	I-NP
buffer	buffer	NN	I-NP
(	(	-LRB-	0
Tris-HCl	Tris-HCl	NNP	B-NP
/	/	NNP	I-NP
NaCl	NaCl	NNP	I-NP
/	/	CD	0
0.1	0.1	CD	0
%	%	NN	0
NaN3	NaN3	CD	B-NP
)	)	-RRB-	0
.	.	.	0
50	50	CD	0
culture	culture	NN	B-NP
supernatant	supernatant	NNS	I-NP
microliter	microliter	NN	I-NP
was	was	VBD	0
then	then	RB	0
applied	applied	VBN	0
to	to	TO	0
each	each	DT	0
well	well	NN	0
that	that	WDT	0
had	had	VBD	0
been	been	VBN	0
filled	filled	VBN	0
previously	previously	RB	0
with	with	IN	0
50	50	CD	0
sample/conjugate	sample/conjugate	NN	B-NP
diluent	diluent	NN	I-NP
microliter	microliter	NN	I-NP
(	(	-LRB-	0
Tris-HCl	Tris-HCl	NN	B-NP
/	/	NN	I-NP
NaCl	NaCl	NN	I-NP
/	/	NN	I-NP
gelatin	gelatin	NN	I-NP
/	/	NN	I-NP
Tween-20	Tween-20	NN	I-NP
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
plates	plates	NN	0
were	were	VBD	0
allowed	allowed	VBN	0
to	to	TO	0
incubate	incubate	VB	0
for	for	IN	0
30	30	CD	0
to	to	TO	0
60	60	CD	0
minutes	minutes	NNS	0
on	on	IN	0
a	a	DT	0
rotator	rotator	NN	B-NP
at	at	IN	0
room	room	NN	B-NP
temperature	temperature	NN	I-NP
.	.	.	0
They	They	PRP	0
were	were	VBD	0
then	then	RB	0
washed	washed	VBD	0
three	three	CD	0
times	times	NNS	0
with	with	IN	0
a	a	DT	0
wash	wash	JJ	B-NP
solution	solution	NN	I-NP
(	(	-LRB-	0
imidazole	imidazole	NN	B-NP
/	/	NN	I-NP
NaCl	NaCl	NN	I-NP
/	/	NN	I-NP
Tween-20	Tween-20	NN	I-NP
)	)	-RRB-	0
.	.	.	0
A	A	DT	0
goat	goat	JJ	B-NP
anti-human	anti-human	JJ	I-NP
kappa-HRP	kappa-HRP	NN	I-NP
(	(	-LRB-	0
Southern	Southern	NNP	0
Biotechnologies	Biotechnologies	NNP	0
)	)	-RRB-	0
conjugate	conjugate	NN	0
was	was	VBD	0
diluted	diluted	VBN	0
1	1	CD	0
:	:	:	0
250	250	CD	0
in	in	IN	0
the	the	DT	0
sample	sample	NN	B-NP
/	/	NN	I-NP
conjugate	conjugate	NN	I-NP
diluent	diluent	NN	I-NP
and	and	CC	0
100	100	CD	0
microliter	microliter	NN	B-NP
was	was	VBD	0
added	added	VBN	0
to	to	TO	0
the	the	DT	0
wells	wells	NNS	0
.	.	.	0
The	The	DT	0
plates	plates	NN	0
were	were	VBD	0
incubated	incubated	VBN	0
on	on	IN	0
a	a	DT	0
rotator	rotator	NN	B-NP
for	for	IN	0
30	30	CD	0
to	to	TO	0
60	60	CD	0
minutes	minutes	NNS	0
at	at	IN	0
room	room	NN	B-NP
temperature	temperature	NN	I-NP
.	.	.	0
They	They	PRP	0
were	were	VBD	0
washed	washed	VBN	0
6	6	CD	0
times	times	NNS	0
using	using	VBG	0
the	the	DT	0
wash	wash	JJ	B-NP
buffer	buffer	NN	I-NP
,	,	,	0
and	and	CC	0
then	then	RB	0
incubated	incubated	VBN	0
with	with	IN	0
100	100	CD	0
abt	abt	NNP	B-NP
l/well	l/well	NN	I-NP
developing	developing	VBG	0
substrate	substrate	NNS	0
(	(	-LRB-	0
Kirkgaard	Kirkgaard	NNP	0
Perry	Perry	NNP	0
Laboratories	Laboratories	NNPS	0
)	)	-RRB-	0
for	for	IN	0
8	8	CD	0
minutes	minutes	NNS	0
at	at	IN	0
room	room	NN	B-NP
temperature	temperature	NN	I-NP
.	.	.	0
The	The	DT	0
reaction	reaction	NN	0
was	was	VBD	0
stopped	stopped	VBN	0
with	with	IN	0
100	100	CD	0
L	L	NNP	B-NP
/	/	NNP	I-NP
well	well	RB	I-NP
of	of	IN	0
diluted	diluted	JJ	0
Quench	Quench	JJ	0
buffer	buffer	NN	B-NP
(	(	-LRB-	0
Kirkgaard	Kirkgaard	NNP	0
Perry	Perry	NNP	0
Laboratories	Laboratories	NNPS	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
absorbance	absorbance	JJ	B-NP
value	value	NN	I-NP
at	at	IN	0
405	405	CD	0
nm	nm	NN	B-NP
was	was	VBD	0
determined	determined	VBN	0
using	using	VBG	0
an	an	DT	0
automated	automated	VBN	B-NP
microtiter	microtiter	NN	I-NP
plate	plate	NN	I-NP
ELISA	ELISA	NNP	I-NP
reader	reader	NN	I-NP
(	(	-LRB-	0
cere	cere	NN	B-NP
UV900HI	UV900HI	NNP	0
,	,	,	0
Bioteck	Bioteck	NNP	B-NP
,	,	,	0
Winooski	Winooski	NNP	B-NP
,	,	,	0
Vt.	Vt.	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
controls	controls	NNS	0
for	for	IN	0
the	the	DT	0
ELISA	ELISA	NNP	B-NP
assay	assay	NN	I-NP
were	were	VBD	0
a	a	DT	0
human	human	JJ	0
IgG1K	IgG1K	FW	0
myeloma	myeloma	FW	0
protein	protein	FW	0
(	(	-LRB-	0
Biodesign	Biodesign	NNP	B-NP
International	International	NNP	0
)	)	-RRB-	0
and	and	CC	0
supernatant	supernatant	VB	0
collected	collected	VBN	0
from	from	IN	0
non-transfected	non-transfected	NNP	0
NSO	NSO	NNP	B-NP
cells	cells	NNS	0
.	.	.	0
This	This	DT	0
assay	assay	NN	B-NP
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
8	8	CD	0
)	)	-RRB-	0
demonstrates	demonstrates	VBZ	0
that	that	IN	0
the	the	DT	0
transfection	transfection	NN	B-NP
of	of	IN	0
cells	cells	NNS	0
with	with	IN	0
this	this	DT	0
plasmid	plasmid	JJ	0
construct	construct	JJ	0
results	results	NNS	0
in	in	IN	0
the	the	DT	0
cells	cells	NNS	0
producing	producing	VBG	0
a	a	DT	0
molecule	molecule	NN	B-NP
containing	containing	VBG	0
both	both	DT	0
human	human	JJ	0
heavy	heavy	JJ	0
chain	chain	NN	0
(	(	-LRB-	0
IgG	IgG	NNP	B-NP
)	)	-RRB-	0
and	and	CC	0
light	light	JJ	0
chain	chain	NN	0
(	(	-LRB-	0
kappa	kappa	LS	B-NP
)	)	-RRB-	0
domains	domains	NN	0
.	.	.	0
The	The	DT	0
supernatant	supernatant	NN	B-NP
were	were	VBD	0
then	then	RB	0
assayed	assayed	VBN	0
for	for	IN	0
the	the	DT	0
ability	ability	NN	B-NP
of	of	IN	0
the	the	DT	0
expressed	expressed	JJ	0
antibody	antibody	NN	B-NP
to	to	TO	0
bind	bind	VB	0
to	to	TO	0
Stx1	Stx1	CD	B-NP
protein	protein	NN	I-NP
by	by	IN	0
ELISA	ELISA	NNP	B-NP
.	.	.	0
The	The	DT	0
activity	activity	NN	0
assays	assays	NNS	0
were	were	VBD	0
preformed	preformed	VBN	0
in	in	IN	0
8-well	8-well	CD	0
strips	strips	NNS	0
from	from	IN	0
96-well	96-well	FW	0
microtiter	microtiter	NN	B-NP
plate	plate	NN	I-NP
(	(	-LRB-	0
Maxisorp	Maxisorp	NNP	B-NP
F8	F8	NNP	I-NP
;	;	:	0
Nunc	Nunc	NNP	B-NP
,	,	,	0
Inc.	Inc.	NNP	0
)	)	-RRB-	0
coated	coated	VBN	0
with	with	IN	0
approximately	approximately	RB	0
0.1	0.1	CD	0
g	g	NN	B-NP
/	/	VBP	I-NP
well	well	RB	I-NP
purified	purified	JJ	0
Stx1	Stx1	NN	B-NP
received	received	VBD	0
from	from	IN	0
Alison	Alison	NNP	B-NP
O	O	NNP	I-NP
'	'	POS	0
Brien	Brien	NNP	0
(	(	-LRB-	0
or	or	CC	0
obtained	obtained	VBD	0
as	as	RB	0
described	described	VBN	0
in	in	IN	0
Example	Example	NNP	0
7	7	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
plate	plate	NN	0
coating	coating	NN	0
and	and	CC	0
ELISA	ELISA	NNP	B-NP
procedure	procedure	NN	I-NP
was	was	VBD	0
performed	performed	VBN	0
in	in	IN	0
the	the	DT	0
same	same	JJ	0
manner	manner	NN	0
as	as	IN	0
the	the	DT	0
antibody	antibody	NN	B-NP
assay	assay	NN	I-NP
above	above	IN	0
with	with	IN	0
the	the	DT	0
tmb	tmb	NN	B-NP
substitution	substitution	NN	I-NP
(	(	-LRB-	0
Kirkgaard	Kirkgaard	NNP	0
Perry	Perry	NNP	0
Laboratories	Laboratories	NNPS	0
)	)	-RRB-	0
for	for	IN	0
abt	abt	NNP	B-NP
as	as	IN	0
a	a	DT	0
developing	developing	VBG	0
substrate	substrate	NNS	0
.	.	.	0
The	The	DT	0
absorbance	absorbance	JJ	B-NP
value	value	NN	I-NP
at	at	IN	0
450	450	CD	0
nm	nm	NN	B-NP
was	was	VBD	0
determined	determined	VBN	0
using	using	VBG	0
an	an	DT	0
automated	automated	VBN	B-NP
microtiter	microtiter	NN	I-NP
plate	plate	NN	I-NP
ELISA	ELISA	NNP	I-NP
reader	reader	NN	I-NP
(	(	-LRB-	0
cere	cere	NN	B-NP
UV900HI	UV900HI	NNP	0
,	,	,	0
Bioteck	Bioteck	NNP	B-NP
,	,	,	0
Winooski	Winooski	NNP	B-NP
,	,	,	0
Vt.	Vt.	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
As	As	IN	0
a	a	DT	0
positive	positive	JJ	B-NP
control	control	NN	I-NP
,	,	,	0
the	the	DT	0
monoclonal	monoclonal	NN	B-NP
antibody	antibody	NN	I-NP
13c4	13c4	NN	I-NP
original	original	JJ	I-NP
mouse	mouse	NN	I-NP
was	was	VBD	0
used	used	VBN	0
,	,	,	0
and	and	CC	0
assayed	assayed	NN	0
with	with	IN	0
a	a	DT	0
goat	goat	JJ	B-NP
anti-mouse	anti-mouse	JJ	I-NP
IgG	IgG	JJ	I-NP
conjugate	conjugate	NNS	0
(	(	-LRB-	0
Jackson	Jackson	NNP	0
Laboratories	Laboratories	NNPS	0
)	)	-RRB-	0
at	at	IN	0
a	a	DT	0
1	1	CD	0
:	:	:	0
2000	2000	CD	0
dilution	dilution	NN	0
.	.	.	0
This	This	DT	0
assay	assay	NN	B-NP
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
9	9	CD	0
)	)	-RRB-	0
demonstrates	demonstrates	VBZ	0
that	that	IN	0
the	the	DT	0
transfection	transfection	NN	B-NP
of	of	IN	0
cells	cells	NNS	0
with	with	IN	0
this	this	DT	0
plasmid	plasmid	JJ	0
construct	construct	JJ	0
results	results	NNS	0
in	in	IN	0
cells	cells	NNS	0
producing	producing	VBG	B-NP
immunoglobulin	immunoglobulin	NN	I-NP
that	that	IN	0
binds	binds	VBG	0
to	to	TO	0
Stx1	Stx1	CD	B-NP
.	.	.	0
Neither	Neither	DT	0
mouse	mouse	NN	0
nor	nor	CC	0
human	human	JJ	0
IgG	IgG	JJ	0
1K	1K	NN	0
lacking	lacking	VBG	0
the	the	DT	0
anti-Stx	anti-Stx	JJ	B-NP
variable	variable	JJ	0
region	region	NN	0
bound	bound	VBN	0
the	the	DT	0
toxin	toxin	NN	B-NP
.	.	.	0
ehec	ehec	NN	B-NP
anti-stx2	anti-stx2	NN	I-NP
antibody	antibody	NN	I-NP
humanization	humanization	NN	I-NP
:	:	:	0
11E10	11E10	LS	B-NP
The	The	DT	0
following	following	JJ	0
examples	examples	NNS	0
4-7	4-7	VBP	0
relate	relate	VBN	0
to	to	TO	0
anti-Stx2	anti-Stx2	CD	B-NP
and	and	CC	0
-Stx2	-Stx2	CD	0
variant	variant	JJ	0
antibody	antibody	NN	B-NP
11E10	11E10	NN	I-NP
and	and	CC	0
its	its	PRP$	0
humanized	humanized	JJ	0
counterpart	counterpart	NN	0
H11E10	H11E10	NN	0
.	.	.	0
The	The	DT	0
hybridoma	hybridoma	JJ	B-NP
cell	cell	NN	I-NP
line	line	NN	I-NP
producing	producing	VBG	0
the	the	DT	0
11	11	CD	0
E10	E10	CD	B-NP
antibody	antibody	NN	I-NP
(	(	-LRB-	0
Anti-Stx2	Anti-Stx2	NNP	B-NP
)	)	-RRB-	0
was	was	VBD	0
deposited	deposited	VBN	0
on	on	IN	0
Aug.	Aug.	NNP	0
1	1	CD	0
,	,	,	0
1990	1990	CD	0
,	,	,	0
at	at	IN	0
the	the	DT	0
American	American	NNP	0
Type	Type	NNP	B-NP
Culture	Culture	NNP	I-NP
Collection	Collection	NNP	I-NP
,	,	,	0
10801	10801	CD	0
University	University	NNP	0
Boulevard	Boulevard	NNP	0
,	,	,	0
manassa	manassa	NNP	B-NP
,	,	,	0
Va.	Va.	NNP	0
,	,	,	0
20110-2209	20110-2209	NNP	0
,	,	,	0
under	under	IN	0
Accession	Accession	NNP	B-NP
No	No	NNP	0
.	.	.	0
CRL	CRL	NNP	B-NP
1987	1987	CD	0
,	,	,	0
and	and	CC	0
can	can	MD	0
be	be	VB	0
obtained	obtained	VBN	0
from	from	IN	0
the	the	DT	0
ATCC	ATCC	NNP	B-NP
,	,	,	0
or	or	CC	0
,	,	,	0
as	as	RB	0
here	here	RB	0
,	,	,	0
from	from	IN	0
Dr.	Dr.	NNP	B-NP
Alison	Alison	NNP	B-NP
O	O	NNP	I-NP
'	'	POS	0
Brien	Brien	NNP	0
(	(	-LRB-	0
for	for	IN	0
details	details	NNS	0
of	of	IN	0
hybridoma	hybridoma	JJ	B-NP
preparation	preparation	NN	I-NP
,	,	,	0
see	see	VB	0
Perera	Perera	NNP	0
,	,	,	0
L.	L.	NNP	B-NP
P.	P.	NNP	I-NP
et	et	NNP	0
al.	al.	NNP	0
,	,	,	0
J	J	NNP	B-NP
Clinical	Clinical	NNP	I-NP
Microbil.	Microbil.	NNP	I-NP
,	,	,	0
26	26	CD	0
:	:	:	0
2127-2131	2127-2131	CD	0
(	(	-LRB-	0
1988	1988	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
.	.	.	0
A	A	DT	0
vial	vial	NN	0
of	of	IN	0
the	the	DT	0
cell	cell	NN	0
line	line	NN	0
was	was	VBD	0
thawed	thawed	CD	0
,	,	,	0
washed	washed	VBN	0
with	with	IN	0
serum	serum	JJ	B-NP
free	free	JJ	0
medium	medium	NN	0
and	and	CC	0
then	then	RB	0
resuspended	resuspended	VBN	0
in	in	IN	0
IMDM	IMDM	NNP	B-NP
(	(	-LRB-	0
Mediatech	Mediatech	NNP	B-NP
)	)	-RRB-	0
complete	complete	JJ	0
media	media	NNS	0
supplemented	supplemented	VBN	0
with	with	IN	0
10	10	CD	0
%	%	NN	0
FBS	FBS	NNP	B-NP
(	(	-LRB-	0
Irvine	Irvine	NNP	0
)	)	-RRB-	0
.	.	.	0
Total	Total	JJ	B-NP
RNA	RNA	NNP	I-NP
was	was	VBD	0
isolated	isolated	VBN	0
from	from	IN	0
1	1	CD	0
107	107	CD	0
11e10	11e10	NN	B-NP
cell	cell	NN	I-NP
using	using	VBG	0
the	the	DT	0
RNeasy	RNeasy	JJ	B-NP
RNA	RNA	NNP	I-NP
Isolation	Isolation	NNP	I-NP
kit	kit	NN	I-NP
(	(	-LRB-	0
Qiagen	Qiagen	NNP	B-NP
)	)	-RRB-	0
following	following	VBG	0
the	the	DT	0
manufacturer	manufacturer	NN	0
's	's	POS	0
procedure	procedure	NN	0
.	.	.	0
The	The	DT	0
RNA	RNA	NNP	B-NP
was	was	VBD	0
dissolved	dissolved	VBN	0
in	in	IN	0
10	10	CD	0
mm	mm	NN	B-NP
tri	tri	NNP	I-NP
,	,	,	0
0.1	0.1	CD	0
mM	mM	JJ	B-NP
EDTA	EDTA	NNP	I-NP
(	(	-LRB-	0
pH	pH	NNP	B-NP
8.4	8.4	CD	0
)	)	-RRB-	0
containing	containing	VBG	0
0.03	0.03	CD	0
U	U	NNP	0
/	/	NNP	0
g	g	VBD	0
Prime	Prime	NNP	B-NP
RNase	RNase	NNP	I-NP
Inhibitor	Inhibitor	NNP	I-NP
(	(	-LRB-	0
5	5	CD	0
-3	-3	CD	0
)	)	-RRB-	0
to	to	TO	0
a	a	DT	0
final	final	JJ	B-NP
concentration	concentration	NN	I-NP
of	of	IN	0
0.63	0.63	CD	0
g	g	CD	0
/	/	CD	0
l	l	NN	0
.	.	.	0
FIG.	FIG.	CD	0
1	1	CD	0
shows	shows	NNS	0
the	the	DT	0
strategy	strategy	NN	0
for	for	IN	0
cloning	cloning	VBG	0
the	the	DT	0
variable	variable	JJ	0
region	region	NN	0
gene	gene	NN	0
fragments	fragments	NNS	0
and	and	CC	0
FIG.	FIG.	CD	0
5	5	CD	0
lists	lists	NNS	0
the	the	DT	0
oligonucleotide	oligonucleotide	JJ	B-NP
primer	primer	NN	I-NP
used	used	VBN	0
.	.	.	0
The	The	DT	0
11E10	11E10	JJ	B-NP
total	total	JJ	I-NP
RNA	RNA	NNP	I-NP
(	(	-LRB-	0
2.5	2.5	CD	0
g	g	CD	0
)	)	-RRB-	0
was	was	VBD	0
converted	converted	VBN	0
to	to	TO	0
cDNA	cDNA	JJ	0
by	by	IN	0
using	using	VBG	0
Superscript	Superscript	NNP	0
11-MMLV	11-MMLV	NNP	0
Reverse	Reverse	NNP	0
Transcriptase	Transcriptase	NNP	0
(	(	-LRB-	0
Life	Life	NNP	0
Technologies	Technologies	NNPS	0
)	)	-RRB-	0
according	according	VBG	0
to	to	TO	0
manufacturer	manufacturer	NN	0
's	's	POS	0
procedures	procedures	NNS	0
.	.	.	0
The	The	DT	0
mouse	mouse	NN	0
light	light	NN	0
chain	chain	NN	0
(	(	-LRB-	0
JS153	JS153	NNP	B-NP
,	,	,	0
JS154	JS154	NNP	B-NP
,	,	,	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
11	11	CD	0
and	and	CC	0
12	12	CD	0
)	)	-RRB-	0
and	and	CC	0
mouse	mouse	JJ	0
heavy	heavy	JJ	0
chain	chain	NN	0
(	(	-LRB-	0
JS300	JS300	NNP	B-NP
,	,	,	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
6	6	CD	0
)	)	-RRB-	0
were	were	VBD	0
used	used	VBN	0
as	as	IN	0
specific	specific	JJ	0
primers	primers	NN	0
.	.	.	0
The	The	DT	0
first	first	JJ	0
strand	strand	JJ	0
cdna	cdna	NN	B-NP
synthesis	synthesis	NN	I-NP
product	product	NN	I-NP
were	were	VBD	0
then	then	RB	0
purified	purified	VBP	0
using	using	VBG	0
a	a	DT	0
concentrator	concentrator	JJ	B-NP
device	device	NN	I-NP
centricon-30	centricon-30	NN	I-NP
(	(	-LRB-	0
Amicon	Amicon	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
Of	Of	IN	0
the	the	DT	0
70	70	CD	0
l	l	NN	0
of	of	IN	0
cDNA	cDNA	JJ	B-NP
recovered	recovered	NN	I-NP
,	,	,	0
3.5	3.5	CD	0
l	l	NNS	0
was	was	VBD	0
used	used	VBN	0
as	as	IN	0
pcr	pcr	NN	B-NP
template	template	JJ	I-NP
dna	dna	NN	I-NP
.	.	.	0
typical	typical	JJ	B-NP
pcr	pcr	NN	I-NP
amplification	amplification	NN	I-NP
reaction	reaction	NN	I-NP
(	(	-LRB-	0
100	100	CD	0
l	l	CD	0
)	)	-RRB-	0
contained	contained	VBD	B-NP
template	template	JJ	I-NP
DNA	DNA	NN	I-NP
,	,	,	0
50	50	CD	0
pmole	pmole	NN	B-NP
of	of	IN	0
the	the	DT	0
appropriate	appropriate	JJ	0
primers	primers	NNS	0
(	(	-LRB-	0
JS153	JS153	NNP	B-NP
,	,	,	0
JS154	JS154	NNP	B-NP
and	and	CC	0
JS009	JS009	NNP	B-NP
,	,	,	0
JS010	JS010	NNP	B-NP
,	,	,	0
JS011	JS011	NNP	B-NP
,	,	,	0
JS012	JS012	NNP	B-NP
,	,	,	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
7-12	7-12	CD	0
for	for	IN	0
light	light	JJ	0
chains	chains	NNS	0
,	,	,	0
JS160	JS160	NNP	B-NP
,	,	,	0
JS161	JS161	NNP	B-NP
,	,	,	0
JS162	JS162	NNP	B-NP
and	and	CC	0
JS001	JS001	NNP	B-NP
,	,	,	0
JS002	JS002	NNP	B-NP
,	,	,	0
JS003	JS003	NNP	B-NP
,	,	,	0
JS004	JS004	NNP	B-NP
,	,	,	0
JS008	JS008	NNP	B-NP
,	,	,	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
28-30	28-30	CD	0
,	,	,	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
2-5	2-5	CD	0
for	for	IN	0
heavy	heavy	JJ	0
chains	chains	NNS	0
)	)	-RRB-	0
,	,	,	0
2.5	2.5	CD	0
units	units	NNS	0
of	of	IN	0
ExTaq	ExTaq	JJ	B-NP
polymerasa	polymerasa	NN	I-NP
(	(	-LRB-	0
PanVera	PanVera	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
1	1	CD	0
ExTaq	ExTaq	JJ	B-NP
reaction	reaction	NN	I-NP
buffer	buffer	NN	I-NP
,	,	,	0
200	200	CD	0
M	M	NNP	0
dNTP	dNTP	NNP	B-NP
,	,	,	0
and	and	CC	0
2	2	CD	0
mM	mM	JJ	B-NP
MgCl2	MgCl2	NN	I-NP
.	.	.	0
The	The	DT	0
template	template	NN	B-NP
was	was	VBD	0
denatured	denatured	VBN	0
by	by	IN	0
an	an	DT	0
initial	initial	JJ	0
five	five	CD	0
minute	minute	NN	B-NP
incubation	incubation	NN	I-NP
at	at	IN	0
96	96	CD	0
C.	C.	CD	0
The	The	DT	0
products	products	NNS	0
were	were	VBD	0
amplified	amplified	VBN	0
by	by	IN	0
35	35	CD	0
thermal	thermal	JJ	B-NP
cycle	cycle	NN	I-NP
of	of	IN	0
96	96	CD	0
C.	C.	NNP	0
for	for	IN	0
1	1	CD	0
min.	min.	CD	B-NP
,	,	,	0
55	55	CD	0
C.	C.	NNP	0
for	for	IN	0
30	30	CD	0
sec.	sec.	CD	0
,	,	,	0
and	and	CC	0
72	72	CD	0
C.	C.	NNP	0
for	for	IN	0
30	30	CD	0
sec	sec	NN	0
,	,	,	0
followed	followed	VBN	0
by	by	IN	0
5	5	CD	0
min.	min.	CD	B-NP
at	at	IN	0
72	72	CD	0
C.	C.	NNP	0
The	The	NNP	0
pcr	pcr	NN	B-NP
product	product	NN	I-NP
from	from	IN	0
the	the	DT	0
successful	successful	JJ	0
reactions	reactions	NNS	0
were	were	VBD	0
purified	purified	VBN	0
using	using	VBG	0
the	the	DT	0
Wizard	Wizard	NNP	B-NP
PCR	PCR	NNP	I-NP
Purification	Purification	NNP	I-NP
system	system	NN	I-NP
(	(	-LRB-	0
Promega	Promega	NNP	B-NP
)	)	-RRB-	0
as	as	IN	0
per	per	IN	0
manufacturer	manufacturer	NN	0
's	's	POS	0
procedure	procedure	NN	0
.	.	.	0
The	The	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
pcr	pcr	NN	I-NP
product	product	NN	I-NP
(	(	-LRB-	0
approximately	approximately	RB	0
400	400	CD	0
bp	bp	CD	B-NP
)	)	-RRB-	0
and	and	CC	0
the	the	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
pcr	pcr	NN	I-NP
product	product	NN	I-NP
(	(	-LRB-	0
approximately	approximately	RB	0
350	350	CD	0
bp	bp	CD	B-NP
)	)	-RRB-	0
were	were	VBD	0
then	then	RB	0
cloned	cloned	VBN	0
into	into	IN	0
a	a	DT	0
dna	dna	NN	B-NP
sequence	sequence	NN	I-NP
determination	determination	NN	I-NP
bacterial	bacterial	JJ	I-NP
vector	vector	NN	I-NP
.	.	.	0
pcr	pcr	NN	B-NP
fragment	fragment	NN	I-NP
ligation	ligation	NN	I-NP
were	were	VBD	0
carried	carried	VBN	0
out	out	RP	0
into	into	IN	0
the	the	DT	0
pCR2.1	pCR2.1	JJ	0
T	T	NN	B-NP
/	/	VBZ	I-NP
A	A	DT	I-NP
style	style	NN	I-NP
cloning	cloning	NN	I-NP
vector	vector	NN	I-NP
(	(	-LRB-	0
Invitrogen	Invitrogen	NNP	B-NP
)	)	-RRB-	0
following	following	VBG	0
the	the	DT	0
manufacturer	manufacturer	NN	0
's	's	POS	0
procedures	procedures	NNS	0
using	using	VBG	0
a	a	DT	0
3	3	CD	0
:	:	:	0
1	1	CD	0
insert	insert	NN	0
to	to	TO	0
molar	molar	JJ	B-NP
ratio	ratio	NN	I-NP
vector	vector	VB	I-NP
.	.	.	0
Two	Two	CD	0
l	l	NN	0
of	of	IN	0
the	the	DT	0
ligation	ligation	JJ	B-NP
reaction	reaction	NN	I-NP
were	were	VBD	0
used	used	VBN	0
to	to	TO	0
transform	transform	VB	0
the	the	DT	0
INV	INV	NNP	B-NP
F	F	NNP	0
competent	competent	JJ	0
cells	cells	NNS	0
(	(	-LRB-	0
Invitrogen	Invitrogen	NNP	B-NP
)	)	-RRB-	0
as	as	IN	0
per	per	IN	0
the	the	DT	0
manufacturer	manufacturer	NN	0
's	's	POS	0
procedure	procedure	NN	0
.	.	.	0
containing	containing	VBG	B-NP
dna	dna	NN	I-NP
insert	insert	NN	I-NP
plasmid	plasmid	NN	I-NP
clone	clone	NN	I-NP
were	were	VBD	0
identified	identified	VBN	0
using	using	VBG	0
diagnostic	diagnostic	JJ	B-NP
restriction	restriction	NN	I-NP
enzyme	enzyme	NN	I-NP
digest	digest	NN	I-NP
,	,	,	0
with	with	IN	0
EcoRI	EcoRI	NNP	B-NP
(	(	-LRB-	0
new	new	JJ	B-NP
england	england	NNP	I-NP
biolab	biolab	NN	I-NP
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
plasmid	plasmid	NN	B-NP
dna	dna	NN	I-NP
sequence	sequence	NN	I-NP
containing	containing	VBG	0
the	the	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
insert	insert	NN	I-NP
of	of	IN	0
the	the	DT	0
appropriate	appropriate	JJ	0
size	size	NN	0
(	(	-LRB-	0
400	400	CD	0
bp	bp	CD	B-NP
)	)	-RRB-	0
was	was	VBD	0
then	then	RB	0
determined	determined	VBN	0
.	.	.	0
The	The	DT	0
final	final	JJ	B-NP
consensus	consensus	NN	I-NP
DNA	DNA	NN	I-NP
sequence	sequence	NN	I-NP
of	of	IN	0
the	the	DT	0
heavy	heavy	JJ	0
11e10	11e10	NN	B-NP
chain	chain	NN	I-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
is	is	VBZ	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
6	6	CD	0
with	with	IN	0
the	the	DT	0
complementarity	complementarity	NN	B-NP
determining	determining	VBG	I-NP
region	region	NN	I-NP
indicated	indicated	VBD	0
by	by	IN	0
underlining	underlining	NN	0
.	.	.	0
The	The	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
plasmid	plasmid	NNS	I-NP
clone	clone	NN	I-NP
needed	needed	VBN	0
to	to	TO	0
be	be	VB	0
further	further	RB	0
characterized	characterized	VBN	0
because	because	IN	0
the	the	DT	0
hybridoma	hybridoma	JJ	B-NP
cell	cell	NN	I-NP
line	line	NN	I-NP
that	that	WDT	0
expresses	expresses	VBZ	0
the	the	DT	0
11E10	11E10	JJ	B-NP
antibody	antibody	NN	I-NP
was	was	VBD	0
made	made	VBN	0
by	by	IN	0
fusing	fusing	JJ	0
mouse	mouse	NN	B-NP
splenocyte	splenocyte	NN	I-NP
with	with	IN	0
sp20	sp20	NN	B-NP
myeloma	myeloma	CD	I-NP
cell	cell	NN	I-NP
.	.	.	0
The	The	DT	0
SP20	SP20	JJ	B-NP
cell	cell	NN	I-NP
line	line	NN	I-NP
transcribes	transcribes	VBD	0
a	a	DT	0
kappa	kappa	JJ	B-NP
pseudogene	pseudogene	NN	I-NP
light	light	JJ	0
chain	chain	NN	0
.	.	.	0
The	The	DT	0
pseudogene	pseudogene	JJ	B-NP
transcript	transcript	NN	I-NP
,	,	,	0
when	when	WRB	0
converted	converted	VBN	0
to	to	TO	0
cDNA	cDNA	JJ	0
by	by	IN	0
RT-PCR	RT-PCR	NNP	B-NP
,	,	,	0
contains	contains	VBZ	0
an	an	DT	0
AflIII	AflIII	JJ	B-NP
restriction	restriction	NN	I-NP
site	site	NN	I-NP
.	.	.	0
For	For	IN	0
this	this	DT	0
reason	reason	NN	0
,	,	,	0
the	the	DT	0
plasmid	plasmid	JJ	B-NP
clone	clone	NN	I-NP
for	for	IN	0
the	the	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
were	were	VBD	0
digested	digested	VBN	0
with	with	IN	0
AflIII	AflIII	JJ	0
and	and	CC	0
those	those	DT	0
products	products	NNS	0
that	that	WDT	0
did	did	VBD	0
not	not	RB	0
cut	cut	VB	0
were	were	VBD	0
then	then	RB	0
submitted	submitted	VBN	0
for	for	IN	0
DNA	DNA	NNP	B-NP
sequencing	sequencing	NN	I-NP
.	.	.	0
The	The	DT	0
final	final	JJ	B-NP
consensus	consensus	NN	I-NP
sequence	sequence	NN	I-NP
of	of	IN	0
the	the	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
is	is	VBZ	0
shown	shown	VBN	0
in	in	IN	0
FIG.	FIG.	CD	0
6	6	CD	0
,	,	,	0
with	with	IN	0
the	the	DT	0
complementarity	complementarity	NN	B-NP
determining	determining	VBG	I-NP
region	region	NN	I-NP
indicated	indicated	VBD	0
by	by	IN	0
underlining	underlining	NN	0
.	.	.	0
The	The	DT	0
variable	variable	JJ	0
region	region	NN	0
gene	gene	NN	0
fragments	fragments	NNS	0
were	were	VBD	0
re-amplified	re-amplified	JJ	0
by	by	IN	0
PCR	PCR	NNP	B-NP
using	using	VBG	0
primers	primers	NNS	0
that	that	WDT	0
adapted	adapted	VBD	0
the	the	DT	0
fragments	fragments	NN	0
for	for	IN	0
cloning	cloning	NN	B-NP
into	into	IN	0
the	the	DT	0
expression	expression	NN	B-NP
vector	vector	NN	I-NP
(	(	-LRB-	0
see	see	VB	0
FIGS.	FIGS.	CD	0
5	5	CD	0
and	and	CC	0
7	7	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
front	front	NN	I-NP
primer	primer	NN	I-NP
(	(	-LRB-	0
11E10HF	11E10HF	NNP	0
,	,	,	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
37	37	CD	0
)	)	-RRB-	0
includes	includes	VBZ	0
a	a	DT	0
5	5	CD	0
tail	tail	NN	0
that	that	IN	0
encodes	encodes	VBG	0
the	the	DT	0
C-terminus	C-terminus	JJ	B-NP
of	of	IN	0
the	the	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
leader	leader	NN	I-NP
and	and	CC	0
an	an	DT	0
cloning	cloning	NN	B-NP
nrui	nrui	NN	I-NP
restriction	restriction	NN	I-NP
site	site	NN	I-NP
,	,	,	0
while	while	IN	0
the	the	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
reverse	reverse	NN	I-NP
primer	primer	NN	I-NP
(	(	-LRB-	0
11E10HB	11E10HB	NNP	0
,	,	,	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
38	38	CD	0
)	)	-RRB-	0
adds	adds	VBZ	0
a	a	DT	0
3	3	CD	0
cloning	cloning	NN	B-NP
ecori	ecori	NN	I-NP
restriction	restriction	NN	I-NP
site	site	NN	I-NP
.	.	.	0
The	The	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
front	front	NN	I-NP
primer	primer	NN	I-NP
(	(	-LRB-	0
11E10LF	11E10LF	NNP	0
,	,	,	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
39	39	CD	0
)	)	-RRB-	0
includes	includes	VBZ	0
a	a	DT	0
5	5	CD	0
tail	tail	NN	0
that	that	IN	0
encodes	encodes	VBG	0
the	the	DT	0
C-terminus	C-terminus	JJ	B-NP
of	of	IN	0
the	the	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
leader	leader	NN	I-NP
and	and	CC	0
an	an	DT	0
EcoRV	EcoRV	JJ	B-NP
restriction	restriction	NN	I-NP
site	site	NN	I-NP
at	at	IN	0
the	the	DT	0
N-terminus	N-terminus	JJ	B-NP
of	of	IN	0
the	the	DT	0
light	light	JJ	0
cloning	cloning	NN	B-NP
chain	chain	NN	I-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
,	,	,	0
while	while	IN	0
the	the	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
reverse	reverse	NN	I-NP
primer	primer	NN	I-NP
(	(	-LRB-	0
11E10LB	11E10LB	NNP	0
,	,	,	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
40	40	CD	0
)	)	-RRB-	0
adds	adds	VBZ	0
a	a	DT	0
3	3	CD	0
joining	joining	VBG	B-NP
region-kappa	region-kappa	JJ	I-NP
exon	exon	JJ	I-NP
splice	splice	NNS	I-NP
junction	junction	VBP	I-NP
dna	dna	NN	I-NP
sequence	sequence	NN	I-NP
followed	followed	VBN	0
by	by	IN	0
a	a	DT	0
cloning	cloning	NN	B-NP
bstbi	bstbi	NN	I-NP
restriction	restriction	NN	I-NP
site	site	NN	I-NP
.	.	.	0
pcr	pcr	NN	B-NP
were	were	VBD	0
performed	performed	VBN	0
as	as	RB	0
described	described	VBN	0
above	above	IN	0
except	except	NN	0
,	,	,	0
following	following	VBG	0
a	a	DT	0
5	5	CD	0
min.	min.	CD	B-NP
incubation	incubation	NN	0
at	at	IN	0
96	96	CD	0
C.	C.	NNP	0
,	,	,	0
the	the	DT	0
pcr	pcr	NN	B-NP
parameter	parameter	NN	I-NP
were	were	VBD	0
30	30	CD	0
thermal	thermal	JJ	B-NP
cycle	cycle	NN	I-NP
of	of	IN	0
96	96	CD	0
C.	C.	NNP	0
for	for	IN	0
1	1	CD	0
min.	min.	CD	B-NP
,	,	,	0
62	62	CD	0
C.	C.	NNP	0
for	for	IN	0
30	30	CD	0
sec.	sec.	CD	0
,	,	,	0
and	and	CC	0
70	70	CD	0
C.	C.	NNP	0
for	for	IN	0
30	30	CD	0
sec.	sec.	CD	0
,	,	,	0
followed	followed	VBN	0
by	by	IN	0
5	5	CD	0
min.	min.	CD	B-NP
at	at	IN	0
72	72	CD	0
C	C	NNP	0
.	.	.	0
The	The	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
PCR	PCR	NNP	I-NP
product	product	NN	I-NP
was	was	VBD	0
then	then	RB	0
subcloned	subcloned	VBN	0
into	into	IN	0
a	a	DT	0
mammalian	mammalian	NN	B-NP
expression	expression	NN	I-NP
plasmid	plasmid	NN	I-NP
vector	vector	NN	I-NP
(	(	-LRB-	0
pJRS315	pJRS315	NNP	B-NP
,	,	,	0
produced	produced	VBD	0
as	as	RB	0
set	set	VBN	0
forth	forth	RB	0
below	below	RB	0
in	in	IN	0
Example	Example	NNP	0
5	5	CD	0
)	)	-RRB-	0
for	for	IN	0
production	production	NN	0
of	of	IN	0
recombinant	recombinant	FW	0
chimeric	chimeric	NN	B-NP
mouse/human	mouse/human	NN	I-NP
antibody	antibody	NN	I-NP
molecule	molecule	NN	I-NP
.	.	.	0
The	The	DT	0
resulting	resulting	VBG	B-NP
vector	vector	JJ	I-NP
clone	clone	NN	I-NP
was	was	VBD	0
designated	designated	VBN	B-NP
pACE1	pACE1	CD	I-NP
.	.	.	0
Before	Before	IN	0
the	the	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
could	could	MD	0
be	be	VB	0
subcloned	subcloned	VBN	0
into	into	IN	0
the	the	DT	0
mammalian	mammalian	JJ	B-NP
expression	expression	NN	I-NP
vector	vector	NN	I-NP
,	,	,	0
it	it	PRP	0
was	was	VBD	0
subcloned	subcloned	VBN	0
into	into	IN	0
the	the	DT	0
pCR2.1	pCR2.1	JJ	0
T	T	NN	B-NP
/	/	VBZ	I-NP
A	A	DT	I-NP
style	style	NN	I-NP
cloning	cloning	NN	I-NP
vector	vector	VBP	I-NP
previously	previously	RB	0
described	described	VBN	0
.	.	.	0
The	The	DT	0
resulting	resulting	VBG	B-NP
plasmid	plasmid	NN	I-NP
was	was	VBD	0
designated	designated	VBN	0
pACELC	pACELC	JJ	0
and	and	CC	0
digested	digested	NN	0
,	,	,	0
with	with	IN	0
BstBI	BstBI	NNP	B-NP
/	/	NNP	I-NP
EcoRV	EcoRV	NNP	I-NP
,	,	,	0
to	to	TO	0
cut	cut	VB	0
out	out	RP	0
the	the	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
.	.	.	0
The	The	DT	0
variable	variable	JJ	0
region	region	NN	0
was	was	VBD	0
then	then	RB	0
subcloned	subcloned	VBN	0
into	into	IN	0
the	the	DT	0
mammalian	mammalian	JJ	B-NP
expression	expression	NN	I-NP
vector	vector	NN	I-NP
containing	containing	VBG	0
the	the	DT	0
11E10	11E10	JJ	B-NP
heavy	heavy	JJ	I-NP
chain	chain	NN	I-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
(	(	-LRB-	0
pACE1	pACE1	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
final	final	JJ	B-NP
expression	expression	NN	I-NP
vector	vector	NN	I-NP
clone	clone	NN	I-NP
was	was	VBD	0
designated	designated	VBN	B-NP
pACE4	pACE4	CD	I-NP
.	.	.	0
This	This	DT	0
vector	vector	JJ	B-NP
result	result	NN	I-NP
in	in	IN	0
the	the	DT	0
production	production	NN	0
of	of	IN	0
recombinant	recombinant	JJ	0
antibody	antibody	NN	0
molecules	molecules	NNS	0
under	under	IN	0
the	the	DT	0
control	control	NN	0
of	of	IN	0
the	the	DT	0
CMV	CMV	NNP	0
transcriptional	transcriptional	NN	B-NP
promoter	promoter	NN	I-NP
.	.	.	0
The	The	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
molecule	molecule	NN	I-NP
are	are	VBP	0
direct	direct	JJ	0
cDNA	cDNA	JJ	0
constructs	constructs	NN	0
that	that	IN	0
fuse	fuse	VBG	0
the	the	DT	0
variable	variable	JJ	0
region	region	NN	0
sequence	sequence	NN	0
directly	directly	RB	0
into	into	IN	0
the	the	DT	0
human	human	JJ	0
IgG1	IgG1	CD	B-NP
constant	constant	JJ	0
domain	domain	NN	0
.	.	.	0
The	The	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
molecule	molecule	NN	I-NP
,	,	,	0
on	on	IN	0
the	the	DT	0
other	other	JJ	0
hand	hand	NN	0
,	,	,	0
have	have	VBP	0
a	a	DT	0
mouse	mouse	NN	B-NP
kappa	kappa	VBZ	I-NP
intron	intron	JJ	I-NP
region	region	NN	I-NP
3	3	CD	0
of	of	IN	0
the	the	DT	0
variable	variable	JJ	0
region	region	NN	0
coding	coding	NN	0
fragment	fragment	NN	0
.	.	.	0
After	After	IN	0
splicing	splicing	NN	0
,	,	,	0
the	the	DT	0
variable	variable	JJ	0
region	region	NN	0
becomes	becomes	VBZ	0
fused	fused	VBN	0
to	to	TO	0
a	a	DT	0
human	human	JJ	0
kappa	kappa	JJ	B-NP
constant	constant	JJ	0
region	region	NN	B-NP
exon	exon	NN	I-NP
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
7	7	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
vector	vector	NN	B-NP
selectable	selectable	JJ	I-NP
marker	marker	NN	I-NP
in	in	IN	0
mammalian	mammalian	JJ	B-NP
cell	cell	NN	I-NP
is	is	VBZ	0
neomycin	neomycin	JJ	0
(	(	-LRB-	0
G418	G418	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
For	For	IN	0
the	the	DT	0
production	production	NN	0
of	of	IN	0
pACE1	pACE1	NNP	B-NP
,	,	,	0
the	the	DT	0
11E10	11E10	JJ	B-NP
heavy	heavy	JJ	I-NP
chain	chain	NN	I-NP
PCR	PCR	NNP	I-NP
product	product	NN	I-NP
(	(	-LRB-	0
approximately	approximately	RB	0
400	400	CD	0
bp	bp	CD	B-NP
)	)	-RRB-	0
was	was	VBD	0
digested	digested	VBN	0
with	with	IN	0
NruI	NruI	JJ	0
and	and	CC	0
EcoRI	EcoRI	NNP	B-NP
(	(	-LRB-	0
new	new	JJ	B-NP
england	england	NNP	I-NP
biolab	biolab	NN	I-NP
)	)	-RRB-	0
,	,	,	0
purified	purified	VBZ	0
using	using	VBG	0
a	a	DT	0
Qiaquick	Qiaquick	NNP	B-NP
PCR	PCR	NNP	I-NP
Purification	Purification	NNP	I-NP
column	column	NN	I-NP
(	(	-LRB-	0
Qiagen	Qiagen	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
as	as	RB	0
described	described	VBN	0
by	by	IN	0
the	the	DT	0
manufacturer	manufacturer	NN	B-NP
,	,	,	0
and	and	CC	0
ligated	ligated	NN	0
into	into	IN	0
NruI	NruI	JJ	B-NP
/	/	CD	I-NP
EcoRI	EcoRI	JJ	I-NP
digested	digested	NN	I-NP
and	and	CC	0
gel-purified	gel-purified	NNP	0
pJRS315	pJRS315	NNP	B-NP
,	,	,	0
resulting	resulting	VBG	0
in	in	IN	0
plasmid	plasmid	CD	B-NP
pACE1	pACE1	CD	I-NP
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
7	7	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
11E10	11E10	JJ	0
light	light	JJ	0
chain	chain	NN	B-NP
PCR	PCR	NNP	I-NP
product	product	NN	I-NP
(	(	-LRB-	0
approximately	approximately	RB	0
350	350	CD	0
bp	bp	CD	B-NP
)	)	-RRB-	0
was	was	VBD	0
cloned	cloned	VBN	0
into	into	IN	0
the	the	DT	0
T	T	NN	B-NP
/	/	VBZ	I-NP
A	A	DT	I-NP
cloning	cloning	JJ	I-NP
vector	vector	NN	I-NP
as	as	IN	0
per	per	IN	0
manufacturer	manufacturer	NN	0
's	's	POS	0
instruction	instruction	NN	B-NP
.	.	.	0
The	The	DT	0
resulting	resulting	JJ	0
clone	clone	NN	B-NP
,	,	,	0
pACELC	pACELC	NNP	B-NP
,	,	,	0
was	was	VBD	0
digested	digested	VBN	0
with	with	IN	0
EcoRV	EcoRV	JJ	0
and	and	CC	0
BstBI	BstBI	NNP	B-NP
(	(	-LRB-	0
new	new	JJ	B-NP
england	england	NNP	I-NP
biolab	biolab	NN	I-NP
)	)	-RRB-	0
and	and	CC	0
the	the	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
fragment	fragment	NN	I-NP
was	was	VBD	0
gel-purified	gel-purified	JJ	0
.	.	.	0
This	This	DT	0
fragment	fragment	NN	0
was	was	VBD	0
then	then	RB	0
ligated	ligated	VBN	0
into	into	IN	0
the	the	DT	0
EcoRV	EcoRV	JJ	B-NP
/	/	CD	I-NP
BstBI	BstBI	JJ	I-NP
digested	digested	NN	I-NP
and	and	CC	0
gel-purified	gel-purified	NNP	0
pACE1	pACE1	NNP	B-NP
,	,	,	0
resulting	resulting	VBG	0
in	in	IN	0
plasmid	plasmid	CD	B-NP
pACE4	pACE4	CD	I-NP
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
7	7	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
sequence	sequence	NN	0
of	of	IN	0
the	the	DT	0
heavy	heavy	JJ	0
and	and	CC	0
light	light	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
was	was	VBD	0
verified	verified	VBN	0
prior	prior	RB	0
to	to	TO	0
mammalian	mammalian	VB	0
cell	cell	NN	B-NP
transfection	transfection	NN	I-NP
.	.	.	0
The	The	DT	0
plasmid	plasmid	JJ	B-NP
pJRS315	pJRS315	NN	I-NP
is	is	VBZ	0
the	the	DT	0
expression	expression	NN	B-NP
plasmid	plasmid	NN	I-NP
into	into	IN	0
which	which	WDT	0
the	the	DT	0
variable	variable	JJ	0
regions	regions	NNS	0
of	of	IN	0
the	the	DT	0
11E10	11E10	JJ	B-NP
antibody	antibody	NN	I-NP
were	were	VBD	0
cloned	cloned	VBN	0
.	.	.	0
This	This	DT	0
plasmid	plasmid	NN	B-NP
is	is	VBZ	0
a	a	DT	0
derivative	derivative	JJ	B-NP
of	of	IN	0
a	a	DT	0
basic	basic	JJ	0
expression	expression	NN	B-NP
vector	vector	NN	I-NP
,	,	,	0
plasmid	plasmid	CD	B-NP
pSUN15	pSUN15	CD	I-NP
,	,	,	0
that	that	WDT	0
contains	contains	VBZ	0
no	no	DT	0
antibody	antibody	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
coding	coding	NN	I-NP
information	information	NN	I-NP
,	,	,	0
pJRS315	pJRS315	NNP	B-NP
was	was	VBD	0
created	created	VBN	0
using	using	VBG	0
dna	dna	NN	B-NP
fragment	fragment	NN	I-NP
ligation	ligation	NN	I-NP
and	and	CC	0
site	site	NN	0
directed	directed	VBD	0
mutagenesis	mutagenesis	JJ	B-NP
step	step	NN	I-NP
.	.	.	0
The	The	DT	0
result	result	NN	0
was	was	VBD	0
a	a	DT	0
vector	vector	NN	B-NP
that	that	WDT	0
expresses	expresses	VBZ	0
both	both	DT	0
antibody	antibody	NN	B-NP
chain	chain	NN	I-NP
with	with	IN	0
CMV	CMV	NNP	0
promoter	promoter	FW	0
driven	driven	FW	0
transcription	transcription	NN	B-NP
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
17	17	CD	0
)	)	-RRB-	0
.	.	.	0
Neomycin	Neomycin	JJ	B-NP
resistance	resistance	NN	I-NP
serves	serves	VBZ	0
as	as	IN	0
the	the	DT	0
dominant	dominant	JJ	0
mammalian	mammalian	JJ	B-NP
cell	cell	NN	I-NP
transfection	transfection	NN	I-NP
selectable	selectable	JJ	I-NP
marker	marker	NN	I-NP
.	.	.	0
In	In	IN	0
addition	addition	NN	B-NP
,	,	,	0
it	it	PRP	0
has	has	VBZ	0
been	been	VBN	0
designed	designed	VBN	0
to	to	TO	0
allow	allow	VB	0
convenient	convenient	JJ	0
cloning	cloning	NN	B-NP
of	of	IN	0
any	any	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
as	as	IN	0
an	an	DT	0
EcoRV	EcoRV	JJ	B-NP
/	/	CD	I-NP
BstBI	BstBI	JJ	I-NP
fragment	fragment	NN	I-NP
,	,	,	0
any	any	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
as	as	IN	0
a	a	DT	0
NruI	NruI	JJ	B-NP
/	/	CD	I-NP
EcoRI	EcoRI	JJ	I-NP
fragment	fragment	NN	I-NP
,	,	,	0
and	and	CC	0
any	any	DT	0
heavy	heavy	JJ	0
chain	chain	NN	0
constant	constant	JJ	0
domain	domain	NN	0
as	as	IN	0
an	an	DT	0
EcoRI	EcoRI	JJ	B-NP
/	/	CD	I-NP
NotI	NotI	JJ	I-NP
fragment	fragment	NN	I-NP
.	.	.	0
These	These	DT	0
restriction	restriction	NN	B-NP
site	site	NN	I-NP
were	were	VBD	0
chosen	chosen	VBN	0
because	because	IN	0
they	they	PRP	0
occur	occur	VBP	0
rarely	rarely	RB	0
(	(	-LRB-	0
if	if	IN	0
ever	ever	RB	0
)	)	-RRB-	0
in	in	IN	0
human	human	JJ	0
and	and	CC	0
mouse	mouse	JJ	0
variable	variable	JJ	0
regions	regions	NNS	0
.	.	.	0
There	There	EX	0
is	is	VBZ	0
a	a	DT	0
mouse	mouse	NN	B-NP
J	J	NNP	I-NP
region	region	NN	I-NP
/	/	NN	I-NP
kappa	kappa	NNP	I-NP
intron	intron	NN	I-NP
fragment	fragment	NN	I-NP
fused	fused	FW	0
to	to	TO	0
a	a	DT	0
human	human	JJ	0
kappum	kappum	NN	B-NP
exon	exon	VBP	I-NP
so	so	RB	0
that	that	IN	0
after	after	IN	0
post-transcriptional	post-transcriptional	NN	B-NP
splicing	splicing	FW	0
a	a	FW	0
mouse	mouse	NN	B-NP
/	/	NN	I-NP
human	human	JJ	I-NP
chimeric	chimeric	NN	I-NP
kappa	kappa	NNP	I-NP
light	light	JJ	0
chain	chain	NN	0
is	is	VBZ	0
produced	produced	VBN	0
.	.	.	0
The	The	DT	0
backbone	backbone	NN	0
of	of	IN	0
the	the	DT	0
vector	vector	NN	B-NP
was	was	VBD	0
the	the	DT	0
plasmid	plasmid	JJ	B-NP
pCDNA3	pCDNA3	NNP	I-NP
(	(	-LRB-	0
Invitrogen	Invitrogen	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
This	This	DT	0
plasmid	plasmid	NN	B-NP
was	was	VBD	0
cut	cut	VBN	0
with	with	IN	0
HindIII	HindIII	NNP	B-NP
/	/	NNP	I-NP
XhoI	XhoI	NNP	I-NP
and	and	CC	0
a	a	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
polylinker	polylinker	NN	I-NP
DNA	DNA	NN	I-NP
fragment	fragment	NN	I-NP
was	was	VBD	0
inserted	inserted	VBN	0
to	to	TO	0
create	create	VB	0
the	the	DT	0
starting	starting	VBG	0
light	light	JJ	0
chain	chain	NN	B-NP
vector	vector	NN	I-NP
.	.	.	0
This	This	DT	0
linker	linker	NN	B-NP
contained	contained	VBD	0
the	the	DT	0
restriction	restriction	NN	B-NP
site	site	NN	I-NP
HindIII	HindIII	JJ	0
,	,	,	0
KpnI	KpnI	NNP	B-NP
,	,	,	0
ClaI	ClaI	NNP	B-NP
,	,	,	0
PmlI	PmlI	NNP	B-NP
,	,	,	0
EcoRV	EcoRV	NNP	B-NP
,	,	,	0
XmaI	XmaI	NNP	B-NP
,	,	,	0
BamHI	BamHI	JJ	0
and	and	CC	0
XhoI	XhoI	JJ	0
to	to	TO	0
facilitate	facilitate	VB	0
subsequent	subsequent	JJ	0
cloning	cloning	JJ	B-NP
step	step	NN	I-NP
to	to	TO	0
create	create	VB	0
the	the	DT	0
plasmid	plasmid	JJ	B-NP
pCDNA3.LCPL	pCDNA3.LCPL	NN	I-NP
.	.	.	0
A	A	DT	0
SmaI	SmaI	JJ	B-NP
/	/	NNP	I-NP
BclI	BclI	NNP	I-NP
DNA	DNA	NNP	I-NP
fragment	fragment	VBZ	0
containing	containing	VBG	0
a	a	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
leader	leader	NN	I-NP
,	,	,	0
anti-CKMB	anti-CKMB	JJ	B-NP
kappa	kappa	JJ	I-NP
light	light	JJ	0
chain	chain	NN	B-NP
genomic	genomic	NN	I-NP
fragment	fragment	NN	I-NP
,	,	,	0
and	and	CC	0
3	3	CD	0
UTR	UTR	NNP	B-NP
was	was	VBD	0
cloned	cloned	VBN	0
into	into	IN	0
the	the	DT	0
pcdna3	pcdna3	NN	B-NP
ecorv/bamhi	ecorv/bamhi	NN	I-NP
site	site	NN	I-NP
.	.	.	0
The	The	DT	0
mouse	mouse	NN	B-NP
kappa	kappa	NN	I-NP
intron	intron	NN	I-NP
,	,	,	0
exon	exon	NN	B-NP
and	and	CC	0
3	3	CD	0
UTR	UTR	NN	B-NP
in	in	IN	0
this	this	DT	0
fragment	fragment	NN	0
was	was	VBD	0
derived	derived	VBN	0
from	from	IN	0
LCPXK2	LCPXK2	NNP	B-NP
received	received	VBD	0
from	from	IN	0
Dr.	Dr.	NNP	B-NP
Richard	Richard	NNP	0
Near	Near	NNP	0
(	(	-LRB-	0
Near	Near	NNP	0
,	,	,	0
R.	R.	NNP	B-NP
I.	I.	NNP	I-NP
et	et	NNP	0
al.	al.	NNP	0
,	,	,	0
Mol	Mol	NNP	B-NP
.	.	.	0
Immunol.	Immunol.	CD	B-NP
27	27	CD	0
:	:	:	0
901-909	901-909	CD	0
,	,	,	0
(	(	-LRB-	0
1990	1990	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
.	.	.	0
mutagenesi	mutagenesi	NN	B-NP
was	was	VBD	0
then	then	RB	0
performed	performed	VBN	0
to	to	TO	0
eliminate	eliminate	VB	0
an	an	DT	0
NruI	NruI	JJ	0
(	(	-LRB-	0
209	209	LS	0
)	)	-RRB-	0
,	,	,	0
MluI	MluI	NNP	B-NP
(	(	-LRB-	0
229	229	CD	0
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
BstBI	BstBI	NNP	B-NP
(	(	-LRB-	0
2962	2962	CD	0
)	)	-RRB-	0
and	and	CC	0
to	to	TO	0
introduce	introduce	VB	0
an	an	DT	0
NheI	NheI	JJ	0
(	(	-LRB-	0
1229	1229	CD	0
)	)	-RRB-	0
and	and	CC	0
a	a	DT	0
BamHI	BamHI	JJ	0
(	(	-LRB-	0
1214	1214	CD	0
)	)	-RRB-	0
site	site	NN	0
to	to	TO	0
create	create	VB	0
pcDNA3mut.LCPL.LCVK	pcDNA3mut.LCPL.LCVK	NNP	0
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
12	12	CD	0
)	)	-RRB-	0
.	.	.	0
A	A	DT	0
second	second	JJ	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
vector	vector	NN	I-NP
was	was	VBD	0
constructed	constructed	VBN	0
from	from	IN	0
the	the	DT	0
pcDNA3mut.LCPL.LCVK	pcDNA3mut.LCPL.LCVK	JJ	0
plasmid	plasmid	NN	0
by	by	IN	0
replacing	replacing	VBG	0
the	the	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
expression	expression	NN	I-NP
region	region	NN	I-NP
(	(	-LRB-	0
HindIII	HindIII	NNP	B-NP
/	/	NNP	I-NP
XhoI	XhoI	NNP	I-NP
)	)	-RRB-	0
with	with	IN	0
a	a	DT	0
heavy	heavy	JJ	0
chain	chain	NN	0
polylinker	polylinker	VBZ	0
consisting	consisting	VBG	0
of	of	IN	0
restriction	restriction	NN	B-NP
site	site	NN	I-NP
HpaI	HpaI	JJ	0
,	,	,	0
BspEI	BspEI	NNP	B-NP
,	,	,	0
EcoRV	EcoRV	NNP	B-NP
,	,	,	0
KpnI	KpnI	NNP	B-NP
,	,	,	0
and	and	CC	0
XhoI	XhoI	JJ	0
.	.	.	0
This	This	DT	0
plasmid	plasmid	NN	B-NP
was	was	VBD	0
digested	digested	VBN	0
with	with	IN	0
EcorRV	EcorRV	JJ	0
and	and	CC	0
KpnI	KpnI	JJ	0
.	.	.	0
A	A	DT	0
SmaI	SmaI	JJ	B-NP
/	/	CD	I-NP
KpnI	KpnI	JJ	I-NP
digested	digested	JJ	I-NP
DNA	DNA	NN	I-NP
fragment	fragment	NN	I-NP
containing	containing	VBG	0
a	a	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
leader	leader	NN	I-NP
and	and	CC	0
an	an	DT	0
anti-CKMB	anti-CKMB	JJ	0
IgG2b	IgG2b	CD	0
mouse	mouse	NN	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
genomic	genomic	NN	I-NP
fragment	fragment	NN	I-NP
was	was	VBD	0
then	then	RB	0
ligated	ligated	VBN	0
into	into	IN	0
the	the	DT	0
EcoRV	EcoRV	JJ	0
/	/	FW	0
KpnI	KpnI	FW	0
digested	digested	VBN	B-NP
plasmid	plasmid	NN	I-NP
.	.	.	0
A	A	DT	0
KpnI	KpnI	JJ	B-NP
/	/	CD	I-NP
SalI	SalI	JJ	I-NP
oligonucleotida	oligonucleotida	NN	I-NP
fragment	fragment	VBP	0
containing	containing	VBG	0
a	a	DT	0
3	3	CD	0
UTR	UTR	NNP	B-NP
and	and	CC	0
a	a	DT	0
NotI	NotI	JJ	0
upstream	upstream	NN	0
of	of	IN	0
the	the	DT	0
SalI	SalI	JJ	B-NP
site	site	NN	I-NP
was	was	VBD	0
subsequently	subsequently	RB	0
cloned	cloned	VBN	0
into	into	IN	0
the	the	DT	0
KpnI	KpnI	JJ	0
/	/	FW	0
XhoI	XhoI	FW	0
digested	digested	VBN	B-NP
plasmid	plasmid	NN	I-NP
(	(	-LRB-	0
knocking	knocking	VBG	0
out	out	RP	0
the	the	DT	0
XhoI	XhoI	JJ	B-NP
site	site	NN	I-NP
)	)	-RRB-	0
,	,	,	0
to	to	TO	0
create	create	VB	0
the	the	DT	0
plasmid	plasmid	JJ	0
pCDNA3mUt.HCPL.HCV2b	pCDNA3mUt.HCPL.HCV2b	NNP	0
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
13	13	CD	0
)	)	-RRB-	0
.	.	.	0
From	From	IN	0
this	this	DT	0
point	point	NN	0
,	,	,	0
two	two	CD	0
vectors	vectors	NNS	0
were	were	VBD	0
created	created	VBN	0
that	that	WDT	0
did	did	VBD	0
not	not	RB	0
have	have	VB	0
any	any	DT	0
of	of	IN	0
the	the	DT	0
anti-CKMB	anti-CKMB	JJ	B-NP
variable	variable	NN	I-NP
or	or	CC	0
constant	constant	JJ	0
domain	domain	NN	B-NP
dna	dna	NN	I-NP
sequence	sequence	NN	I-NP
.	.	.	0
This	This	DT	0
was	was	VBD	0
done	done	VBN	0
by	by	IN	0
cutting	cutting	VBG	0
the	the	DT	0
plasmid	plasmid	JJ	0
pcDNA3mut.LCPL.LCVK	pcDNA3mut.LCPL.LCVK	NN	0
with	with	IN	0
EcoRV	EcoRV	NNP	B-NP
/	/	NNP	I-NP
XhoI	XhoI	NNP	I-NP
and	and	CC	0
inserting	inserting	VBG	0
a	a	DT	0
linker	linker	JJ	B-NP
oligonucleotida	oligonucleotida	NN	I-NP
fragment	fragment	VBP	0
containing	containing	VBG	0
EcoRV	EcoRV	JJ	0
,	,	,	0
BstBI	BstBI	NNP	B-NP
,	,	,	0
and	and	CC	0
xhoi	xhoi	NN	B-NP
site	site	NN	I-NP
to	to	TO	0
create	create	VB	0
pSUN9	pSUN9	NNP	B-NP
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
14	14	CD	0
)	)	-RRB-	0
.	.	.	0
In	In	IN	0
a	a	DT	0
similar	similar	JJ	0
way	way	NN	0
,	,	,	0
the	the	DT	0
anti-CKMB	anti-CKMB	JJ	B-NP
fragment	fragment	NN	I-NP
in	in	IN	0
pCDNA3mut.HCPL.HCV2b	pCDNA3mut.HCPL.HCV2b	NNP	0
(	(	-LRB-	0
NruI	NruI	NNP	B-NP
/	/	NNP	I-NP
NotI	NotI	NNP	I-NP
)	)	-RRB-	0
was	was	VBD	0
replaced	replaced	VBN	0
by	by	IN	0
a	a	DT	0
linker	linker	JJ	B-NP
oligonucleotida	oligonucleotida	NN	I-NP
fragment	fragment	VBP	0
containing	containing	VBG	0
NruI	NruI	JJ	0
,	,	,	0
EcoRI	EcoRI	JJ	0
and	and	CC	0
noti	noti	NN	B-NP
site	site	NN	I-NP
to	to	TO	0
create	create	VB	0
pSUN10	pSUN10	NNP	B-NP
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
15	15	CD	0
)	)	-RRB-	0
.	.	.	0
A	A	DT	0
human	human	JJ	0
kappa	kappa	JJ	B-NP
light	light	JJ	0
chain	chain	NN	0
constant	constant	JJ	0
domain	domain	NN	0
was	was	VBD	0
then	then	RB	0
cloned	cloned	VBN	0
into	into	IN	0
pSUN9	pSUN9	CD	B-NP
as	as	IN	0
a	a	DT	0
BstBI	BstBI	JJ	B-NP
/	/	CD	I-NP
XhoI	XhoI	JJ	I-NP
fragment	fragment	NN	I-NP
,	,	,	0
and	and	CC	0
a	a	DT	0
human	human	JJ	0
IgG1	IgG1	CD	B-NP
constant	constant	JJ	0
domain	domain	NN	0
was	was	VBD	0
cloned	cloned	VBN	0
into	into	IN	0
pSUN10	pSUN10	CD	B-NP
as	as	IN	0
a	a	DT	0
EcoRI	EcoRI	JJ	B-NP
/	/	CD	I-NP
NotI	NotI	JJ	I-NP
fragment	fragment	NN	I-NP
.	.	.	0
A	A	DT	0
BglII	BglII	JJ	B-NP
/	/	CD	I-NP
NheI	NheI	JJ	I-NP
fragment	fragment	NN	I-NP
from	from	IN	0
the	the	DT	0
human	human	JJ	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
vector	vector	NN	I-NP
was	was	VBD	0
then	then	RB	0
cloned	cloned	VBN	0
into	into	IN	0
the	the	DT	0
human	human	JJ	0
light	light	JJ	0
chain	chain	NN	B-NP
vector	vector	NN	I-NP
cut	cut	NN	I-NP
with	with	IN	0
BamHI	BamHI	JJ	0
/	/	CD	0
NheI	NheI	JJ	0
to	to	TO	0
create	create	VB	0
pSUN15	pSUN15	NNP	B-NP
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
16	16	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
plasmid	plasmid	JJ	B-NP
pJRS315	pJRS315	NN	I-NP
was	was	VBD	0
then	then	RB	0
constructed	constructed	VBN	0
using	using	VBG	0
pSUN15	pSUN15	NN	B-NP
through	through	IN	0
the	the	DT	0
following	following	JJ	0
process	process	NN	0
.	.	.	0
A	A	DT	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
region	region	NN	I-NP
from	from	IN	0
another	another	DT	0
,	,	,	0
unrelated	unrelated	JJ	0
,	,	,	0
hybridoma	hybridoma	JJ	B-NP
cell	cell	NN	I-NP
line	line	NN	I-NP
(	(	-LRB-	0
approximately	approximately	RB	0
400	400	CD	0
bp	bp	CD	B-NP
)	)	-RRB-	0
was	was	VBD	0
digested	digested	VBN	0
with	with	IN	0
NruI	NruI	JJ	0
and	and	CC	0
EcoRI	EcoRI	NNP	B-NP
(	(	-LRB-	0
new	new	JJ	B-NP
england	england	NNP	I-NP
biolab	biolab	NN	I-NP
)	)	-RRB-	0
,	,	,	0
purified	purified	VBZ	0
using	using	VBG	0
a	a	DT	0
Qiaquick	Qiaquick	NNP	B-NP
PCR	PCR	NNP	I-NP
Purification	Purification	NNP	I-NP
column	column	NN	I-NP
(	(	-LRB-	0
Qiagen	Qiagen	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
as	as	RB	0
described	described	VBN	0
by	by	IN	0
the	the	DT	0
manufacturer	manufacturer	NN	B-NP
,	,	,	0
and	and	CC	0
ligated	ligated	NN	0
into	into	IN	0
NruI	NruI	JJ	B-NP
/	/	CD	I-NP
EcoRI	EcoRI	JJ	I-NP
digested	digested	NN	I-NP
and	and	CC	0
gel-purified	gel-purified	NNP	0
pSUN15	pSUN15	NNP	B-NP
,	,	,	0
resulting	resulting	VBG	0
in	in	IN	0
plasmid	plasmid	CD	B-NP
pJRS311	pJRS311	CD	I-NP
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
16	16	CD	0
)	)	-RRB-	0
.	.	.	0
At	At	IN	0
this	this	DT	0
point	point	NN	0
,	,	,	0
a	a	DT	0
BstBI	BstBI	JJ	0
/	/	NNP	0
NotI	NotI	NNP	0
(	(	-LRB-	0
new	new	JJ	B-NP
england	england	NNP	I-NP
biolab	biolab	NN	I-NP
)	)	-RRB-	0
DNA	DNA	NNP	B-NP
fragment	fragment	NN	I-NP
containing	containing	FW	0
a	a	FW	0
mouse	mouse	NN	B-NP
kappa	kappa	NNP	I-NP
J-kappa	J-kappa	NN	I-NP
intron	intron	NN	I-NP
fragment	fragment	NN	I-NP
fused	fused	FW	0
to	to	TO	0
a	a	DT	0
human	human	JJ	0
kappa	kappa	JJ	B-NP
exon	exon	JJ	I-NP
fragment	fragment	NN	I-NP
was	was	VBD	0
digested	digested	VBN	0
and	and	CC	0
gel-purified	gel-purified	JJ	0
from	from	IN	0
the	the	DT	0
vector	vector	JJ	0
tKMC180C2	tKMC180C2	NN	0
.	.	.	0
This	This	DT	0
fragment	fragment	NN	0
was	was	VBD	0
ligated	ligated	VBN	0
into	into	IN	0
the	the	DT	0
backbone	backbone	NN	0
of	of	IN	0
pJRS311	pJRS311	CD	B-NP
digested	digested	NN	I-NP
with	with	IN	0
BstBI	BstBI	NNP	B-NP
/	/	NNP	I-NP
NotI	NotI	NNP	I-NP
and	and	CC	0
gel-purified	gel-purified	JJ	0
resulting	resulting	VBG	0
in	in	IN	0
the	the	DT	0
plasmid	plasmid	JJ	B-NP
pJRS315	pJRS315	NNP	I-NP
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
17	17	CD	0
)	)	-RRB-	0
.	.	.	0
A.	A.	NNP	0
Transfection	Transfection	NNP	B-NP
of	of	IN	0
NSO	NSO	NNP	B-NP
Cells	Cells	NNPS	0
The	The	DT	0
plasmid	plasmid	JJ	B-NP
pACE4	pACE4	NN	I-NP
was	was	VBD	0
transfected	transfected	VBN	0
into	into	IN	0
NSO	NSO	NNP	B-NP
cells	cells	NNS	0
using	using	VBG	0
electroporation	electroporation	NN	B-NP
.	.	.	0
The	The	DT	0
plasmid	plasmid	NN	B-NP
was	was	VBD	0
linearized	linearized	VBN	0
with	with	IN	0
a	a	DT	0
PvuI	PvuI	JJ	B-NP
restriction	restriction	NN	I-NP
enzyme	enzyme	VBD	I-NP
digestion.	digestion.	CD	I-NP
40	40	CD	0
g	g	NN	0
of	of	IN	0
digested	digested	JJ	0
plasmid	plasmid	JJ	B-NP
DNA	DNA	NN	I-NP
was	was	VBD	0
mixed	mixed	VBN	0
with	with	IN	0
7	7	CD	0
106	106	CD	0
cells	cells	NNS	0
in	in	IN	0
a	a	DT	0
total	total	JJ	B-NP
volume	volume	NN	I-NP
of	of	IN	0
400	400	CD	0
L	L	NNP	0
and	and	CC	0
incubated	incubated	NN	0
at	at	IN	0
room	room	NN	B-NP
temperature	temperature	NN	I-NP
with	with	IN	0
gentle	gentle	JJ	0
agitation	agitation	NN	B-NP
for	for	IN	0
one	one	CD	0
minute.	minute.	CD	0
10	10	CD	0
L	L	NNP	0
of	of	IN	0
dimethyl	dimethyl	NN	B-NP
sulfoxide	sulfoxide	NN	I-NP
(	(	-LRB-	0
Sigma	Sigma	NNP	B-NP
)	)	-RRB-	0
were	were	VBD	0
added	added	VBN	0
to	to	TO	0
a	a	DT	0
final	final	JJ	B-NP
concentration	concentration	NN	I-NP
of	of	IN	0
1.25	1.25	CD	0
%	%	NN	0
.	.	.	0
The	The	DT	0
cell	cell	NN	B-NP
/	/	NNP	I-NP
DNA	DNA	NNP	I-NP
/	/	NNP	I-NP
DMSO	DMSO	NNP	I-NP
mix	mix	NN	I-NP
was	was	VBD	0
transferred	transferred	VBN	0
to	to	TO	0
a	a	DT	0
cold	cold	JJ	0
0.4	0.4	CD	0
centimeter	centimeter	CD	B-NP
cuvetta	cuvetta	NN	I-NP
and	and	CC	0
subjected	subjected	VBN	0
to	to	TO	0
one	one	CD	0
pulse	pulse	NN	0
of	of	IN	0
250	250	CD	0
volts	volts	NN	0
,	,	,	0
960	960	CD	0
F.	F.	CD	0
The	The	DT	0
cells	cells	NNS	0
were	were	VBD	0
transferred	transferred	VBN	0
to	to	TO	0
one	one	CD	0
well	well	RB	0
of	of	IN	0
a	a	DT	0
six-well	six-well	JJ	B-NP
plate	plate	NN	I-NP
containing	containing	VBG	0
5	5	CD	0
ml	ml	NN	0
of	of	IN	0
non-selective	non-selective	JJ	B-NP
medium	medium	JJ	I-NP
supplemented	supplemented	VBN	0
with	with	IN	0
dimethyl	dimethyl	NN	B-NP
sulfoxide	sulfoxide	NN	I-NP
(	(	-LRB-	0
final	final	JJ	B-NP
concentration	concentration	NN	I-NP
of	of	IN	0
1.25	1.25	CD	0
%	%	NN	0
)	)	-RRB-	0
.	.	.	0
After	After	IN	0
24	24	CD	0
hours	hours	NNS	0
at	at	IN	0
37	37	CD	0
C.	C.	NNP	0
and	and	CC	0
10	10	CD	0
%	%	NN	0
C02	C02	NN	B-NP
,	,	,	0
the	the	DT	0
cells	cells	NNS	0
were	were	VBD	0
plated	plated	VBN	0
out	out	RP	0
into	into	IN	0
96-well	96-well	CD	0
microtiter	microtiter	CD	B-NP
plate	plate	NN	I-NP
.	.	.	0
As	As	IN	0
colonies	colonies	NNS	0
appeared	appeared	VBD	0
,	,	,	0
the	the	DT	0
supernatant	supernatant	NN	B-NP
were	were	VBD	0
assayed	assayed	VBN	0
for	for	IN	0
the	the	DT	0
production	production	NN	0
of	of	IN	0
humanized	humanized	JJ	0
antibody	antibody	NN	B-NP
and	and	CC	0
for	for	IN	0
the	the	DT	0
capability	capability	NN	0
for	for	IN	0
the	the	DT	0
expressed	expressed	JJ	0
antibody	antibody	NN	B-NP
to	to	TO	0
bind	bind	VB	0
to	to	TO	0
the	the	DT	0
Stx2	Stx2	JJ	B-NP
toxin	toxin	NN	I-NP
.	.	.	0
antibody	antibody	NN	B-NP
production	production	NN	I-NP
b.	b.	NN	I-NP
assay	assay	NN	I-NP
Antibody	Antibody	NN	B-NP
production	production	NN	I-NP
and	and	CC	0
activity	activity	NN	0
assays	assays	NN	0
for	for	IN	0
the	the	DT	0
stable	stable	JJ	0
transfectant	transfectant	NN	B-NP
were	were	VBD	0
performed	performed	VBN	0
in	in	IN	0
8-well	8-well	CD	0
strips	strips	NNS	0
from	from	IN	0
96-well	96-well	FW	0
microtiter	microtiter	NN	B-NP
plate	plate	NN	I-NP
(	(	-LRB-	0
Maxisorp	Maxisorp	NNP	B-NP
F8	F8	NNP	I-NP
;	;	:	0
Nunc	Nunc	NNP	B-NP
,	,	,	0
Inc.	Inc.	NNP	0
)	)	-RRB-	0
coated	coated	VBN	0
with	with	IN	0
a	a	DT	0
1	1	CD	0
:	:	:	0
500	500	CD	0
dilution	dilution	NN	0
of	of	IN	0
goat	goat	JJ	B-NP
anti-Human	anti-Human	JJ	I-NP
F	F	NN	I-NP
(	(	-LRB-	I-NP
ab	ab	LS	I-NP
)	)	-RRB-	I-NP
2	2	CD	0
anti-IgG	anti-IgG	JJ	B-NP
antibody	antibody	NN	I-NP
(	(	-LRB-	0
Southern	Southern	NNP	0
Biotechnology	Biotechnology	NNP	0
)	)	-RRB-	0
using	using	VBG	0
a	a	DT	0
bicarbonate	bicarbonate	JJ	B-NP
coating	coating	NN	I-NP
buffer	buffer	NN	I-NP
,	,	,	0
pH	pH	JJ	0
8.5	8.5	CD	0
.	.	.	0
The	The	DT	0
plates	plates	NN	0
were	were	VBD	0
covered	covered	VBN	0
with	with	IN	0
pressure	pressure	NN	0
sensitive	sensitive	JJ	B-NP
film	film	NN	I-NP
(	(	-LRB-	0
Falcon	Falcon	NNP	0
,	,	,	0
Becton	Becton	NNP	0
Dickinson	Dickinson	NNP	0
)	)	-RRB-	0
and	and	CC	0
incubated	incubated	JJ	0
overnight	overnight	JJ	0
at	at	IN	0
4	4	CD	0
c.	c.	NN	B-NP
plate	plate	NN	I-NP
are	are	VBP	0
then	then	RB	0
washed	washed	VBN	0
once	once	RB	0
with	with	IN	0
wash	wash	JJ	B-NP
solution	solution	NN	I-NP
(	(	-LRB-	0
imidazole	imidazole	NN	B-NP
/	/	NN	I-NP
NaCl	NaCl	NN	I-NP
/	/	NNP	0
0.4	0.4	CD	0
%	%	NN	0
Tween-20	Tween-20	CD	B-NP
)	)	-RRB-	0
.	.	.	0
100	100	CD	0
L	L	NNP	0
of	of	IN	0
culture	culture	NN	B-NP
supernatant	supernatant	NN	I-NP
was	was	VBD	0
then	then	RB	0
applied	applied	VBN	0
and	and	CC	0
allowed	allowed	VBN	0
to	to	TO	0
incubate	incubate	VB	0
for	for	IN	0
30	30	CD	0
minutes	minutes	NNS	0
on	on	IN	0
a	a	DT	0
plate	plate	NN	B-NP
rotator	rotator	NN	I-NP
at	at	IN	0
room	room	NN	B-NP
temperature	temperature	NN	I-NP
.	.	.	0
The	The	DT	0
plates	plates	NN	0
were	were	VBD	0
washed	washed	VBN	0
five	five	CD	0
times	times	NNS	0
with	with	IN	0
wash	wash	JJ	B-NP
solution	solution	NN	I-NP
(	(	-LRB-	0
imidazole	imidazole	NN	B-NP
/	/	NN	I-NP
NaCl	NaCl	NN	I-NP
/	/	NNP	0
0.4	0.4	CD	0
%	%	NN	0
Tween-20	Tween-20	CD	B-NP
)	)	-RRB-	0
.	.	.	0
A	A	DT	0
goat	goat	JJ	B-NP
anti-human	anti-human	JJ	I-NP
kappa-HRP	kappa-HRP	NN	I-NP
(	(	-LRB-	0
Southern	Southern	NNP	0
Biotechnology	Biotechnology	NNP	0
)	)	-RRB-	0
conjugate	conjugate	NN	0
was	was	VBD	0
diluted	diluted	VBN	0
1	1	CD	0
:	:	:	0
800	800	CD	0
in	in	IN	0
the	the	DT	0
sample	sample	NN	B-NP
/	/	NN	I-NP
conjugate	conjugate	NN	I-NP
diluent	diluent	NN	I-NP
and	and	CC	0
100	100	CD	0
L	L	NNP	0
was	was	VBD	0
added	added	VBN	0
to	to	TO	0
the	the	DT	0
samples	samples	NNS	0
,	,	,	0
then	then	RB	0
incubated	incubated	VBN	0
on	on	IN	0
a	a	DT	0
plate	plate	NN	B-NP
rotator	rotator	NN	I-NP
for	for	IN	0
30	30	CD	0
minutes	minutes	NNS	0
at	at	IN	0
room	room	NN	B-NP
temperature	temperature	NN	I-NP
.	.	.	0
The	The	DT	0
samples	samples	NNS	0
were	were	VBD	0
washed	washed	VBN	0
as	as	IN	0
above	above	JJ	0
and	and	CC	0
then	then	RB	0
incubated	incubated	VBN	0
with	with	IN	0
100	100	CD	0
L	L	NNP	0
per	per	IN	0
well	well	RB	0
of	of	IN	0
abt	abt	NNP	B-NP
developing	developing	VBG	0
substrate	substrate	NNS	0
(	(	-LRB-	0
Kirkgaard	Kirkgaard	NNP	0
Perry	Perry	NNP	0
Laboratories	Laboratories	NNPS	0
)	)	-RRB-	0
and	and	CC	0
the	the	DT	0
absorbance	absorbance	JJ	B-NP
value	value	NN	I-NP
at	at	IN	0
405	405	CD	0
nm	nm	NN	B-NP
was	was	VBD	0
determined	determined	VBN	0
using	using	VBG	0
an	an	DT	0
automated	automated	JJ	0
microtiter	microtiter	JJ	B-NP
plate	plate	NN	I-NP
ELISA	ELISA	NNP	I-NP
Reader	Reader	NNP	I-NP
(	(	-LRB-	0
cere	cere	NN	B-NP
UV900Hl	UV900Hl	NNP	0
,	,	,	0
BioTek	BioTek	NNP	0
Instruments	Instruments	NNP	0
,	,	,	0
Winooski	Winooski	NNP	B-NP
,	,	,	0
Vt.	Vt.	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
This	This	DT	0
assay	assay	NN	B-NP
(	(	-LRB-	0
see	see	VB	0
FIG.	FIG.	CD	0
10	10	CD	0
)	)	-RRB-	0
demonstrates	demonstrates	VBZ	0
that	that	IN	0
the	the	DT	0
transfection	transfection	NN	B-NP
of	of	IN	0
cells	cells	NNS	0
with	with	IN	0
this	this	DT	0
plasmid	plasmid	JJ	0
construct	construct	JJ	0
results	results	NNS	0
in	in	IN	0
cells	cells	NNS	0
producing	producing	VBG	0
a	a	DT	0
molecule	molecule	NN	B-NP
containing	containing	VBG	0
both	both	DT	0
human	human	JJ	0
IgG	IgG	JJ	0
and	and	CC	0
kappa	kappa	JJ	B-NP
domain	domain	NN	I-NP
.	.	.	0
The	The	DT	0
supernatant	supernatant	NN	B-NP
were	were	VBD	0
then	then	RB	0
assayed	assayed	VBN	0
for	for	IN	0
the	the	DT	0
ability	ability	NN	B-NP
of	of	IN	0
the	the	DT	0
expressed	expressed	JJ	0
antibody	antibody	NN	B-NP
to	to	TO	0
bind	bind	VB	0
to	to	TO	0
EHEC	EHEC	NNP	B-NP
Stx2	Stx2	NNP	I-NP
toxin	toxin	NN	I-NP
.	.	.	0
The	The	DT	0
activity	activity	NN	B-NP
assay	assay	NN	I-NP
was	was	VBD	0
performed	performed	VBN	0
,	,	,	0
as	as	RB	0
above	above	RB	0
,	,	,	0
using	using	VBG	0
plates	plates	JJ	0
coated	coated	NN	0
at	at	IN	0
1	1	CD	0
g	g	CD	B-NP
/	/	CD	I-NP
ml	ml	NN	I-NP
with	with	IN	0
Stx2	Stx2	CD	B-NP
toxin	toxin	NN	I-NP
(	(	-LRB-	0
obtained	obtained	VBN	0
as	as	IN	0
in	in	IN	0
Example	Example	NNP	0
7	7	CD	0
from	from	IN	0
Dr.	Dr.	NNP	B-NP
O	O	NNP	0
'	'	POS	0
Brien	Brien	NNP	0
's	's	POS	0
lab	lab	NN	0
)	)	-RRB-	0
in	in	IN	0
a	a	DT	0
bicarbonate	bicarbonate	JJ	B-NP
coating	coating	NN	I-NP
buffer	buffer	NN	I-NP
,	,	,	0
pH	pH	JJ	0
8.5	8.5	CD	0
.	.	.	0
This	This	DT	0
assay	assay	NN	B-NP
demonstrates	demonstrates	VBZ	0
that	that	IN	0
the	the	DT	0
transfection	transfection	NN	B-NP
of	of	IN	0
cells	cells	NNS	0
with	with	IN	0
this	this	DT	0
plasmid	plasmid	JJ	0
construct	construct	NN	0
can	can	MD	0
result	result	VB	0
in	in	IN	0
the	the	DT	0
production	production	NN	0
of	of	IN	0
a	a	DT	0
humanized	humanized	JJ	0
monoclonal	monoclonal	NN	B-NP
antibody	antibody	NN	I-NP
11e10	11e10	NN	I-NP
mouse	mouse	NN	I-NP
chimeric	chimeric	JJ	I-NP
version	version	NN	I-NP
which	which	WDT	0
effectively	effectively	RB	0
binds	binds	JJ	0
Shiga	Shiga	JJ	B-NP
toxin	toxin	NN	I-NP
type	type	NN	I-NP
2	2	CD	0
(	(	-LRB-	0
FIG.	FIG.	CD	0
11	11	CD	0
)	)	-RRB-	0
.	.	.	0
Together	Together	RB	0
,	,	,	0
these	these	DT	0
assays	assays	JJ	0
demonstrate	demonstrate	NN	0
that	that	IN	0
the	the	DT	0
transfection	transfection	NN	B-NP
of	of	IN	0
cells	cells	NNS	0
with	with	IN	0
this	this	DT	0
plasmid	plasmid	JJ	0
construct	construct	NN	0
can	can	MD	0
result	result	VB	0
in	in	IN	0
the	the	DT	0
production	production	NN	0
of	of	IN	0
a	a	DT	0
stable	stable	JJ	0
cell	cell	NN	0
line	line	NN	0
that	that	WDT	0
produces	produces	VBZ	0
a	a	DT	0
humanized	humanized	JJ	0
11e10	11e10	NN	B-NP
mouse	mouse	NN	I-NP
hybridoma	hybridoma	NN	I-NP
antibody	antibody	NN	I-NP
chimeric	chimeric	JJ	I-NP
version	version	NN	I-NP
.	.	.	0
A.	A.	NNP	0
Vero	Vero	NNP	B-NP
Cell	Cell	NNP	I-NP
Cytotoxicity	Cytotoxicity	NNP	I-NP
Assay	Assay	NNPS	I-NP
The	The	DT	0
efficacy	efficacy	NN	0
of	of	IN	0
the	the	DT	0
humanized	humanized	JJ	0
antibody	antibody	NN	B-NP
to	to	TO	0
Shiga	Shiga	NNP	B-NP
toxin	toxin	NN	I-NP
obtained	obtained	VBD	0
as	as	RB	0
detailed	detailed	VBN	0
in	in	IN	0
Examples	Examples	NNP	0
1	1	CD	0
through	through	IN	0
6	6	CD	0
was	was	VBD	0
determined	determined	VBN	0
by	by	IN	0
assaying	assaying	VBG	0
their	their	PRP$	0
ability	ability	NN	B-NP
to	to	TO	0
protect	protect	VB	0
Vero	Vero	JJ	0
cells	cells	NNS	0
from	from	IN	0
toxin	toxin	NN	B-NP
.	.	.	0
cytotoxicity	cytotoxicity	NN	B-NP
assay	assay	NN	I-NP
were	were	VBD	0
performed	performed	VBN	0
essentially	essentially	RB	0
as	as	RB	0
described	described	VBN	0
by	by	IN	0
Gentry	Gentry	NNP	0
and	and	CC	0
Dalrymple	Dalrymple	NNP	0
,	,	,	0
J.	J.	NNP	B-NP
Clin	Clin	NNP	I-NP
.	.	.	0
Microbiol	Microbiol	NNP	B-NP
,	,	,	0
12	12	CD	0
:	:	:	0
361-366	361-366	CD	0
(	(	-LRB-	0
1980	1980	CD	0
)	)	-RRB-	0
.	.	.	0
Briefly	Briefly	RB	0
,	,	,	0
toxin	toxin	NN	B-NP
was	was	VBD	0
obtained	obtained	VBN	0
from	from	IN	0
cultures	cultures	NNS	0
of	of	IN	0
E.	E.	NNP	0
coli	coli	VBD	0
k-12	k-12	NN	B-NP
strain	strain	NN	I-NP
that	that	WDT	0
contained	contained	VBD	0
either	either	DT	0
plasmid	plasmid	JJ	B-NP
pLPSH3	pLPSH3	NNP	I-NP
(	(	-LRB-	0
encodes	encodes	UH	0
Stx	Stx	UH	B-NP
;	;	:	0
J.	J.	NNP	0
Infect	Infect	NNP	0
.	.	.	0
Disease	Disease	NNP	0
164	164	CD	0
:	:	:	0
344-352	344-352	CD	0
(	(	-LRB-	0
1991	1991	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
or	or	CC	0
pMJ	pMJ	JJ	0
100	100	CD	0
(	(	-LRB-	0
encodes	encodes	FW	0
Stx2	Stx2	NN	B-NP
;	;	:	0
Inf.	Inf.	CD	B-NP
and	and	CC	0
Immunity	Immunity	NNP	0
,	,	,	0
57	57	CD	0
:	:	:	0
3743-3750	3743-3750	CD	0
(	(	-LRB-	0
1989	1989	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
.	.	.	0
Bacteria	Bacteria	NNS	0
were	were	VBD	0
disrupted	disrupted	VBN	0
by	by	IN	0
sonic	sonic	JJ	B-NP
lysi	lysi	NN	I-NP
and	and	CC	0
clarified	clarified	VBN	0
by	by	IN	0
centrifugation	centrifugation	NN	B-NP
.	.	.	0
The	The	DT	0
extracts	extracts	NN	0
were	were	VBD	0
serially	serially	VBN	0
diluted	diluted	VBN	0
in	in	IN	0
tissue	tissue	NN	0
culture	culture	NN	0
medium	medium	NN	0
(	(	-LRB-	0
Dulbecco	Dulbecco	NNP	B-NP
modified	modified	VBD	0
Eagle	Eagle	NNP	0
medium	medium	NN	0
containing	containing	VBG	0
10	10	CD	0
%	%	NN	0
fetal	fetal	JJ	B-NP
calf	calf	JJ	I-NP
serum	serum	NN	I-NP
,	,	,	0
0.8	0.8	CD	0
mM	mM	JJ	B-NP
glutamine	glutamine	NN	I-NP
,	,	,	0
500	500	CD	0
U	U	NNP	0
of	of	IN	0
penicillin	penicillin	JJ	B-NP
G	G	NNP	I-NP
per	per	FW	0
ml	ml	FW	0
,	,	,	0
and	and	CC	0
500	500	CD	0
mg	mg	NN	B-NP
of	of	IN	0
streptomycin	streptomycin	FW	0
per	per	FW	0
ml	ml	FW	0
)	)	-RRB-	0
.	.	.	0
One	One	CD	0
hundred	hundred	CD	0
microliter	microliter	NN	B-NP
of	of	IN	0
10-fold	10-fold	JJ	0
dilutions	dilutions	NN	0
of	of	IN	0
the	the	DT	0
lysate	lysate	NN	B-NP
were	were	VBD	0
added	added	VBN	0
to	to	TO	0
microtiter	microtiter	VB	0
plate	plate	NN	0
wells	wells	NNS	0
containing	containing	VBG	0
about	about	IN	0
104	104	CD	0
Vero	Vero	JJ	0
cells	cells	NNS	0
in	in	IN	0
100	100	CD	0
l	l	NN	0
of	of	IN	0
medium	medium	NN	0
.	.	.	0
The	The	DT	0
tissue	tissue	NN	0
culture	culture	NN	0
cells	cells	NNS	0
were	were	VBD	0
incubated	incubated	VBN	0
at	at	IN	0
37	37	CD	0
C.	C.	NNP	0
in	in	IN	0
5	5	CD	0
%	%	NN	0
CO2	CO2	NN	B-NP
for	for	IN	0
48	48	CD	0
hours	hours	NNS	0
and	and	CC	0
then	then	RB	0
fixed	fixed	VBN	B-NP
and	and	CC	0
stained	stained	NN	0
with	with	IN	0
crystal	crystal	NN	0
violet	violet	NN	0
.	.	.	0
The	The	DT	0
intensity	intensity	NN	0
of	of	IN	0
color	color	NN	0
of	of	IN	0
the	the	DT	0
fixed	fixed	JJ	0
and	and	CC	0
stained	stained	JJ	0
cells	cells	NNS	0
was	was	VBD	0
measured	measured	VBN	0
with	with	IN	0
a	a	DT	0
Titertek	Titertek	JJ	B-NP
reader	reader	NN	I-NP
at	at	IN	0
620	620	CD	0
nm	nm	NN	B-NP
.	.	.	0
Incubation	Incubation	NNP	0
without	without	IN	0
antibody	antibody	NN	B-NP
provides	provides	VBZ	0
a	a	DT	0
standard	standard	JJ	0
toxicity	toxicity	JJ	0
curve	curve	NN	0
for	for	IN	0
the	the	DT	0
Stx	Stx	NNP	B-NP
.	.	.	0
B.	B.	NNP	B-NP
Antisera	Antisera	NNP	I-NP
Neutralization	Neutralization	NNP	I-NP
Assay	Assay	NNPS	I-NP
humanized	humanized	VBN	B-NP
mouse	mouse	NN	I-NP
antibody	antibody	NN	I-NP
obtained	obtained	VBD	0
according	according	VBG	0
to	to	TO	0
the	the	DT	0
methods	methods	NNS	0
described	described	VBN	0
in	in	IN	0
Examples	Examples	NNP	0
1	1	CD	0
through	through	IN	0
6	6	CD	0
were	were	VBD	0
tested	tested	VBN	0
for	for	IN	0
toxin	toxin	NN	B-NP
neutralization	neutralization	NN	I-NP
.	.	.	0
cytotoxic	cytotoxic	JJ	B-NP
activity	activity	NN	I-NP
neutralization	neutralization	NN	I-NP
was	was	VBD	0
described	described	VBN	0
in	in	IN	0
great	great	JJ	0
detail	detail	NN	0
in	in	IN	0
Schmitt	Schmitt	NNP	0
et	et	NNP	0
al.	al.	NNP	0
,	,	,	0
Infect.	Infect.	NNP	0
and	and	CC	0
Immun.	Immun.	NNP	B-NP
,	,	,	0
59	59	CD	0
:	:	:	0
1065-1073	1065-1073	CD	0
(	(	-LRB-	0
1991	1991	CD	0
)	)	-RRB-	0
.	.	.	0
Briefly	Briefly	RB	0
,	,	,	0
lysate	lysate	NN	B-NP
were	were	VBD	0
incubated	incubated	VBN	0
with	with	IN	0
serial	serial	JJ	0
dilutions	dilutions	NN	0
of	of	IN	0
the	the	DT	0
humanized	humanized	JJ	0
mouse	mouse	NN	B-NP
antibody	antibody	NN	I-NP
at	at	IN	0
37	37	CD	0
C.	C.	NNP	0
for	for	IN	0
2	2	CD	0
hours	hours	NNS	0
.	.	.	0
One	One	CD	0
hundred	hundred	CD	0
microliter	microliter	NN	B-NP
of	of	IN	0
the	the	DT	0
samples	samples	NNS	0
were	were	VBD	0
then	then	RB	0
added	added	VBD	0
to	to	TO	0
Vero	Vero	NNP	0
cells	cells	NNS	0
as	as	RB	0
described	described	VBN	0
above	above	IN	0
.	.	.	0
TABLE	TABLE	NN	0
1	1	CD	0
required	required	VBN	B-NP
ng	ng	VBD	I-NP
vero	vero	NNP	I-NP
cell	cell	NN	I-NP
neutralization	neutralization	NN	I-NP
assay	assay	NN	I-NP
antibody	antibody	NN	I-NP
to	to	TO	0
Neut.	Neut.	CD	B-NP
1	1	CD	0
CD50*	CD50*	CD	B-NP
Mouse	Mouse	CD	I-NP
13C4	13C4	CD	I-NP
25	25	CD	0
Humanized	Humanized	CD	B-NP
13C4	13C4	CD	I-NP
26	26	CD	0
Mouse	Mouse	CD	B-NP
11E10	11E10	CD	I-NP
2.7	2.7	CD	0
Humanized	Humanized	CD	B-NP
11E10	11E10	CD	I-NP
82.8	82.8	CD	0
*	*	NNP	0
(	(	-LRB-	0
1	1	CD	0
CD50	CD50	CD	B-NP
=	=	SYM	0
1	1	CD	0
pg	pg	CD	B-NP
pure	pure	JJ	0
toxin	toxin	NN	B-NP
)	)	-RRB-	0
A.	A.	NNP	0
Protection	Protection	NNP	0
Against	Against	NNP	0
Injection	Injection	NNP	B-NP
with	with	IN	0
Crude	Crude	NNP	B-NP
Stx1	Stx1	NNP	I-NP
Toxin	Toxin	NNP	I-NP
.	.	.	0
At	At	IN	0
day	day	NN	0
zero	zero	CD	0
,	,	,	0
groups	groups	NNS	0
of	of	IN	0
five	five	CD	0
cd-1	cd-1	NN	B-NP
mouse	mouse	NN	I-NP
were	were	VBD	0
injected	injected	VBN	0
intraperitoneally	intraperitoneally	NNS	0
(	(	-LRB-	0
0.1	0.1	CD	0
ml	ml	CD	0
)	)	-RRB-	0
with	with	IN	0
antibody	antibody	CD	0
H13C4	H13C4	CD	0
(	(	-LRB-	0
humanized	humanized	FW	0
-Stx1B	-Stx1B	FW	0
)	)	-RRB-	0
,	,	,	0
13C4	13C4	NNP	B-NP
(	(	-LRB-	0
mouse	mouse	FW	0
-Stx1B	-Stx1B	FW	0
)	)	-RRB-	0
,	,	,	0
H11E10	H11E10	NNP	0
(	(	-LRB-	0
humanized	humanized	FW	0
-Stx2A	-Stx2A	FW	0
)	)	-RRB-	0
,	,	,	0
or	or	CC	0
phosphate	phosphate	NN	B-NP
buffered	buffered	FW	0
saline	saline	FW	0
(	(	-LRB-	0
PBS	PBS	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
These	These	DT	0
injections	injections	NNS	0
were	were	VBD	0
repeated	repeated	VBN	0
at	at	IN	0
day	day	NN	0
1	1	CD	0
.	.	.	0
The	The	DT	0
mice	mice	NNS	0
were	were	VBD	0
then	then	RB	0
challenged	challenged	VBN	0
by	by	IN	0
intravenous	intravenous	JJ	B-NP
injection	injection	NN	I-NP
with	with	IN	0
crude	crude	JJ	0
Stx1	Stx1	CD	B-NP
toxin	toxin	NN	I-NP
(	(	-LRB-	0
obtained	obtained	VBN	0
as	as	RB	0
described	described	VBN	0
in	in	IN	0
Example	Example	NNP	0
7	7	CD	0
)	)	-RRB-	0
at	at	IN	0
doses	doses	NNS	0
of	of	IN	0
1.7	1.7	CD	0
105	105	CD	0
or	or	CC	0
1.7	1.7	CD	0
106	106	CD	0
CD50	CD50	CD	B-NP
.	.	.	0
These	These	DT	0
doses	doses	NN	0
of	of	IN	0
toxin	toxin	NN	B-NP
were	were	VBD	0
chosen	chosen	VBN	0
following	following	VBG	0
preliminary	preliminary	JJ	B-NP
experiment	experiment	NN	I-NP
with	with	IN	0
toxin	toxin	NN	B-NP
varying	varying	VBG	I-NP
amount	amount	NN	I-NP
.	.	.	0
Mice	Mice	NNS	0
were	were	VBD	0
monitored	monitored	VBN	0
for	for	IN	0
21	21	CD	0
days	days	NNS	0
.	.	.	0
The	The	DT	0
results	results	NNS	0
(	(	-LRB-	0
Table	Table	NNP	0
2	2	CD	0
)	)	-RRB-	0
show	show	VBP	0
clearly	clearly	RB	0
that	that	IN	0
the	the	DT	0
injected	injected	JJ	0
antibody	antibody	NN	B-NP
protect	protect	VB	0
the	the	DT	0
mice	mice	NNS	0
against	against	IN	0
at	at	IN	0
least	least	JJS	0
10	10	CD	0
times	times	NNS	0
the	the	DT	0
normal	normal	JJ	B-NP
lethal	lethal	JJ	I-NP
toxin	toxin	NN	I-NP
dose	dose	NN	I-NP
.	.	.	0
As	As	IN	0
a	a	DT	0
negative	negative	JJ	B-NP
control	control	NN	I-NP
,	,	,	0
the	the	DT	0
antibody	antibody	NN	B-NP
to	to	TO	0
Stx2	Stx2	NNP	B-NP
did	did	VBD	0
not	not	RB	0
protect	protect	VB	0
against	against	IN	0
Stx1	Stx1	CD	B-NP
toxin	toxin	NN	I-NP
challenge	challenge	NN	I-NP
,	,	,	0
indicating	indicating	VBG	0
that	that	IN	0
the	the	DT	0
protection	protection	NN	0
was	was	VBD	0
specific	specific	JJ	0
to	to	TO	0
the	the	DT	0
toxin	toxin	NN	B-NP
/	/	CD	I-NP
antibody	antibody	NN	I-NP
pair	pair	NN	I-NP
,	,	,	0
and	and	CC	0
was	was	VBD	0
not	not	RB	0
an	an	DT	0
antibody	antibody	NN	B-NP
preparation	preparation	NN	I-NP
process	process	NN	I-NP
artifact	artifact	NN	I-NP
.	.	.	0
TABLE	TABLE	NN	0
2	2	CD	0
cd-1	cd-1	NN	B-NP
mouse	mouse	NN	I-NP
Injected	Injected	NNP	0
Intravenously	Intravenously	NNP	0
with	with	IN	0
ab	ab	NN	B-NP
crude	crude	JJ	I-NP
stx1	stx1	NN	I-NP
g/kg	g/kg	NN	I-NP
to	to	TO	0
Protect	Protect	NNP	0
from	from	IN	0
Antibody	Antibody	NNP	B-NP
(	(	-LRB-	0
dose	dose	NN	B-NP
/	/	NN	I-NP
mouse	mouse	NN	I-NP
)	)	-RRB-	0
#	#	#	0
LD50	LD50	CD	B-NP
Protected	Protected	NNP	0
Against	Against	NNP	0
1LD50*	1LD50*	NNP	B-NP
Murine	Murine	NNP	I-NP
13C4	13C4	NNP	I-NP
(	(	-LRB-	0
1.4	1.4	CD	0
g	g	CD	0
)	)	-RRB-	0
10	10	CD	0
6.1	6.1	CD	0
Humanized	Humanized	NNP	B-NP
13C4	13C4	NNP	I-NP
(	(	-LRB-	0
4.1	4.1	CD	0
g	g	CD	0
)	)	-RRB-	0
20	20	CD	0
8.9	8.9	CD	0
Humanized	Humanized	NNP	B-NP
11E10	11E10	NNP	I-NP
(	(	-LRB-	0
232	232	CD	0
g	g	CD	0
)	)	-RRB-	0
0	0	CD	0
No	No	DT	0
protection	protection	NN	0
*	*	NNP	0
(	(	-LRB-	0
1	1	CD	0
LD50	LD50	CD	B-NP
=	=	SYM	0
30	30	CD	0
ng	ng	JJ	B-NP
crude	crude	NN	0
Stx1	Stx1	CD	B-NP
)	)	-RRB-	0
B.	B.	NNP	B-NP
Protection	Protection	NNP	I-NP
Against	Against	NNP	0
Oral	Oral	NNP	B-NP
Infection	Infection	NNP	I-NP
with	with	IN	0
stx2-producing	stx2-producing	NN	B-NP
ehec	ehec	NN	I-NP
strain	strain	NN	I-NP
.	.	.	0
Two	Two	CD	0
different	different	JJ	0
strains	strains	NNS	0
of	of	IN	0
mice	mice	NNS	0
and	and	CC	0
bacteria	bacteria	NNS	0
were	were	VBD	0
used	used	VBN	0
in	in	IN	0
these	these	DT	0
studies	studies	NNS	0
to	to	TO	0
test	test	VB	0
efficacy	efficacy	VBN	0
against	against	IN	0
both	both	DT	0
Stx2	Stx2	NNP	B-NP
and	and	CC	0
Stx2-variant	Stx2-variant	NNP	B-NP
.	.	.	0
DBA	DBA	NNP	B-NP
/	/	CD	0
2J	2J	CD	0
mice	mice	NNS	0
were	were	VBD	0
challenged	challenged	VBN	0
with	with	IN	0
EHEC	EHEC	NNP	B-NP
strain	strain	NN	I-NP
86-24	86-24	FW	0
(	(	-LRB-	0
O157	O157	NNP	B-NP
:	:	:	0
H7	H7	CD	0
,	,	,	0
Stx2+	Stx2+	CD	B-NP
)	)	-RRB-	0
and	and	CC	0
cd-1	cd-1	NN	B-NP
mouse	mouse	NN	I-NP
were	were	VBD	0
challenged	challenged	VBN	0
with	with	IN	0
strain	strain	NN	0
B2F1	B2F1	NNP	B-NP
(	(	-LRB-	0
O91	O91	NNP	B-NP
:	:	:	0
H21	H21	CD	B-NP
,	,	,	0
Stx2-variant+	Stx2-variant+	CD	B-NP
)	)	-RRB-	0
.	.	.	0
While	While	IN	0
E.	E.	NNP	0
coli	coli	FW	0
strain	strain	FW	0
B2F1	B2F1	NN	B-NP
is	is	VBZ	0
normally	normally	RB	0
fatal	fatal	JJ	0
to	to	TO	0
both	both	DT	0
mice	mice	JJ	0
strains	strains	NNS	0
,	,	,	0
E.	E.	NNP	B-NP
coli	coli	NN	I-NP
strain	strain	NN	I-NP
86-24	86-24	FW	0
is	is	VBZ	0
fatal	fatal	JJ	0
to	to	TO	0
DBA	DBA	NNP	B-NP
/	/	CD	0
2J	2J	CD	0
mice	mice	NNS	0
,	,	,	0
while	while	IN	0
cd-1	cd-1	NN	B-NP
mouse	mouse	NN	I-NP
will	will	MD	0
survive	survive	VB	0
86-24	86-24	CD	0
infection	infection	NN	B-NP
.	.	.	0
At	At	IN	0
day	day	NN	0
zero	zero	CD	0
,	,	,	0
antibody	antibody	FW	0
H11E10	H11E10	FW	0
(	(	-LRB-	0
humanized	humanized	FW	0
-Stx2A	-Stx2A	FW	0
)	)	-RRB-	0
or	or	CC	0
11E10	11E10	NNP	B-NP
(	(	-LRB-	0
mouse	mouse	FW	0
-Stx2A	-Stx2A	FW	0
)	)	-RRB-	0
was	was	VBD	0
injected	injected	VBN	0
intraperitoneally	intraperitoneally	NNS	0
(	(	-LRB-	0
0.1	0.1	CD	0
ml	ml	CD	0
)	)	-RRB-	0
into	into	IN	0
groups	groups	NNS	0
of	of	IN	0
four	four	CD	0
or	or	CC	0
five	five	CD	0
mice	mice	NNS	0
.	.	.	0
control	control	NN	B-NP
group	group	NN	I-NP
included	included	VBD	0
mice	mice	NNS	0
that	that	WDT	0
had	had	VBD	0
received	received	VBN	B-NP
antibody	antibody	NN	I-NP
13C4	13C4	NNP	I-NP
(	(	-LRB-	0
mouse	mouse	FW	0
-Stx1B	-Stx1B	FW	0
)	)	-RRB-	0
,	,	,	0
mice	mice	NNS	0
that	that	WDT	0
had	had	VBD	0
received	received	VBN	B-NP
11E10	11E10	CD	I-NP
ascites	ascites	JJ	I-NP
fluid	fluid	NN	I-NP
(	(	-LRB-	0
mouse	mouse	FW	0
-Stx2A	-Stx2A	FW	0
)	)	-RRB-	0
,	,	,	0
or	or	CC	0
mice	mice	NNS	0
that	that	WDT	0
had	had	VBD	0
received	received	VBN	B-NP
pb	pb	NN	I-NP
instead	instead	RB	0
of	of	IN	0
antibody	antibody	NN	B-NP
.	.	.	0
Mice	Mice	NNS	0
were	were	VBD	0
given	given	VBN	0
streptomycin	streptomycin	NNS	0
(	(	-LRB-	0
5	5	CD	0
g	g	CD	B-NP
/	/	CD	I-NP
L	L	NNP	I-NP
)	)	-RRB-	0
in	in	IN	0
their	their	PRP$	0
drinking	drinking	NN	B-NP
water	water	NN	I-NP
to	to	TO	0
decrease	decrease	VB	0
normal	normal	JJ	B-NP
intestinal	intestinal	JJ	I-NP
flus	flus	NN	I-NP
and	and	CC	0
their	their	PRP$	0
food	food	NN	0
was	was	VBD	0
removed	removed	VBN	0
.	.	.	0
Streptomycin	Streptomycin	JJ	0
resistant	resistant	JJ	0
derivatives	derivatives	NNS	0
of	of	IN	0
strains	strains	CD	0
86-24	86-24	CD	0
(	(	-LRB-	0
O157	O157	NNP	B-NP
:	:	:	0
H7	H7	CD	0
,	,	,	0
Stx2+	Stx2+	CD	B-NP
)	)	-RRB-	0
and	and	CC	0
B2F1	B2F1	NNP	B-NP
(	(	-LRB-	0
O91	O91	NNP	B-NP
:	:	:	0
H21	H21	CD	B-NP
,	,	,	0
Stx2-variant+	Stx2-variant+	CD	B-NP
)	)	-RRB-	0
were	were	VBD	0
grown	grown	VBN	0
overnight	overnight	JJ	0
in	in	IN	0
L	L	NNP	0
broth	broth	NN	0
.	.	.	0
The	The	DT	0
following	following	JJ	0
day	day	NN	0
(	(	-LRB-	0
day	day	NN	0
1	1	CD	0
)	)	-RRB-	0
the	the	DT	0
mice	mice	NNS	0
received	received	VBD	0
a	a	DT	0
second	second	JJ	0
test	test	NN	B-NP
antibody	antibody	NN	I-NP
injection	injection	NN	I-NP
,	,	,	0
control	control	NN	B-NP
antibody	antibody	NN	I-NP
,	,	,	0
or	or	CC	0
phosphate	phosphate	NN	B-NP
buffered	buffered	NN	I-NP
saline	saline	JJ	I-NP
.	.	.	0
The	The	DT	0
mice	mice	NNS	0
were	were	VBD	0
immediately	immediately	RB	0
fed	fed	VBN	0
1010	1010	CD	0
CFU	CFU	NN	B-NP
of	of	IN	0
86-24	86-24	NNP	0
that	that	WDT	0
had	had	VBD	0
been	been	VBN	0
pelleted	pelleted	NNS	0
and	and	CC	0
resuspended	resuspended	NN	B-NP
in	in	IN	0
20	20	CD	0
%	%	NN	0
sucrosa	sucrosa	NN	B-NP
or	or	CC	0
103	103	CD	0
CFU	CFU	NN	B-NP
of	of	IN	0
B2F1	B2F1	NNP	B-NP
that	that	WDT	0
had	had	VBD	0
been	been	VBN	0
serially	serially	RB	0
diluted	diluted	VBN	0
in	in	IN	0
20	20	CD	0
%	%	NN	0
sucrose	sucrose	NN	B-NP
.	.	.	0
Food	Food	NNP	0
was	was	VBD	0
returned	returned	VBN	0
to	to	TO	0
the	the	DT	0
cage	cage	NN	0
and	and	CC	0
the	the	DT	0
mice	mice	NNS	0
were	were	VBD	0
monitored	monitored	VBN	0
for	for	IN	0
21	21	CD	0
days	days	NNS	0
.	.	.	0
(	(	-LRB-	0
CFU=Colony	CFU=Colony	NNP	B-NP
forming	forming	VBG	B-NP
unit	unit	NN	I-NP
)	)	-RRB-	0
As	As	RB	0
shown	shown	VBN	0
in	in	IN	0
Table	Table	NNP	0
3	3	CD	0
,	,	,	0
immunization	immunization	VBG	B-NP
of	of	IN	0
the	the	DT	0
mice	mice	NNS	0
with	with	IN	0
the	the	DT	0
either	either	RB	0
the	the	DT	0
murine	murine	NN	B-NP
or	or	CC	0
the	the	DT	0
humanized	humanized	JJ	0
anti-stx2	anti-stx2	NN	B-NP
antibody	antibody	NN	I-NP
resulted	resulted	VBD	0
in	in	IN	0
complete	complete	JJ	0
protection	protection	NN	0
from	from	IN	0
a	a	DT	0
enterohemorrhagic	enterohemorrhagic	NN	B-NP
escherichia	escherichia	NN	I-NP
coli	coli	NN	I-NP
lethal	lethal	JJ	I-NP
oral	oral	JJ	I-NP
dose	dose	NN	I-NP
.	.	.	0
Immunization	Immunization	NNP	B-NP
with	with	IN	0
mouse	mouse	CD	B-NP
13C4	13C4	CD	I-NP
antibody	antibody	NN	I-NP
,	,	,	0
prepared	prepared	VBN	0
in	in	IN	0
the	the	DT	0
same	same	JJ	0
way	way	NN	0
but	but	CC	0
immunoreactive	immunoreactive	NN	B-NP
with	with	IN	0
the	the	DT	0
Stx1	Stx1	JJ	B-NP
toxin	toxin	NN	I-NP
instead	instead	RB	0
of	of	IN	0
the	the	DT	0
Stx2	Stx2	JJ	B-NP
toxin	toxin	NN	I-NP
did	did	VBD	0
not	not	RB	0
protect	protect	VB	0
the	the	DT	0
mice	mice	NNS	0
from	from	IN	0
challenge	challenge	NN	0
with	with	IN	0
86-24	86-24	NNP	0
,	,	,	0
a	a	DT	0
result	result	NN	0
that	that	WDT	0
indicates	indicates	VBZ	0
the	the	DT	0
immunospecificity	immunospecificity	NN	B-NP
of	of	IN	0
the	the	DT	0
response	response	NN	0
.	.	.	0
TABLE	TABLE	NN	0
3	3	CD	0
DBA	DBA	NNP	B-NP
/	/	NNP	0
2J	2J	NNP	0
Mice	Mice	NNP	0
Fed	Fed	NNP	0
1010	1010	CD	0
CFU	CFU	CD	B-NP
0157	0157	CD	0
(	(	-LRB-	0
Stx2	Stx2	NNP	B-NP
)	)	-RRB-	0
Antibody	Antibody	NNP	B-NP
(	(	-LRB-	0
dose	dose	NN	B-NP
/	/	NN	I-NP
mouse	mouse	NN	I-NP
)	)	-RRB-	0
Survivors	Survivors	NNP	0
Murine	Murine	NNP	B-NP
13C4	13C4	NNP	I-NP
(	(	-LRB-	0
1.4	1.4	CD	0
g	g	CD	0
)	)	-RRB-	0
0	0	CD	0
/	/	CD	0
5	5	CD	0
Murine	Murine	NNP	B-NP
11E10	11E10	NNP	I-NP
(	(	-LRB-	0
1.0	1.0	CD	0
g	g	CD	0
)	)	-RRB-	0
5	5	CD	0
/	/	CD	0
5	5	CD	0
Humanized	Humanized	NNP	B-NP
11E10	11E10	NNP	I-NP
(	(	-LRB-	0
1.0	1.0	CD	0
g	g	CD	0
)	)	-RRB-	0
5	5	CD	0
/	/	CD	0
5	5	CD	0
similar	similar	JJ	B-NP
result	result	NN	I-NP
are	are	VBP	0
illustrated	illustrated	VBN	0
in	in	IN	0
Table	Table	NNP	0
4	4	CD	0
,	,	,	0
where	where	WRB	0
the	the	DT	0
more	more	RBR	0
resistant	resistant	JJ	0
cd-1	cd-1	NN	B-NP
mouse	mouse	NN	I-NP
were	were	VBD	0
fed	fed	VBN	0
the	the	DT	0
B2F1	B2F1	NNP	B-NP
E.	E.	NNP	0
coli	coli	JJ	B-NP
strain	strain	NN	I-NP
which	which	WDT	0
produces	produces	VBZ	0
Stx2-variant	Stx2-variant	CD	B-NP
toxin	toxin	NN	I-NP
.	.	.	0
Without	Without	IN	0
treatment	treatment	NN	0
with	with	IN	0
antibody	antibody	NN	B-NP
,	,	,	0
mortality	mortality	NN	0
was	was	VBD	0
total	total	JJ	0
,	,	,	0
but	but	CC	0
both	both	PDT	0
the	the	DT	0
mouse	mouse	NN	0
and	and	CC	0
the	the	DT	0
humanized	humanized	JJ	0
antibody	antibody	NN	B-NP
protected	protected	VBN	0
against	against	IN	0
Stx2-variant	Stx2-variant	CD	B-NP
in	in	IN	0
a	a	DT	0
dose	dose	JJ	0
dependent	dependent	JJ	0
manner	manner	NN	0
.	.	.	0
TABLE	TABLE	NN	0
4	4	CD	0
cd-1	cd-1	NN	B-NP
mouse	mouse	NN	I-NP
Fed	Fed	NNP	0
103	103	CD	0
CFU	CFU	NNP	B-NP
O91	O91	NNP	0
:	:	:	0
H21	H21	CD	B-NP
(	(	-LRB-	0
Stx2-variant	Stx2-variant	NNP	B-NP
)	)	-RRB-	0
Antibody	Antibody	NNP	B-NP
(	(	-LRB-	0
dose	dose	NN	B-NP
/	/	NN	I-NP
mouse	mouse	NN	I-NP
)	)	-RRB-	0
Survivors	Survivors	NNP	0
phosphate	phosphate	NN	B-NP
buffered	buffered	NN	I-NP
saline	saline	JJ	I-NP
0	0	CD	0
/	/	CD	0
5	5	CD	0
Murine	Murine	NNP	B-NP
11E10	11E10	NNP	I-NP
(	(	-LRB-	0
8.7	8.7	CD	0
g	g	CD	0
)	)	-RRB-	0
1	1	CD	0
/	/	CD	0
4*	4*	CD	0
Murine	Murine	NNP	0
11E10	11E10	NNP	0
(	(	-LRB-	0
6.45	6.45	CD	0
mg	mg	CD	B-NP
)	)	-RRB-	0
5	5	CD	0
/	/	CD	0
5	5	CD	0
Humanized	Humanized	NNP	B-NP
11E10	11E10	NNP	I-NP
(	(	-LRB-	0
23.2	23.2	CD	0
g	g	CD	0
)	)	-RRB-	0
0	0	CD	0
/	/	CD	0
5	5	CD	0
Humanized	Humanized	NNP	B-NP
11E10	11E10	NNP	I-NP
(	(	-LRB-	0
232	232	CD	0
g	g	CD	0
)	)	-RRB-	0
5	5	CD	0
/	/	CD	0
5	5	CD	0
Protective	Protective	JJ	B-NP
dose	dose	NN	I-NP
between	between	IN	0
10.1	10.1	CD	0
and	and	CC	0
1.0	1.0	FW	0
mg	mg	NN	B-NP
/	/	NN	I-NP
kg	kg	NN	I-NP
*Delayed	*Delayed	RB	0
mean	mean	VB	0
time	time	NN	0
to	to	TO	0
death	death	NN	0
by	by	IN	0
3.4	3.4	CD	0
days	days	NNS	0
The	The	DT	0
subject	subject	JJ	0
invention	invention	NN	0
also	also	RB	0
provides	provides	VBZ	0
for	for	IN	0
a	a	DT	0
variety	variety	NN	0
of	of	IN	0
methods	methods	NNS	0
of	of	IN	0
treating	treating	VBG	0
,	,	,	0
ameliorating	ameliorating	NN	0
,	,	,	0
or	or	CC	0
preventing	preventing	VBG	0
,	,	,	0
the	the	DT	0
diseases	diseases	NNS	0
and	and	CC	0
effects	effects	NNS	0
associated	associated	VBN	0
with	with	IN	0
exposure	exposure	NN	0
to	to	TO	0
Shiga	Shiga	NNP	B-NP
toxin	toxin	NN	I-NP
.	.	.	0
positive	positive	JJ	B-NP
clinical	clinical	JJ	I-NP
response	response	NN	I-NP
in	in	IN	0
humans	humans	NNS	0
have	have	VBP	0
been	been	VBN	0
obtained	obtained	VBN	0
with	with	IN	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
,	,	,	0
and	and	CC	0
one	one	CD	0
skilled	skilled	NN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
would	would	MD	0
know	know	VB	0
how	how	WRB	0
to	to	TO	0
employ	employ	VB	0
anti-Stx	anti-Stx	JJ	B-NP
humanized	humanized	JJ	0
monoclonal	monoclonal	JJ	B-NP
antibody	antibody	NN	I-NP
in	in	IN	0
humans	humans	NNS	0
.	.	.	0
(	(	-LRB-	0
See	See	FW	0
Fagerberg	Fagerberg	FW	0
et	et	FW	0
al.	al.	FW	0
,	,	,	0
Cancer	Cancer	NNP	B-NP
Research	Research	NNP	I-NP
,	,	,	0
55	55	CD	0
:	:	:	0
1824-27	1824-27	CD	0
(	(	-LRB-	0
1995	1995	CD	0
)	)	-RRB-	0
;	;	:	0
Eur	Eur	NNP	B-NP
.	.	.	0
J.	J.	NNP	B-NP
Cancer	Cancer	NNP	I-NP
,	,	,	0
2	2	CD	0
:	:	:	0
261-267	261-267	CD	0
(	(	-LRB-	0
1995	1995	CD	0
)	)	-RRB-	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
precise	precise	JJ	0
dosage	dosage	NN	0
of	of	IN	0
humanized	humanized	JJ	0
anti-Shiga	anti-Shiga	JJ	B-NP
toxin	toxin	NN	I-NP
antibody	antibody	NN	I-NP
administered	administered	VBN	0
to	to	TO	0
a	a	DT	0
patient	patient	NN	0
for	for	IN	0
treatment	treatment	NN	0
of	of	IN	0
these	these	DT	0
diseases	diseases	NNS	0
will	will	MD	0
vary	vary	VB	0
in	in	IN	0
accordance	accordance	NN	0
with	with	IN	0
factors	factors	NNS	0
appreciated	appreciated	VBN	0
by	by	IN	0
the	the	DT	0
typical	typical	JJ	0
clinician	clinician	NN	B-NP
.	.	.	0
These	These	DT	0
factors	factors	NNS	0
include	include	VBP	0
(	(	-LRB-	0
but	but	CC	0
are	are	VBP	0
not	not	RB	0
limited	limited	VBN	0
to	to	TO	0
)	)	-RRB-	0
size	size	NN	0
,	,	,	0
age	age	NN	0
,	,	,	0
overall	overall	JJ	0
health	health	NN	0
,	,	,	0
the	the	DT	0
extent	extent	NN	0
of	of	IN	0
infection	infection	NN	B-NP
,	,	,	0
and	and	CC	0
other	other	JJ	0
medications	medications	NNS	0
being	being	VBG	0
administered	administered	VBN	0
to	to	TO	0
said	said	VBD	0
patient	patient	NN	0
.	.	.	0
The	The	DT	0
development	development	NN	0
of	of	IN	0
a	a	DT	0
precise	precise	JJ	0
treatment	treatment	NN	B-NP
regimen	regimen	NN	I-NP
will	will	MD	0
require	require	VB	0
optimization	optimization	VBN	0
through	through	IN	0
routine	routine	JJ	B-NP
medical	medical	JJ	I-NP
procedure	procedure	NN	I-NP
well	well	RB	0
known	known	VBN	0
to	to	TO	0
those	those	DT	0
in	in	IN	0
the	the	DT	0
medical	medical	JJ	B-NP
art	art	NN	I-NP
.	.	.	0
Examples	Examples	NNS	0
of	of	IN	0
potential	potential	JJ	B-NP
patient	patient	NN	I-NP
group	group	NN	I-NP
would	would	MD	0
include	include	VB	0
(	(	-LRB-	0
but	but	CC	0
not	not	RB	0
be	be	VB	0
limited	limited	VBN	0
to	to	TO	0
)	)	-RRB-	0
young	young	JJ	0
children	children	NNS	0
with	with	IN	0
bloody	bloody	JJ	0
diarrhea	diarrhea	NN	0
but	but	CC	0
no	no	DT	0
white	white	JJ	0
cells	cells	NNS	0
in	in	IN	0
the	the	DT	0
stool	stool	NN	0
,	,	,	0
patients	patients	NNS	0
with	with	IN	0
indications	indications	NNS	0
of	of	IN	0
hemolytic	hemolytic	NN	B-NP
uremic	uremic	NN	I-NP
syndrome	syndrome	NN	I-NP
,	,	,	0
patients	patients	NNS	0
with	with	IN	0
shiga	shiga	NN	B-NP
toxin	toxin	NN	I-NP
positive	positive	JJ	I-NP
stool	stool	JJ	I-NP
sample	sample	NN	I-NP
test	test	NN	I-NP
,	,	,	0
siblings	siblings	NNS	0
or	or	CC	0
daycare	daycare	JJ	B-NP
cohort	cohort	NN	I-NP
in	in	IN	0
contact	contact	NN	0
with	with	IN	0
a	a	DT	0
case	case	NN	0
(	(	-LRB-	0
as	as	IN	0
a	a	DT	0
passive	passive	JJ	B-NP
preventative	preventative	JJ	I-NP
measure	measure	NN	I-NP
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
any	any	DT	0
patient	patient	NN	0
with	with	IN	0
diarrhea	diarrhea	NNS	0
(	(	-LRB-	0
not	not	RB	0
necessarily	necessarily	RB	0
bloody	bloody	JJ	0
)	)	-RRB-	0
that	that	WDT	0
has	has	VBZ	0
been	been	VBN	0
in	in	IN	0
contact	contact	NN	0
with	with	IN	0
an	an	DT	0
identified	identified	JJ	0
case	case	NN	0
.	.	.	0
A	A	DT	0
typical	typical	JJ	0
dosage	dosage	NN	0
of	of	IN	0
about	about	IN	0
5	5	CD	0
mg	mg	CD	B-NP
/	/	CD	I-NP
kg	kg	JJ	I-NP
body	body	NN	I-NP
weight	weight	NN	I-NP
of	of	IN	0
humanized	humanized	NNS	0
13C4	13C4	VBP	0
combined	combined	VBN	0
with	with	IN	0
about	about	IN	0
10	10	CD	0
mg	mg	CD	B-NP
/	/	CD	I-NP
kg	kg	JJ	I-NP
body	body	NN	I-NP
weight	weight	NN	I-NP
of	of	IN	0
humanized	humanized	JJ	0
11E10	11E10	NN	B-NP
would	would	MD	0
be	be	VB	0
contemplated	contemplated	VBN	0
.	.	.	0
This	This	DT	0
combined	combined	JJ	0
formulation	formulation	NN	B-NP
could	could	MD	0
be	be	VB	0
administered	administered	VBN	0
to	to	TO	0
the	the	DT	0
patient	patient	NN	0
twice	twice	RB	0
to	to	TO	0
ensure	ensure	VB	0
effectiveness	effectiveness	NN	0
.	.	.	0
Inclusion	Inclusion	NN	0
of	of	IN	0
both	both	DT	0
types	types	NNS	0
of	of	IN	0
humanized	humanized	JJ	0
antibody	antibody	NN	B-NP
together	together	RB	0
provides	provides	VBZ	0
assurance	assurance	NN	0
that	that	IN	0
the	the	DT	0
patient	patient	NN	0
will	will	MD	0
be	be	VB	0
protected	protected	VBN	0
against	against	IN	0
all	all	DT	0
types	types	NNS	0
of	of	IN	0
Shiga	Shiga	NNP	B-NP
toxin	toxin	NN	I-NP
.	.	.	0
The	The	DT	0
person	person	NN	0
skilled	skilled	NN	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
would	would	MD	0
understand	understand	VB	0
how	how	WRB	0
to	to	TO	0
use	use	VB	0
and	and	CC	0
practice	practice	VB	0
the	the	DT	0
invention	invention	NN	0
based	based	VBN	0
on	on	IN	0
the	the	DT	0
above	above	JJ	0
disclosure	disclosure	NN	0
.	.	.	0
Other	Other	JJ	0
embodiments	embodiments	NN	0
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
will	will	MD	0
be	be	VB	0
apparent	apparent	JJ	0
to	to	TO	0
those	those	DT	0
skilled	skilled	JJ	0
in	in	IN	0
the	the	DT	0
art	art	NN	0
from	from	IN	0
specification	specification	NN	B-NP
consideration	consideration	NN	I-NP
and	and	CC	0
practice	practice	NN	0
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
disclosed	disclosed	VBD	0
herein	herein	VBN	0
.	.	.	0
It	It	PRP	0
is	is	VBZ	0
intended	intended	VBN	0
that	that	IN	0
the	the	DT	0
specification	specification	NN	B-NP
and	and	CC	0
examples	examples	NNS	0
be	be	VB	0
considered	considered	VBN	0
as	as	IN	0
exemplary	exemplary	VBG	0
only	only	RB	0
,	,	,	0
with	with	IN	0
the	the	DT	0
true	true	JJ	0
scope	scope	NN	0
and	and	CC	0
spirit	spirit	NN	0
of	of	IN	0
the	the	DT	0
invention	invention	NN	0
being	being	VBG	0
indicated	indicated	VBN	0
by	by	IN	0
the	the	DT	0
following	following	JJ	0
claims	claims	NNS	0
.	.	.	0
What	What	WP	0
is	is	VBZ	0
claimed	claimed	VBN	0
is	is	VBZ	0
:	:	:	0
1	1	LS	0
.	.	.	0
An	An	DT	0
isolated	isolated	FW	0
nucleic	nucleic	JJ	B-NP
acid	acid	JJ	I-NP
molecule	molecule	NN	I-NP
comprising	comprising	FW	0
a	a	FW	0
sequence	sequence	FW	0
encoding	encoding	FW	0
an	an	FW	0
anti-Stx2	anti-Stx2	NN	B-NP
antibody	antibody	NN	I-NP
heavy	heavy	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
,	,	,	0
wherein	wherein	NN	0
said	said	VBD	0
anti-Stx2	anti-Stx2	CD	B-NP
heavy	heavy	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
CDR	CDR	NNP	B-NP
selected	selected	VBD	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
:	:	:	0
CDR1	CDR1	CD	B-NP
amino	amino	CD	0
acids	acids	CD	0
11-15	11-15	CD	0
of	of	IN	0
SEQ	SEQ	NNP	B-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
44	44	CD	0
,	,	,	0
CDR2	CDR2	NN	B-NP
amino	amino	FW	0
acids	acids	FW	0
50-66	50-66	FW	0
of	of	IN	0
SEQ	SEQ	NNP	B-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
44	44	CD	0
,	,	,	0
and	and	CC	0
CDR3	CDR3	CD	B-NP
amino	amino	CD	0
acids	acids	CD	0
99-108	99-108	CD	0
of	of	IN	0
SEQ	SEQ	NNP	B-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
44.	44.	CD	0
2	2	CD	0
.	.	.	0
The	The	DT	0
isolated	isolated	JJ	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
anti-Stx2	anti-Stx2	JJ	B-NP
heavy	heavy	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
comprises	comprises	VBZ	0
the	the	DT	0
amino	amino	JJ	0
acid	acid	NN	0
sequence	sequence	NN	0
of	of	IN	0
SEQ	SEQ	NNP	B-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
44.	44.	CD	0
3	3	CD	0
.	.	.	0
The	The	DT	0
isolated	isolated	JJ	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
of	of	IN	0
claim	claim	NN	0
1	1	CD	0
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
anti-Stx2	anti-Stx2	JJ	B-NP
heavy	heavy	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
comprises	comprises	VBZ	0
the	the	DT	0
amino	amino	JJ	0
acid	acid	NN	0
sequence	sequence	NN	0
of	of	IN	0
the	the	DT	0
heavy	heavy	JJ	0
murine	murine	JJ	B-NP
11e10	11e10	NN	I-NP
antibody	antibody	NN	I-NP
chain	chain	NN	I-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
(	(	-LRB-	0
ATCC	ATCC	UH	B-NP
Accession	Accession	UH	0
No	No	UH	0
.	.	.	0
CRL	CRL	NNP	B-NP
1987	1987	CD	0
)	)	-RRB-	0
.	.	.	0
4	4	LS	0
.	.	.	0
The	The	DT	0
isolated	isolated	JJ	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
of	of	IN	0
claim	claim	NN	0
2	2	CD	0
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
isolated	isolated	JJ	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
comprises	comprises	VBZ	0
the	the	DT	0
seq	seq	NN	B-NP
id	id	NN	I-NP
nucleic	nucleic	JJ	I-NP
acid	acid	NN	I-NP
sequence	sequence	NN	I-NP
NO	NO	NNP	0
:	:	:	0
43.	43.	CD	0
5	5	CD	0
.	.	.	0
An	An	DT	0
isolated	isolated	JJ	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
comprising	comprising	VBG	0
a	a	DT	0
sequence	sequence	NN	0
encoding	encoding	VBD	0
an	an	DT	0
anti-Stx2	anti-Stx2	JJ	B-NP
antibody	antibody	NN	I-NP
light	light	NN	I-NP
chain	chain	NN	I-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
,	,	,	0
wherein	wherein	NN	0
said	said	VBD	0
anti-Stx2	anti-Stx2	CD	B-NP
light	light	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
CDR	CDR	NNP	B-NP
selected	selected	VBD	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
:	:	:	0
CDR1	CDR1	CD	B-NP
amino	amino	CD	0
acids	acids	CD	0
4-40	4-40	CD	0
of	of	IN	0
SEQ	SEQ	NNP	B-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
42	42	CD	0
,	,	,	0
CDR2	CDR2	NN	B-NP
amino	amino	FW	0
acids	acids	FW	0
56-62	56-62	FW	0
of	of	IN	0
SEQ	SEQ	NNP	B-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
42	42	CD	0
,	,	,	0
and	and	CC	0
CDR3	CDR3	CD	B-NP
amino	amino	CD	0
acids	acids	CD	0
95-103	95-103	CD	0
of	of	IN	0
SEQ	SEQ	NNP	B-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
42.	42.	CD	0
6	6	CD	0
.	.	.	0
The	The	DT	0
isolated	isolated	JJ	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
of	of	IN	0
claim	claim	NN	0
5	5	CD	0
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
anti-Stx2	anti-Stx2	JJ	B-NP
light	light	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
comprises	comprises	VBZ	0
the	the	DT	0
amino	amino	JJ	0
acid	acid	NN	0
sequence	sequence	NN	0
of	of	IN	0
SEQ	SEQ	NNP	B-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
42.	42.	CD	0
7	7	CD	0
.	.	.	0
The	The	DT	0
isolated	isolated	JJ	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
of	of	IN	0
claim	claim	NN	0
5	5	CD	0
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
anti-Stx2	anti-Stx2	JJ	B-NP
light	light	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
comprises	comprises	VBZ	0
the	the	DT	0
amino	amino	JJ	0
acid	acid	NN	0
sequence	sequence	NN	0
of	of	IN	0
the	the	DT	0
light	light	JJ	0
murine	murine	JJ	B-NP
11e10	11e10	NN	I-NP
antibody	antibody	NN	I-NP
chain	chain	NN	I-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
(	(	-LRB-	0
ATCC	ATCC	UH	B-NP
Accession	Accession	UH	0
No	No	UH	0
.	.	.	0
CRL	CRL	NNP	B-NP
1987	1987	CD	0
)	)	-RRB-	0
.	.	.	0
8	8	CD	0
.	.	.	0
The	The	DT	0
isolated	isolated	JJ	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
of	of	IN	0
claim	claim	NN	0
6	6	CD	0
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
isolated	isolated	JJ	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
comprises	comprises	VBZ	0
the	the	DT	0
seq	seq	NN	B-NP
id	id	NN	I-NP
nucleic	nucleic	JJ	I-NP
acid	acid	NN	I-NP
sequence	sequence	NN	I-NP
NO	NO	NNP	0
:	:	:	0
41.	41.	CD	0
9	9	CD	0
.	.	.	0
The	The	DT	0
isolated	isolated	JJ	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
of	of	IN	0
claims	claims	NNS	0
1	1	CD	0
or	or	CC	0
5	5	CD	0
,	,	,	0
wherein	wherein	NN	0
said	said	VBD	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
further	further	RB	0
comprises	comprises	VBZ	0
a	a	DT	0
sequence	sequence	NN	0
encoding	encoding	VBD	0
a	a	DT	0
human	human	JJ	0
constant	constant	JJ	0
region.	region.	CD	0
10	10	CD	0
.	.	.	0
An	An	DT	0
isolated	isolated	JJ	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
comprising	comprising	VBG	0
a	a	DT	0
sequence	sequence	NN	0
encoding	encoding	VBD	0
an	an	DT	0
anti-Stx2	anti-Stx2	JJ	B-NP
antibody	antibody	NN	I-NP
,	,	,	0
said	said	VBD	0
antibody	antibody	VBN	B-NP
comprising	comprising	VBG	0
a	a	DT	0
heavy	heavy	JJ	0
and	and	CC	0
a	a	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
,	,	,	0
wherein	wherein	NN	0
said	said	VBD	0
heavy	heavy	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
CDR	CDR	NNP	B-NP
selected	selected	VBD	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
:	:	:	0
CDR1	CDR1	CD	B-NP
amino	amino	CD	0
acids	acids	CD	0
11-15	11-15	CD	0
of	of	IN	0
SEQ	SEQ	NNP	B-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
44	44	CD	0
,	,	,	0
CDR2	CDR2	NN	B-NP
amino	amino	FW	0
acids	acids	FW	0
50-66	50-66	FW	0
of	of	IN	0
SEQ	SEQ	NNP	B-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
44	44	CD	0
,	,	,	0
and	and	CC	0
CDR3	CDR3	CD	B-NP
amino	amino	CD	0
acids	acids	CD	0
99-108	99-108	CD	0
and	and	CC	0
SEQ	SEQ	UH	B-NP
ID	ID	UH	I-NP
NO	NO	UH	0
:	:	:	0
44.	44.	CD	0
11	11	CD	0
.	.	.	0
The	The	DT	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
of	of	IN	0
claim	claim	NN	0
10	10	CD	0
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
heavy	heavy	JJ	0
antibody	antibody	NN	B-NP
chain	chain	NN	I-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
comprises	comprises	VBZ	0
the	the	DT	0
amino	amino	JJ	0
acid	acid	NN	0
sequence	sequence	NN	0
of	of	IN	0
SEQ	SEQ	NNP	B-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
44.	44.	CD	0
12	12	CD	0
.	.	.	0
The	The	DT	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
of	of	IN	0
claim	claim	NN	0
10	10	CD	0
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
heavy	heavy	JJ	0
antibody	antibody	NN	B-NP
chain	chain	NN	I-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
comprises	comprises	VBZ	0
the	the	DT	0
amino	amino	JJ	0
acid	acid	NN	0
sequence	sequence	NN	0
of	of	IN	0
the	the	DT	0
heavy	heavy	JJ	0
murine	murine	JJ	B-NP
11e10	11e10	NN	I-NP
antibody	antibody	NN	I-NP
chain	chain	NN	I-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
(	(	-LRB-	0
ATCC	ATCC	UH	B-NP
Accession	Accession	UH	0
No	No	UH	0
.	.	.	0
CRL	CRL	NNP	B-NP
1987	1987	CD	0
)	)	-RRB-	0
.	.	.	0
13	13	CD	0
.	.	.	0
The	The	DT	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
of	of	IN	0
claim	claim	NN	0
11	11	CD	0
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
heavy	heavy	JJ	0
antibody	antibody	NN	B-NP
chain	chain	NN	I-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
comprises	comprises	VBZ	0
the	the	DT	0
seq	seq	NN	B-NP
id	id	NN	I-NP
nucleic	nucleic	JJ	I-NP
acid	acid	NN	I-NP
sequence	sequence	NN	I-NP
NO	NO	NNP	0
:	:	:	0
43.	43.	CD	0
14	14	CD	0
.	.	.	0
The	The	DT	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
of	of	IN	0
claim	claim	NN	0
10	10	CD	0
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
light	light	JJ	0
chain	chain	NN	B-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
comprises	comprises	VBZ	0
a	a	DT	0
CDR	CDR	NNP	B-NP
selected	selected	VBD	0
from	from	IN	0
the	the	DT	0
group	group	NN	0
consisting	consisting	VBG	0
of	of	IN	0
:	:	:	0
CDR1	CDR1	CD	B-NP
amino	amino	CD	0
acids	acids	CD	0
4-40	4-40	CD	0
of	of	IN	0
SEQ	SEQ	NNP	B-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
42	42	CD	0
,	,	,	0
CDR2	CDR2	NN	B-NP
amino	amino	FW	0
acids	acids	FW	0
56-62	56-62	FW	0
of	of	IN	0
SEQ	SEQ	NNP	B-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
42	42	CD	0
,	,	,	0
and	and	CC	0
CDR3	CDR3	CD	B-NP
amino	amino	CD	0
acids	acids	CD	0
95-103	95-103	CD	0
of	of	IN	0
SEQ	SEQ	NNP	B-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
42.	42.	CD	0
15	15	CD	0
.	.	.	0
The	The	DT	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
according	according	VBG	0
to	to	TO	0
claim	claim	VB	0
14	14	CD	0
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
light	light	JJ	0
antibody	antibody	NN	B-NP
chain	chain	NN	I-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
comprises	comprises	VBZ	0
the	the	DT	0
amino	amino	JJ	0
acid	acid	NN	0
sequence	sequence	NN	0
of	of	IN	0
SEQ	SEQ	NNP	B-NP
ID	ID	NNP	I-NP
NO	NO	NNP	0
:	:	:	0
42.	42.	CD	0
16	16	CD	0
.	.	.	0
The	The	DT	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
of	of	IN	0
claim	claim	NN	0
14	14	CD	0
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
light	light	JJ	0
antibody	antibody	NN	B-NP
chain	chain	NN	I-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
comprises	comprises	VBZ	0
the	the	DT	0
amino	amino	JJ	0
acid	acid	NN	0
sequence	sequence	NN	0
of	of	IN	0
the	the	DT	0
light	light	JJ	0
murine	murine	JJ	B-NP
11e10	11e10	NN	I-NP
antibody	antibody	NN	I-NP
chain	chain	NN	I-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
(	(	-LRB-	0
ATCC	ATCC	UH	B-NP
Accession	Accession	UH	0
No	No	UH	0
.	.	.	0
CRL	CRL	NNP	B-NP
1987	1987	CD	0
)	)	-RRB-	0
.	.	.	0
17	17	CD	0
.	.	.	0
The	The	DT	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
of	of	IN	0
claim	claim	NN	0
15	15	CD	0
,	,	,	0
wherein	wherein	VBG	0
the	the	DT	0
light	light	JJ	0
antibody	antibody	NN	B-NP
chain	chain	NN	I-NP
variable	variable	NN	I-NP
domain	domain	NN	I-NP
comprises	comprises	VBZ	0
the	the	DT	0
seq	seq	NN	B-NP
id	id	NN	I-NP
nucleic	nucleic	JJ	I-NP
acid	acid	NN	I-NP
sequence	sequence	NN	I-NP
NO	NO	NNP	0
:	:	:	0
41.	41.	CD	0
18	18	CD	0
.	.	.	0
A	A	DT	0
vector	vector	JJ	0
comprising	comprising	NN	0
and	and	CC	0
capable	capable	JJ	0
of	of	IN	0
expressing	expressing	VBG	0
the	the	DT	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
of	of	IN	0
any	any	DT	0
one	one	NN	0
of	of	IN	0
claims	claims	NNS	0
1	1	CD	0
,	,	,	0
5	5	CD	0
,	,	,	0
10	10	CD	0
,	,	,	0
and	and	CC	0
14.	14.	CD	0
19	19	CD	0
.	.	.	0
A	A	DT	0
host	host	NN	B-NP
cell	cell	NN	I-NP
transformed	transformed	VBN	0
with	with	IN	0
the	the	DT	0
vector	vector	NN	B-NP
of	of	IN	0
claim	claim	NN	0
18.	18.	CD	0
20	20	CD	0
.	.	.	0
A	A	DT	0
method	method	NN	0
of	of	IN	0
producing	producing	VBG	0
an	an	DT	0
anti-Stx2	anti-Stx2	JJ	B-NP
antibody	antibody	NN	I-NP
comprising	comprising	VBG	0
the	the	DT	0
steps	steps	NNS	0
of	of	IN	0
culturing	culturing	VBG	0
a	a	DT	0
host	host	NN	B-NP
cell	cell	NN	I-NP
comprising	comprising	VBG	0
the	the	DT	0
nucleic	nucleic	JJ	B-NP
acid	acid	NN	I-NP
molecule	molecule	NN	I-NP
according	according	VBG	0
to	to	TO	0
any	any	DT	0
one	one	NN	0
of	of	IN	0
claims	claims	NNS	0
1	1	CD	0
,	,	,	0
5	5	CD	0
,	,	,	0
10	10	CD	0
,	,	,	0
and	and	CC	0
14	14	CD	0
,	,	,	0
under	under	IN	0
conditions	conditions	NNS	0
suitable	suitable	JJ	0
for	for	IN	0
expression	expression	NN	0
of	of	IN	0
the	the	DT	0
antibody	antibody	NN	B-NP
and	and	CC	0
recovering	recovering	VBG	0
the	the	DT	0
antibody	antibody	NN	B-NP
.	.	.	0
